Chemokine receptors as therapeutic targets in liver disease by Parker, Richard
CHEMOKINE RECEPTORS AS THERAPEUTIC 
TARGETS IN LIVER DISEASE 
by 
Richard Parker 
 
 
 
 
A thesis submitted to the University of Birmingham for the degree of DOCTOR OF 
PHILOSOPHY 
 
 
 
 
 
 
Centre for Liver Research 
  School of Immunity and Infection  
College of Medical and Dental Sciences  
University of Birmingham 
July 2015
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
Chemokine Receptors as Therapeutic Targets in Liver 
Disease 
 
There is an urgent need for new insights into the pathology of liver disease to underpin new 
therapeutic approaches. Chemokines and their receptors are central to the development of 
liver inflammation. I investigated liver disease using ex-vivo human tissue to analyse gene and 
protein expression in liver and the nature of inflammation. Animal models of liver disease 
were used to investigate the effects of manipulating the chemokine system. 
 
In Non-Alcoholic Fatty Liver Disease (NAFLD) expression of CCL2 is increased. A subset of 
monocytes expressed CD11c and CD206, and maintained CCR2 expression in NAFLD. The 
frequency of this subset was associated with insulin resistance. In animal models of NAFLD, 
antagonism of CCR2 improved liver disease. In mouse models of acute liver failure (ALF), 
expression of CCL25 was an early response after injury, a phenomenon also seen in human 
ALF. Influx of CCR9+ monocytes was a corresponding early event in murine liver. 
Prophylactic administration of a CCR9 antagonist reduced liver injury and macrophage 
infiltration. CXCR6 has contrasting effects in murine liver injury: damaging in acute injury but 
protective in chronic injury. In human liver CXCR6 promotes infiltration Natural Killer cells, 
particularly in primary biliary cirrhosis, but may also promote regeneration of hepatocytes. 
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CHAPTER 1: Chemokine Receptors as Therapeutic Targets 
in Liver Disease  
 
Introduction 
The liver is the largest organ in the body with diverse roles in the metabolism of proteins, 
carbohydrate and lipids (Sherlock's Diseases of the Liver and Biliary System 12th Ed. Dooley 
et al., 2011). It is the site of metabolism of many drugs and toxins. The anatomical position of 
the liver, receiving blood draining from the gut via the portal vein (Bismuth, 2013), requires a 
condition of immune tolerance to prevent catastrophic reaction to harmless proteins 
derived from the diet (Tiegs and Lohse, 2010). In contrast, many liver diseases are 
characterised by infiltration of the liver by immune cells leading to chronic inflammation 
(Colombat et al., 2002, Boisvert et al., 2003, Gadd et  al., 2014), which disrupts the normal 
function of the liver. Overwhelming acute inflammation of the liver, or chronic inflammation 
and increasing hepatic fibrosis, can cause liver failure. The chemokine system plays a critical 
role in the trafficking of immune cells from blood into the liver is activated in disease to 
promote inflammation (Oo and Adams, 2010). This system is an attractive therapeutic target 
in in inflammatory liver diseases where, with the exception of viral hepatitis, there are few 
effective treatments.    
 
 2 
The Liver  
The liver lies in the upper right quadrant of the abdomen, sheltered by the lower ribcage. In 
adults it weighs 1000-1500g. It is formed of two large left and right lobes and a smaller 
caudate lobe (Bismuth, 2013). The lobes are subdivided into segments, each supplied by a 
single artery and single branch of the portal vein. The liver is unique in that it has a dual 
blood supply: the hepatic artery carries 25-30% of inflowing blood, a much larger proportion 
is carried though the portal vein which transports substances from the gut to the liver.  
 
The functional unit of the liver is the lobule. Here blood drains from portal venules into 
hepatic sinusoids (figure 1.1), a specialised environment distinguished by a layer of 
fenestrated endothelium interspersed with Kupffer cells (KC, liver-resident macrophages) 
and overlying pericytes (hepatic stellate cells, HSC) but without a basement membrane.  
Plates of hepatocytes lie beneath the sinusoids and are in contact with particulate matter in 
blood via microvilli extended through endothelial fenestrations. This is an area of low shear 
stress, where hepatocytes, KC and hepatic sinusoidal endothelial cells (HSEC) can all take up 
substances from blood. Hepatic sinusoids drain to a central vein and then to right or left 
hepatic veins, which unite to form the hepatic vein. This drains into the inferior vena cava 
close to the right atrium. Blood from central vein, derived from the portal vein, drains into 
hepatic sinusoids and eventually to small branches of the hepatic veins at the portal triads. 
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Figure 1.1: Schematic of hepatic lobule 
 
 
 
Figure 1.2: the hepatic sinusoid in health and disease 
Above: The hepatic sinusoid is lined by specialised endothelium characterised by fenestrae and a 
lack of a basement membrane. Fenestrae allow sampling of the sinusoid by hepatocytes and Kupffer 
cell patrol the sinusoids. Below: in disease, activation of stellate cells by inflammation and infiltrating 
immune cells causes deposition of collagen. This expands the space of Disse and creates a 
functional basement membrane, a process referred to as capilliarisation of the sinusoid (DeLeve, 
2007, Kubes and Mehal, 2012) 
 
  
 
  
 
 
  
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
  
 
  
 
 
 
Portal triad:  
hepatic vein, hepatic artery, bile 
ductule 
Hepatic 
sinusoid 
Central vein 
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A layer of unique endothelium lines the hepatic sinusoids. HSEC differ from other 
endothelial cell populations by expression of particular cell surface molecules, notably 
scavenger receptors, and the presence of fenestrations (Lalor et al., 2006). There is a 
functional space between endothelial cells and hepatocytes, the Space of Disse. This space is 
occupied by KC and HSC which act as pericytes to modulate sinusoidal blood flow and 
endothelial integrity (DeLeve, 2007). The hepatic endothelial layer is further characterised by 
the lack of a basement membrane (figure 1.2). These features allow constant sampling of 
hepatic blood flow by hepatocytes, KC as well as HSEC, which have potent scavenging 
functions (Elvevold et al., 2004). In cirrhosis, the endothelial layer becomes capiliarised 
(Schaffner and Poper, 1963), a process of deposition of collagen in the space beneath HSEC 
effectively forming a basement membrane as a consequence of inflammation and stellate cell 
activation (Urashima et al., 1993) (Xu et al., 2003).  Capillarisation restricts the normal 
function of the scavenging function of cells of the sinusoid and contributes to hepatic 
dysfunction (Le Couteur et al., 2005). 
 
Bile canaliculi form from grooves in the surface of hepatocytes, and receive substances 
excreted through active and passive processes from hepatocytes. Bile drains from here into 
ductules lined with specialised epithelium, which drain in turn into bile ducts. These coalesce 
to a major duct in each lobe of the liver, which unite outside the liver at the porta hepatis to 
form the common bile duct. Lymphatic drainage from the liver is mainly to coeliac axis 
lymph nodes. There is minor lymph drainage to mediastinal nodes and lymph nodes 
associated with the inferior vena cava. 
 
 5 
Liver disease 
Chronic liver disease is increasing in prevalence in the UK (Leon and McCambridge, 2006) 
(Fleming et al., 2008), due to trends in alcohol consumption, prevalence of viral hepatitis and 
obesity. In addition, mortality due to liver disease has risen, in contrast to other common 
causes of mortality, which have fallen over recent decades (Trust, 2008). This reflects 
advances in many areas of medicine, and the paucity of effective treatment for many chronic 
liver diseases (figure 1.3). Acute liver injury, most often caused by drugs is common (Sgro 
et al., 2002) but is usually mild and self-limiting, acute liver failure is rare (Bretherick et al., 
2011).  
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Figure 1.3: mortality from liver disease has risen compared to other common causes of 
death in the UK 
Mortality from common conditions relative to 1971 showing large increase in deaths due to liver 
disease relative to 1971, in contrast to other common causes of mortality in the UK (Williams et 
al., 2014) 
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In the UK common causes of chronic liver disease include alcoholic and non-alcoholic fatty 
liver disease, viral hepatitis and autoimmune liver disease. Fatty liver disease, caused by 
alcohol or the metabolic syndrome is the most common cause of liver disease in the UK 
accounting for approximately half of all liver disease (Armstrong et al., 2011). The causes of 
cirrhotic liver disease differ slightly to the aetiology of liver disease per se:  alcohol is 
implicated in 38% of cases of cirrhosis, viral hepatitis 5.3%, and autoimmune disease 7.1% 
(Fleming et al., 2008).  
 
Hepatitis B infection causes both acute and chronic disease, largely dependent on the mode 
of transmission: vertical transmission in the peri-natal period or childhood is associated with 
greatly increased risk of chronic disease (Liver, 2012b). Hepatitis C is more common than 
Hepatitis B in Europe (Blachier et al., 2013) and almost always causes chronic infection. 
Improved detection since the discovery of Hepatitis C in the 1980s has established Hepatitis 
C as a major cause of liver-related morbidity and mortality, however better screening and 
infection control methods have limited new infections (Esteban et al., 2008, Lavanchy, 2011). 
Intense research efforts have yielded powerful anti-viral drugs that effectively control 
Hepatitis B infection and new agents that can cure Hepatitis C are entering clinical practice 
(Liver, 2014).  
 
Autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC) and primary sclerosing 
cholangitis (PSC) are rarer autoimmune liver diseases that may progress to end-stage 
cirrhosis and require liver transplantation. Most cases of AIH and some cases of PBC will 
respond to medical treatment, whilst PSC has no universally effective treatment.  
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Liver diseases that are directly relevant to this project are now discussed in more detail.   
 
Non-Alcoholic Fatty Liver Disease 
Non-alcoholic fatty liver disease (NAFLD) describes a spectrum of disease, ranging from 
simple hepatic steatosis (non-alcoholic fatty liver, NAFL), through more advanced non-
alcoholic steatohepatitis (NASH) to cirrhosis (Chalasani et al., 2012). NAFLD is common: 
hepatic steatosis is present in up to one-third of individuals (Browning et al., 2004) in the US, 
and NASH is seen in approximately 10% (Williams et al., 2011). The earlier stages of NAFLD 
are not associated with liver-related outcomes, whereas the presence of advanced fibrosis 
incurs greater risk morbidity and mortality (Adams et al., 2005b, Ekstedt et al., 2014). 
NAFLD is closely associated with the metabolic syndrome up to 75% of people with 
Diabetes Mellitus (DM) have NAFLD (Targher et al., 2007, Leite et al., 2009, Vernon et al., 
2011) and NALFD is almost universal in morbidly obese individuals (Reha et al., 2014) 
 
NASH is associated with a chronic inflammatory cell infiltrate (Gadd et al., 2014) largely 
around portal tracts (Itoh et al., 2013, Wehr et al., 2014). Monocyte infiltration of the liver is 
a feature of both alcoholic and non-alcoholic steatohepatitis (Liaskou et al., 2013). KC are 
activated by multiple pathways in NAFLD and promote hepatic steatosis and insulin 
resistance (Baffy, 2009) (Huang et al., 2010, Lanthier et al., 2011).  
 
Treatment is desirable for patients with NASH to decrease the risk of progressive liver 
disease, and to reduce risk of liver-related morbidity. Many pharmaceutical treatments have 
been investigated, none have shown categorical benefit in NASH (Musso et al., 2010). 
Weight loss is beneficial, but patients must lose 7% of their body mass to gain benefit in 
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terms of liver histology (Promrat et al., 2010). Many patients are unable to achieve or 
maintain such significant weight loss. Given the prevalence of NAFLD, there is an urgent 
need for effective treatments to prevent or treat end-stage liver disease.  
 
Acute liver failure 
Acute liver failure (ALF) is a rare syndrome with an incidence of approximately 6 per 
100,000 people/year (Bower et al., 2007, Bretherick et al., 2011). ALF, characterized by 
jaundice and encephalopathy, is most commonly caused by drugs but may also be caused by 
viral infection and rarely autoimmune disease (Bower et al., 2007, Marudanayagam et al., 
2009, Hadem et al., 2012).  
 
Paracetamol is the most common cause of drug-induced ALF in the UK (Bower et al., 2007, 
Bretherick et al., 2011, Gulmez et al., 2013). Paracetamol-induced ALF has a significant 
associated mortality – 29% at three weeks in a large US cohort (Larson et al., 2005).  
 
Paracetamol induced acute liver failure is characterised by infiltration of liver tissue by a 
mixed infiltrate where macrophages are prominent (Antoniades et al., 2012, Nakamoto et al., 
2012) as well as lymphocytes and neutrophils (Tuncer et al., 2013) (Marques et al., 2012). 
The infiltration of macrophages and neutrophils into liver tissue in ALF is regulated in part by 
chemokines many of which are over-expressed in the acutely injured liver (Tuncer et al., 
2013). The patterns of chemokine expression differs quantitatively and qualitatively between 
aetiologies of ALF, for example work from our laboratory shows greater CCL4 expression 
in paracetamol-induced ALF compared to seronegative hepatitis (Tuncer et al., 2013). 
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Paracetamol-induced ALF is further distinguished from fulminant auto-immune hepatitis 
(AIH) by the pattern of infiltrating cells, where a predominance of lymphocytes and plasma 
cells is seen in AIH (Czaja, 2013).  
 
Acute liver failure of any cause has few treatment options. In the case of paracetamol-
induced liver failure, the only current available treatment is intravenous N-actylcysteine (Lee 
et al., 2011) to replace hepatic stores of glutathione exhausted by the metabolism of excess 
paracetamol. Liver transplantation remains the only treatment option for the minority not 
responding to medical treatment. 
 
Primary Biliary Cirrhosis 
In PBC small intrahepatic bile ducts within the liver become inflamed often associated with a 
characteristic granulomata (Selmi et al., 2011). PBC is a rare condition affecting up to 200 
people in a million (Myers et al., 2009, Boonstra et al., 2012) and the incidence may be 
increasing. It is far more common in women than in men and tends to present in middle age. 
The strong association of PBC with auto-antibodies against mitochondria (anti-mitochondrial 
antibody, AMA) and the presence of auto-reactive T cell in liver tissue and draining lymph 
nodes (Kita et al., 2002) show PBC to be an autoimmune disease. However, AMA are not 
universally found in individuals with PBC and most people with AMA do not develop PBC 
(Michieletti et al., 1994, Mattalia et al., 1998). In addition to alterations of T cell phenotype, 
an increase in the presence of activated NK cells has been observed in PBC (Björkland et al., 
1991). Shimoda et al demonstrated the cytotoxicity of NK cells against autologous biliary 
epithelial cells under certain pro-inflammatory conditions (Shimoda et al., 2011).  
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Treatment with ursodeoxycholic acid slows progression of disease and improves overall 
survival (Lindor et al., 2009) but those who do not respond to treatment have a poor 
prognosis. This group of patients will often require liver transplantation. 
 
Hepatocellular carcinoma 
HCC had an annual incidence of 4.9/100,000 people in the USA in 2005, a three-fold rise 
since 1975 (Altekruse et al., 2009), although incidence of HCC varies depending on the 
prevalence of risk factors such as viral hepatitis (Ferenci et al., 2010). In the west most HCC 
occur on a background of liver cirrhosis (Altekruse et al., 2009). In cirrhosis, loco-regional 
therapy of smaller lesions is occasionally curative but larger lesions require transplantation 
to offer curative treatment (Liver, 2012a).  
 
Multiple aberrations in cell signalling pathways have been described in HCC including cell 
cycle dysregulation, increased angiogenesis and evasion of apoptosis (Calvisi et al., 2007, 
Hoshida et al., 2010, Whittaker et al., 2010). None of these are unique to HCC. The CXC 
chemokine receptor CXCR6 has been reported to be overexpressed in HCC (Gao et al., 
2012), where knock-out of CXCR6 reduced growth, angiogenesis and metastasis of 
hepatoma cells implanted into mice.  
 
Immunology of the liver 
The liver is a unique immunological environment. The influx of blood draining the gut carries 
multiple antigens derived from food and gut bacteria, many of which will be harmless 
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(Crispe, 2009). To prevent immune activation in response to benign particles the liver has 
multiple mechanisms by which tolerance is maintained. Under normal circumstances KC and 
HSEC express anti-inflammatory compounds such as IL-10, PGE2 and TGF-β in response to 
LPS and other antigens, rendering liver resident naïve DCs tolerogenic (Knolle and Gerken, 
2000). In addition, vitamin A secreted by HSC prompt naïve CD4+ to differentiate towards a 
regulatory phenotype (Tiegs and Lohse, 2010). Liver-resident non-T cell lymphoid cells such 
as NK and NKT cells also play a role in maintaining tolerance (Doherty and O'Farrelly, 2000) 
in part through recruitment and activation of T regulatory cells (Santodomingo-Garzon and 
Swain, 2011). 
 
The normal liver contains a large population of lymphocytes, the distribution of which differs 
from that of blood with more NKT and NK cells and proportionally fewer αβ T 
lymphocytes (Norris et al., 1998, Norris et al., 1999) (Hata et al., 1990). These cells are 
found throughout the parenchyma and within portal tracts. Kupffer cells reside in the space 
of Disse and actively patrol the sinusoids.  Liver resident dendritic cells are potent APCs and 
take up antigen and migrate via lymphatics and the sinusoids to draining lymph nodes where 
they activate T cells. HSEC, HSC and hepatocytes can under some circumstances also 
present antigens to lymphocytes and this usually results in tolerance (Racanelli and 
Rehermann, 2006, Tay et al., 2014).  
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Immune cells in liver disease 
Monocyte/macrophages  
Monocytes circulate in blood for a short period after leaving bone marrow before entering 
tissue and differentiating further into macrophages and also dendritic cells (Ziegler-
Heitbrock et al., 2010).  Monocytes in humans can be classified on the basis of CD14 and 
CD16 expression (figure 3.5) into classical CD14++CD16- monocytes that predominate in 
blood; non-classical CD14-CD16++ monocytes that are expanded under inflammatory 
conditions and an intermediate CD14++C16+ population of monocytes which also expand 
under inflammatory conditions. Previous reports from our laboratory have shown that 
diseased liver tissue in NASH and ALD is enriched for monocytes compared to normal 
tissue (Liaskou et al., 2013) due to increases in the non-classical CD14-CD16++ and 
intermediate CD14++CD16+ monocytes. Recent work has demonstrated that CD16+ and 
CD16- cells behave differently after transmigration through hepatic endothelium in vitro: 
CD14++CD16- cells mainly remained sub-endothelial and demonstrated high phagocytic 
capacity whereas CD14++CD16+ and CD14-CD16++ cells often gave rise to DC precursors 
with T-cell inducing properties (Zimmermann et al., 2015). 
 
Tissue resident macrophage populations – Kupffer cells in the case of the liver - are 
established before birth and are able to self-replenish without requiring addition of blood-
borne monocytes (Hashimoto et al., 2013, Yona et al., 2013). These two distinct populations 
have different functions – KC detect liver injury and initiate inflammatory responses which 
are perpetuated and amplified by infiltrating monocytes (Tacke and Zimmermann, 2014).  
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Natural killer cells 
Natural killer (NK) cells are cells of the innate immune system of lymphoid lineage that are 
directly cytotoxic and have cytokine secreting effector functions (Vivier et al., 2008). 
Through prompt recognition of non-self cells NK cells have potent antimicrobial properties 
and also anti-tumour capability. More recently research has demonstrated a regulatory role 
for NK cells through inhibition of macrophages, as well as through modulation of dendritic 
cell actions.  
 
CD56 expression is the hallmark of NK cells in humans and NK cells can be subdivided 
based on their relative expression of CD56 (Vivier et al., 2008). The CD56dim subset is more 
common in peripheral blood whereas CD56hi cells predominate in tissue. Expression of 
CD56 is inverse to CD16 expression (Cooper et al., 2001) where the expression of CD16 is 
required for antibody-mediated cytotoxity through binging of antibody. Accordingly, CD56hi 
NK cells show lower levels of antibody mediated cell killing than CD56dim. CD56hi subsets 
produce more cytokines e.g. IFNγ than cd56dim subset (Cooper et al., 2001) (Poli et al., 
2009).  
 
 
Chemokines  
Chemokines are small cytokines (8-12kDa). They are a phylogenetically ancient feature of 
the immune system with origins around 650 million years ago and found in fish, amphibians 
and birds as well as mammals (DeVries et al., 2006). The human chemokine superfamily 
 15 
comprises 46 known chemokines, which bind to 18 chemokine receptors (Zlotnik et al., 
2006). Chemokine ligands are defined by the arrangement of N-terminal cysteine residues 
(Zlotnik and Yoshie, 2000). Chemokine ligands bind to receptors in defined pairings. Some 
receptors bind more than one ligand, some ligands bind to more than one receptor whilst 
other receptor-ligand pairs are monogamous, i.e. interact only with each other.  
 
Chemokine receptors have seven trans-membrane regions and are G-protein coupled (Allen 
et al., 2007a). Binding of chemokine ligand to it’s receptor generally results in activation of 
multiple intracellular pathways through activation of G-protein coupled receptors (Allen et 
al., 2007b) although binding to decoy chemokine receptors does not elicit an overt signalling 
response but instead internalise, transport or degrade chemokines (Bonecchi et al., 2010).  
 
Activation of chemokine receptor causes activation of the Gα subunit of the associated G- 
intracellular protein, leading to separation of both the Gα subunit and the Gβγ (Allen et al., 
2007b).  Both of these have signalling effects inside the cell although the Gβγ subunit may be 
of greater importance in the context of cell migration (Thelen and Stein, 2008). A variety of 
intracellular pathways are activated including activation of phospholipase lading to calcium 
mobilisation, cell polarisation and integrin mobilisation and activation, (Kinashi, 2005, Thelen 
and Stein, 2008), activation of phosphoinositide 3-kinases leading to cytoskeleton 
rearrangements (Curnock et al., 2002, Rot and von Andrian, 2004). The canonical role of 
chemokines is to exert effects on immune cell trafficking. These effects are fundamental at all 
stages of leukocyte development from positioning within the thymus and bone marrow, 
egress into blood, to recruitment and positioning in sites of inflammation and secondary 
lymphoid tissue (Rot and von Andrian, 2004). Chemokines also have a role in other 
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biological functions for example angiogenesis and embryology (Mehrad et al., 2007, Raz and 
Mahabaleshwar, 2009).  
  
Chemokines in liver disease 
Infiltration of inflammatory cells is a common feature of liver injury (Björkland et al., 1991, 
Boisvert et al., 2003). Differing types of liver disease are associated with distinct patterns of 
infiltration characteristic to differing types of injury (Susca et al., 2001, Lalor et al., 2002). 
Chemokines are produced in the liver by multiple cell types (Afford et al., 1998, Shields et al., 
1999). The combination of chemokines secreted and presented in the liver will contribute to 
the nature of inflammation by driving adhesion and positioning of immune cells within liver 
(Oo and Adams, 2010).  In this thesis I have focussed on the role of specific chemokine 
receptors CCR2, CCR9 and CXCR6. These receptors where investigated on the basis of 
previous reports from our laboratory and others suggesting roles for CCR2, CCR9 and 
CXCR6 in fatty liver disease, acute liver failure and biliary disease respectively. In addition 
the role of CXCR6 in HCC was investigated in view of results examining CXCR6 in hepatic 
leukocyte trafficking.  
 
CCR2 
CCR2 is widely expressed on monocytes and T cells in humans (Charo et al., 1994) (Frade et 
al., 1997) and mice (Mack et al., 2001). CCR2 has several ligands CCL2, CCL7, CCL8, 
CCL13 and CCL16 which are expressed by diverse cell types (Zlotnik and Yoshie, 2000), as 
well as CCL11, which is an antagonist of CCR2 (Ogilvie et al., 2003).   
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Investigations in obesity showed macrophage infiltration of adipose and hepatic tissue to be 
mediated by CCR2 (Kanda et al., 2006, Weisberg et al., 2006). Particular CCR2+ 
monocyte/macrophage subsets have been shown to contribute to insulin resistance: in mice 
CD11b+CD11c+ F4/80+ macrophages contribute to chronic inflammation and insulin 
resistance in mice (Patsouris et al., 2008) and a functionally similar pro-inflammatory 
CD11c+CD206+ monocyte subset are found in human adipose tissue associated with insulin 
resistance (Wentworth et al., 2010). In light of these data most attention in liver disease has 
focused on CCR2/CCL2 in NAFLD.  
 
Individuals with NAFLD have higher serum concentrations of CCL2 than age and gender-
matched controls (Haukeland et al., 2006), and serum CCL2 levels are greater in patients 
with more advanced NASH than those with simple steatosis. Serum CCL2 also correlates 
with levels of ALT, a marker of liver injury and inflammation (Kirovski et al., 2010). In mice, a 
high fat diet increases hepatic and serum CCL2 (Kirovski et al., 2011). Over-expression of 
CCL2 increases hepatic steatosis whereas its lack or reduced activity decreases hepatic 
steatosis (Kanda et al., 2006) (Nio et  al., 2012). CCR2 knockout animals also demonstrate 
reduced steatosis (Weisberg et al., 2006) associated with a reduction in myeloid cell 
infiltration - defined histologically as F4/80+ cells (Miura et al., 2012) or with flow cytometry 
as CD11b+ F4/80dim (Obstfeld et al., 2010). CCR2 knockout mice are also protected against 
carbon tetrachloride-induced fibrosis, attributed to expression of CCR2 by hepatic stellate 
cells (Seki et al., 2009). 
 
The CCR2/CCL2 axis has been targeted with a variety of pharmaceutical agents in animal 
models of fatty liver disease. In addition to confirming a role in the pathogenesis of disease, 
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these studies have demonstrated improved disease when either CCR2 or CCL2 is 
antagonised. Yang et al showed that administration of a CCR2 inhibitor in transgenic mice 
prone to lipotoxicity (Yang et al., 2009) reduced liver weight (as proportion of body mass), 
hepatic pro-inflammatory gene expression and macrophage accumulation. Miura used a 
CCR2 antagonist therapeutically (i.e. once disease was established) in a model of fatty liver 
induced by choline deficient diet (Miura et al., 2012). Again, macrophages were reduced in 
number in the livers of treated animals, assessed by identifying Ly6C+ cells by 
immunohistochemistry. ALT and fibrosis were also reduced. 
 
Baeck and colleagues (Baeck et al., 2012) used an L-RNA oligonucleotide (or Speigelmer) to 
inhibit CCL2, with a non-functional molecule as a control. In mice fed a methionine-choline 
deficient (MCD) diet to induce steatohepatitis, inhibition of CCL2 throughout the dietary 
period reduced accumulation of hepatic fat and infiltration of the liver by F4/80+CD11b+ 
macrophages, without any difference in measures of fibrosis. Therapeutic application of the 
L-RNA olignonucleotide for the final two weeks of an eight-week experiment also reduced 
fat accumulation. 
 
CCR9 
Chemokine-C-receptor 9 (CCR9) is a chemokine receptor with a single ligand, CCL25, in 
both human and mouse (Zaballos et al., 1999). CCR9 expression defines a population of gut-
homing T lymphocytes (Johansson-Lindbom et al., 2003), that migrate to the small bowel 
epithelium in response to locally expressed CCL25 (Svensson et al., 2002, Johansson-
Lindbom et al., 2003) and a population of thymocytes that use CCR9 to enter the thymus. 
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Pro-inflammatory myeloid cells expressing CCR9 have been reported in inflammatory bowel 
disease (Linton et al., 2012) and rheumatoid arthritis (Schmutz et al., 2010) in humans.  
 
CCR9+ macrophages have recently been reported as playing a key role in a mouse model of 
acute liver injury (Nakamoto et al., 2012). In concanavalin A (ConA) induced hepatitis, 
CCR9+ macrophages were increased in number in injured liver tissue, expressed TNFα and 
induced differentiation of naïve CD4 T-cells towards a Th1 phenotype. In CCR9-/- mice 
adoptive transfer of CCR9+ macrophages from wild type mice was required for hepatitis to 
occur after ConA administration. In peripheral blood samples from four human subjects with 
acute liver injury (due to hepatitis B in two patients, and autoimmune hepatitis in two 
patients) CCR9 was up regulated on CD14+CD16+ macrophages, compared to chronic liver 
injury or healthy controls. The same group went on to show that CCR9+ macrophages could 
activate hepatic stellate cells and promote fibrosis in acute and chronic liver injury in mice 
(Chu et al., 2013). 
 
Chemokines are over-expressed in acute liver failure: serum concentration and liver 
expression of CCL2, CCL3, CCL4 and CCL5 were increased in human fulminant hepatic 
failure (26 cases predominantly due to viral hepatitis) compared to healthy controls and also 
chronic liver disease (Leifeld et al., 2003). Antoniades et al showed that CCL2 and CCL3 are 
increased in paracetamol-induced acute liver injury, and associated with necrotic areas 
within ALF liver tissue (Antoniades et al., 2012). Serum CXCL8, CXCL9 and CXCL10 are all 
markedly up regulated in human acute liver failure (Marques et al., 2012) (Tuncer et al., 
2013). 
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CXCR6 
CXCR6 was first described as a G-protein coupled receptor that functioned as a co-
receptor for simian immunodeficiency virus (SIV) and human immunodeficiency virus (HIV) 
(Deng et al., 1997, Liao et al., 1997, Loetscher et al., 1997). CXCL16 is the only ligand for 
CXCR6 (Matloubian et al., 2000). CXCR6 was subsequently shown to be a chemotactic 
receptor for several lymphocyte subsets and to be involved in the patrolling of NKT cells in 
the hepatic sinusoid (Geissmann et al., 2005). 
 
CXCR6+ lymphocytes are enriched in human liver tissue (Kim et al., 2001, Billerbeck et al., 
2010). CXCR6 is expressed by both CD4+ and CD8+ lymphocytes (Unutmaz et al., 2000, 
Kim et al., 2001, Boisvert et al., 2003, Tabata et al., 2005). CXCR6 expression on T 
lymphocytes is linked to markers indicating an effector, tissue-infiltrating phenotype 
(Northfield et al., 2008, Billerbeck et al., 2010). CXCR6 is highly expressed on CD56+ 
lymphoid cells, both NK and NKT cells (Campbell et al., 2001). CD14+ monocytes express 
CXCR6 (Ruth et al., 2006, Huang et al., 2008) as do neutrophils (Gaida et al., 2008). CXCL16 
is expressed in liver by hepatic vascular endothelium, hepatocytes and biliary epithelium 
(Heydtmann et al., 2005). Adhesion of human lymphocytes to biliary epithelial cells ex vivo is 
a CXCL16-dependent process (Heydtmann et al., 2005).  
 
CXCR6-/- mice exhibit a reduced number of NKT cells in sinusoids and are protected against 
T-cell mediated hepatitis, a phenomenon attributed to reduced NKT cell survival 
(Geissmann et al., 2005). In mice, preventing CXCL16/CXCR6 interactions with anti-
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CXCL16 antibodies reduced infiltration of CD3+ lymphocytes in BCG-mediated liver injury 
and protected against liver necrosis (Xu et al., 2005). More recent work (Wehr et al., 2013) 
found that CXCR6-/- mice demonstrated lower serum ALT and fewer infiltrating NKT cells 
compared to wild type mice in carbon tetrachloride-induced acute liver injury. In chronic 
liver injury, CXCR6-/- mice showed less fibrosis and reduced macrophage accumulation. The 
fibrotic response was restored when CXCR6+ NKT cells were adoptively transferred to 
CXCR6-/- mice. 
 
CXCR6 expression in cancer 
The direction of cell trafficking may be seen as the classical role of chemokines, but other 
roles are well reported particularly in embryology, angiogenesis and carcinogenesis (Horuk, 
1998, Bernardini et al., 2003, Spring et al., 2005, Lazennec and Richmond, 2010). CXCR6 is 
expressed in a variety of tumour cell lines and in tumour tissue, often associated with a 
more aggressive phenotype (Porta, 2012). Conversely, CXCR6 knockout mice show 
increased metastasis of melanoma cells to the liver that was ameliorated by activating NKT 
cells (Cullen et al., 2009).  
 
In liver disease, cirrhosis is often complicated by hepatocellular carcinoma (HCC). HCC 
specimens show higher protein expression of CXCR6 in tumour tissue compared to distal, 
non-cancerous liver tissue (Gao et al., 2012). This was variable, with particularly increased 
expression in tumours showing evidence of vascular invasion. In keeping with this CXCR6 
protein expression was inversely correlated with recurrence free survival. In hepatoma cell 
lines, knock down of CXCR6 and of CXCL16 reduced migration in a transwell assay. When 
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CXCR6 deficient hepatoma cells or control hepatoma cells were transplanted into nude 
mice, CXCR6 knockdown tumours grew more slowly. These effects were attributed to 
reduced membrane expression of caveolin-1 and β-catenin, analysed by western blotting. 
Although caveolin-1 is linked to cell cycle progression, no data were shown to describe cell 
proliferation although the authors report that no effects were seen. 
 
Hepatocyte expression of other CXC chemokine receptors has been documented 
(Hogaboam et al., 1999, Bone-Larson et al., 2001, Clarke et al., 2011). CXCR4 and its ligand 
CXCL12 have been reported to influence metastasis of hepatocellular carcinoma (Liu et al., 
2008). Other CXC-chemokine receptors have been implicated in hepatic regeneration 
including CXCR1 (Clarke et al., 2011) and CXCR2  (Hogaboam et  al., 1999, Bone-Larson et 
al., 2001) at least under some circumstances (Kuboki et al., 2008). 
 
Potential for therapeutic manipulation of chemokine system 
The chemokine system has been identified as amenable to pharmaceutical manipulation for 
many years. There has been some scepticism regarding this approach, and evidence of 
binding of multiple ligands to a single receptor that suggests redundancy within the 
chemokine system has been held as a particular barrier. This implies that inhibition of a 
single receptor or ligand may be ineffective if another ligand/receptor interaction will provide 
the same biological effect (Schall and Proudfoot, 2011). This does not reflect more nuanced 
differences in receptor behaviour after activation by different ligands, or differences in spatial 
or temporal expression of receptors (Corbisier et al., 2015). Indeed, drugs that target 
chemokine receptors have been approved for use: maraviroc is a CCR5 antagonist used in 
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the treatment of HIV, and a CXCR4 antagonist plerixafor has recently been approved for 
the mobilisation of haematopoietic stem cells from bone marrow. 
 
In the field of liver medicine, in addition to experiments in pre-clinical animal models with 
pharmaceutical agents targeting the chemokine system, described above, novel agents are 
being studied in early-phase human trials. The efficacy of CCR2 inhibition in humans has 
been studied in various diseases. Whilst there has been considerable interest in targeting 
CCR2 in the treatment of disease associated with insulin resistance (Pirow, 2012, Di 
Prospero et al., 2014). Cencriviroc, a dual CCR2/CCR5 inhibitor initially examined in HIV 
infection is being used in NAFLD (02217475, 2014).  
 
Aims of project 
Liver disease is common in the UK but has few therapeutic options. A common feature of 
most acute and chronic liver disease is the infiltration of liver tissue by inflammatory cells, a 
process mediated in part by chemokines and their receptors. Non-haematopoietic cells also 
express chemokine receptors and signalling through CXC receptors on hepatocytes may be 
protective in injury but pathological in the context of hepatocellular carcinoma. The 
chemokine system is thus implicated in the development of many liver diseases. It is complex 
system but offers potential targets for the treatment of liver disease. The aim of this project 
was to understand the role of chemokines and their receptors in pathogenesis of liver 
disease. In view of previous reports from our laboratory and others, the objectives were to 
focus on chemokine receptors CCR2, CCR9 and CXCR6. These chemokine receptors were 
investigated on the basis of existing data from our group and others suggesting they were 
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involved in the aetiology of liver disease, as discussed in detail above. Where possible disease 
processes were modelled in mice to evaluate the effect of inhibition or knock out of 
chemokine receptors on disease.  
CHAPTER 2: Methods 
 
Human tissue  
Human liver tissue used for experiments was collected at University Hospitals Birmingham 
NHS Foundation Trust (UHB). All liver tissue was obtained through the hepatobiliary 
surgical programme where research Ethics Committee approval has been granted for the 
consensual use of resected or explanted liver tissue. Experimental data were related to 
clinical parameters collected routinely through clinical practice at UHB. 
 
Blood obtained through the haemochromatosis venesection programme at University 
Hospitals Birmingham, or taken from patients at the time of transplantation was used with 
appropriate informed consent and research ethics approval. Serum from patients with 
NAFLD was obtained through the LEAN and NOBLES studies. LEAN is a randomised 
controlled trial of liraglutide in patients with NAFLD (Armstrong et al., 2013), where the 
serum samples used were taken before randomisation. NOBLES are an observational study 
of patients with liver disease that aims to correlate serum markers with histological evidence 
of fibrosis. In both cases serum was separated from whole blood samples and frozen to -
80°C within 1 hour of collection. Collaborators at Kings College, London in accordance with 
local ethics approval, obtained serum from patients with ALF. Control samples were 
sourced from healthy volunteers with informed consent. 
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Isolation and culture of non-parenchymal cells 
Human sinusoidal endothelial cells (HSEC) and biliary epithelial cells (BEC) were isolated 
from explanted human livers by Mrs Gill Muirhead at the Centre for Liver Research. Liver 
was finely chopped before being digested with collagenase and strained through sterile mesh. 
The resulting homogenate, after washing, was layered over 33% and 77% percoll gradients 
and centrifuged at 2000rpm for 25 minutes. The band of cells at the interface of the 33% and 
77% percoll was removed and washed. HSEC and BEC were separated by magnetic bead 
separation using antibodies to human embryonic antigen (HEA) to separate HSEC.  
 
Hepatoma cell lines were used to investigate hepatocyte function. HuH-7.5 and HepG2 cells 
were used from cell lines maintained in the Centre for Liver Research. Primary hepatocytes 
were purchased from Bioreclaimation. They were delivered in aliquots stored in liquid 
nitrogen and immediately transferred to a freezer at -80°C. These hepatocytes were 
defrosted and cultured in collagen-coated T25 Falcon flasks, with a 24-hour period between 
defrosting and any experimental procedure.  
 
Media for culture 
The media used to culture various cell types are detailed in table 2.1. These media were 
supplemented for some experiments, described in the relevant chapter.  Cells were serum-
starved before experiments with additional factors to allow for a pure effect of that factor to 
be analysed. In this case, serum without the addition of bovine or human serum or growth 
factors was used. 
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Culture medium Constituents per 200mL 
BEC medium √mL Dulbeco’s Modified Eagle’s Medium (DMEM)  
90mL Hams F12 nutrient mixture 
2mL 0.2M penicillin/streptomycin 
2mL (2μg/mL) hydrocortisone 
2ml (1μg/mL) cholera toxin 
2mL Tri-ido-thyronine 
20uL hepatocyte growth factor (HGF) (100μg/mL) 
248μL insulin 
Hepatoma/hepatocyte medium 180mL DMEM 
20uL heat inactivated bovine serum albumin (BSA) 
HSEC medium 177.92 mL endothelium serum free medium 
20mL heat inactivated human serum (HIHS) 
2mL 0.2M penicillin/streptomycin 
40μL(50μg/mL) vascular endothelium growth factor 
(VEGF) 
40μL (50μg/mL) hepatocyte growth factor 
Lymphocyte medium 178mL Roswell Park Memorial Institute medium 
20mL heat inactivated BSA 
2mL 0.2M penicillin/streptomycin 
Table 2.1: media used for cell culture 
Base media (DMEM, RPMI, SFM) were obtained from Life Technologies (California, USA), and 
growth factors from Peprotech (New Jersey, USA). BSA and HIHS, hydrocortisone, cholera toxin, tri-
ido-thyronine, insulin and penicillin/streptomycin were obtained from Sigma-Aldrich (Missouri, USA) 
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Immunohistochemistry 
Frozen sections 
Liver tissue from mice or humans was snap frozen in liquid nitrogen, protected either in 
plastic tubes (mice tissue) or foil boats (human tissue). After snap freezing, tissue was stored 
at -80°C. Frozen blocks were cut into 8μm sections, mounted onto glass slides, and fixed by 
immersion in acetone for 5 minutes. Slides were stored at -20°c wrapped in foil until use. 
Paraffin embedded sections 
Liver tissue from mice or humans was placed in formalin until use. Tissue was then 
embedded in paraffin, cut into 8μm sections and mounted onto glass slides.  
Immunohistochemistry procedure 
Frozen sections were defrosted for ten minutes at room temperature before use. 
Endogenous peroxidase activity was quenched by 1% hydrogen peroxidase (Sigma Aldrich, 
Missouri, USA). Non-specific binding was blocked with 2% casein solution for ten minutes 
and 1% horse serum for 20 minutes. After twice washing in Tris-buffered saline (TBS) for 5 
minutes, primary antibodies were diluted to concentrations detailed in table 7.1 and slides 
incubated at 4°c for 12 hours with rocking. After washing slides three times in TBS for five 
minutes each time, secondary antibodies (IMMpress kits, Vector Labs, USA) were applied for 
1 hour at room temperature.  Slides were washed in TBS for five minutes and NovaRed 
(Vector Labs, USA) applied as a chromogen. Slides were incubated in Novared for 2 minutes 
and then washed in tap water. Mayer’s haematoxylin was used as a counterstain, and slides 
were mounted with Immunomount. 
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Paraffin embedded sections were rehydrated by immersion in clearene (6 minutes) and 
ethanol (4 minutes). Endogenous peroxidase activity was quenched by immersion in 
hydrogen peroxidase. Antigen retrieval was performed by incubating slides in high pH 
antigen retrieval solution (Vector) at 65°C overnight (approximately 16 hours). Sections 
were washed in TBS, and non-specific binding blocked with casein and horse serum as above. 
After twice washing in TBS for 5 minutes, primary antibodies were diluted to concentrations 
detailed in table 2.2 and slides incubated at 4°c for 12 hours. After washing slides three 
times in TBS, secondary antibodies (IMMpress kits, Vector Labs, USA) were applied for 1 
hour at room temperature. NovaRed was applied for 2 minutes before washing in tap water 
and counterstaining in filtered Mayer’s haematoxylin for 30 seconds. Slides were dehydrated 
through alcohol (4 minutes incubation) and clearene (6 minutes incubation), and mounted 
with DPX mountant. Sections were visualised on an Axioskop 40 microscope. 
 
For fluorescent staining, the same process was followed as per staining of paraffin-embedded 
slides described above. Secondary antibodies were conjugated to fluorochromes as noted in 
table 2.2. After incubation for one hour at room temperature with secondary antibodies 
diluted in TBS with 0.05% TWEEN-20, slides were washed three times in TBS. 4',6-
Diamidine-2'-phenylindole dihydrochloride (DAPI) diluted 1:1000 in water was added to 
each slide for 1 minute before washing in water, and then filtered Meyer’s haematoxylin 
added for 30 seconds to reduce background fluorescence. Slides were dehydrated with 
alcohol and clearene, and mounted with ProLong Gold Anti-Fade (Life Technologies, 
California, USA). Slides were kept in the dark at 4oC prior to imaging with confocal 
microscopy. Sections were visualised with an Axiovert UV confocal microscope. 
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Antibody Isotype Supplier Catalogue 
number 
Clone Concentration 
used 
Anti-human 
CXCL16 
Polyclonal 
Goat IgG 
R&D systems AF976  10μg/mL 
Anti-human 
CXCR6 
Mouse 
IgG2b 
R&D systems MAB699 56811 10μg/mL 
Anti-human 
CK18 
Mouse IgG1 Dako M7010 DC10 8μg/mL 
Anti-mouse-
Alexa Fluor 
488 
Goat IgG Life 
Technologies 
A28175  2μg/mL 
Anti-mouse 
Alexa Flour 
647 
Rabbit IgG Life 
Technologies 
A21239  2μg/mL 
Goat IgG isotype control R&D systems AB-108-C  10μg/mL 
Mouse IgG2b isotype 
control 
Dako X0944  10μg/mL 
Mouse IgG1 isotype control R&D systems MAB002  8μg/mL 
 
Table 2.2 antibodies used in immunohistochemistry procedures  
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Isolation of RNA  
Isolation of RNA from whole tissue 
RNA was isolated by homogenizing human or murine liver tissue in Trizol (Life 
Technologies, California, USA). Chloroform was added and samples centrifuged at top speed 
in a microfuge for 15 minutes. The upper aqueous layer was removed and the lower layer 
stored for protein retrieval. Isopropanol was added to the aqueous layer and samples 
centrifuged at 12,000rpm for 15 minutes. The resulting RNA pellet was washed in 70% 
ethanol and re-suspended in nuclease free water. Concentration of RNA was measured with 
a Nanophotometer (Implen, Germany) three times and a mean reading recorded. Purity was 
noted with 260/280 nm ratio. 
 
Isolation of RNA from cell pellets 
Qiashredder (Qiagen, USA) was used to disrupt cell pellets and RNA isolated from the 
resulting homogenate using Qiagen RNeasy kits (Qiagen, USA) according to the 
manufacturer’s instructions. The concentration of RNA was measured using a 
Nanophotometer (Implen, Germany). Purity was noted with 260/280 nm ratio.  
 
Synthesis of cDNA 
cDNA was prepared from RNA using Taqman reagents (Life Technologies, California, USA) 
according to the manufacturer’s instructions: briefly, 2 μL of RNA was combined with 
random hexamers,  reverse transcriptase, RNase inhibitor, magnesium chloride and a buffer 
solution. This mixture was heated to 25°C for 10 minutes, 37°C for 30 minutes, 95°C for 5 
minutes and then cooled to 4°C. cDNA was then stored at -20°C until use. 
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Polymerase Chain Reaction 
Probe/primer mixes for genes of interest and appropriate controls were obtained from 
Taqman (Life Technologies, California, USA) and made up with Taqman reagents. A 96 well 
plate was used for reactions, with wells containing cDNA, primer/probe mix (where FAM 
was used for the probe)(table 2.5) and Taqman mastermix. Three replicates were used for 
the gene of interest and three for housekeeping gene. A water control was used in each 
experiment, where water was used in place of cDNA. In addition, a reverse-transcriptase 
control was used, where cDNA synthesis was performed without reverse transcriptase and 
the resulting, presumed cDNA free, control used to rule out the presence of genomic 
cDNA in the samples.  
 
PCR experiments were performed using a Roche Lightcycler 480 machine with cycling 
parameters: 2 minutes at 50°C, 10 minutes at 95oC, followed by 40 cycles of 10 seconds at 
95°C and 1 minute at 60°C. A single quantification measurement was taken during each 
cycle.   
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Gene Catalogue number 
Human 
CCL2 Hs00234140_m1 
CCL25 Hs00608373_m1 
CXCL16 Hs00222859_m1 
CXCR6 Hs01890898_s1 
18S Hs03003631_g1 
Mouse 
Col1a Mm00801666_g1 
Acta-2 Mm00725412_s1 
18S Mm03928990_g1 
B-actin Mm00607939_s1 
 
Table 2.3: Taqman primers used in RT-qPCR reactions 
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PCR gene expression array  
RNA isolated from primary hepatocytes was converted to cDNA using methodology 
described above. Gene expression for a range of signalling pathways was analysed using a 
gene expression array (Qiagen, Netherlands). cDNA (150uL for each well) was added to 
SYBR green mastermix (Qiagen) and RNA free water was added to each well of the 96 well 
plate. Gene expression was analysed using a Roche Lightcycler 480 machine with the 
following settings: 95°c 10 minutes, followed by 45 cycles of 15 seconds at 95°c and 1 
minute at 60°c. Data were analysed using online tools available from Qiagen to identify genes 
that were up-regulated or down-regulated between samples. Housekeeping genes were 
included in the array and the analysis software automatically normalized gene expression 
between samples.  
 
Enzyme Linked Immunosorbent Assays (ELISA) 
Analysis of human serum was performed using commercially available ELISA kits. Serum 
concentration of CCL25 was measured using a DuoSet ELISA kit from R&D Systems (Cat. 
No. DY334, R&D systems, Minnesota, US). Serum CCL2 concentration and CXCL16 
concentration were measured using R&D Systems Quantikine kits (Minneapolis, USA) 
(catalogue numbers PDCP00 and DCX160 respectively). In each case ELISA was performed 
in accordance with manufacturer’s instructions. Recombinant human chemokines were used 
as a positive control (Peprotech, New Jersey USA). Samples were diluted in sample buffer 
1:4 and run in duplicate. A standard curve was generated from known concentrations of 
recombinant chemokine and sample values interpolated from this curve. 
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Isolation of leukocytes  
Isolation of leukocytes from blood 
Whole blood was mixed with an equal volume of PBS. Thirty mL of this mixture was layered 
over 20 mL of Lympholyte (CedarLane Labs, Canada) and centrifuged at 2000rpm/870g for 
25 minutes. The resulting mononuclear cell layer was removed and washed a further three 
times suspending in RPMI and centrigfuing at 2000rpm for 5 minutes. Leukocytes were 
either used immediately or kept suspended in RPMI with 10% FCS at 37°c until use.  
Isolation of leukocytes from human liver tissue 
Liver tissue was dissociated mechanically using a GentleMACS and C-tubes (using program 
Spleen_01_01; Miltenyi, Germany) and the resulting homogenate passed through a fine mesh 
(70 micron pores). After washing three - five times with PBS (until a clear supernatant was 
achieved), 30mL of liver tissue homogenate suspended in PBS was layered over 20mL of 
Lympholyte (CedarLane Labs, Canada), and centrifuged at 2000rpm/870g for 25 minutes. 
The resulting mononuclear cell layer was removed and washed a further three times in PBS. 
Isolation of leukocytes from murine liver tissue 
To isolate leukocytes from tissue, mice  CO2 inhalation  
or terminal anaesthesia
and organs perfused with sterile PBS via left ventricular puncture before removal of 
liver or adipose tissue. These samples were immediately placed into ice-cold RPMI. After 
weighing, tissue was homogenized and passed through a 100um mesh.  
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Flow Cytometry analysis of leukocytes 
Human cells 
Isolated immune cells were suspended in 100μL at 1x106 cells/ml in MACS buffer (PBS 
containing 2% FCS and 1mM EDTA) and incubated with antibodies as shown in table 2.6. 
After incubation for 20 minutes at room temperature, cells were washed and re-suspended 
in PBS and analysed by flow cytometry using a Beckman Coulter Cyan. Cells stained with 
single colours were analysed for compensation and isotype controls were used to define the 
negative populations.  
Mouse cells 
The liver homogenate was washed and re-suspended at 100mg/mL in cold PBS. Next, 100 μL 
of this suspension was incubated with Fc-block (Trustain, Biolegend, California USA) for 20 
minutes at room temperature before incubation with antibodies (table 2.7) in PBS for 30 
minutes at room temperature. After a further washing step with cold PBS, the cell pellet was 
re-suspended in 200μL of cold PBS and a dye to detect live cells added (Invitrogen Live/Dead 
red dye, used at 1:1000 as per manufacturer’s instructions). The sample was incubated for a 
further 15 minutes before a final wash in cold PBS. The cell pellet was re-suspended in 
200μL and filtered through a 70μm mesh. Flow cytometry was performed with a BD 
FACSCanto using BD Diva software and analysed with FlowJo V10. 
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Antibody Fluorochrome Volume 
used per 
100,000 cells 
Isotype Catalogue 
number 
Clone 
CD3 FITC 5 μL Mouse 
IgG2a 
Biolegend 
300306 
HIT3a 
CD3 APC 5 μL Mouse 
IgG1 
R&D Systems 
FAB100a 
UCHT1 
CXCR6 PE 5 μL Mouse 
IgG2a 
Biolegend 
356004 
K041E5 
CCR2 PE 2.5 μL Mouse 
IgG2a 
Biolegend 
357205 
K036C2 
CD8 PerCP-Cy5.5 20 μL Mouse 
IgG1 
BD bioscience 
341050 
SK1 
CD56 V450 5 μL Mouse 
IgG1 
BD bioscience 
560360 
B159 
CD4 V500 5 μL Mouse 
IgG1 
BD bioscience 
560768 
RPA-T4 
CD16 V500 5 μL Mouse 
IgG1 
BD bioscience 
561394 
3G8 
NKp30 APC 5 μL Mouse 
IgG1 
Biolegend 
325209 
P30-15 
Annexin 
V 
APC 5 μL  Biolegend 
640920 
 
7AAD  5 μL  Biolegend 
420404 
 
CD45 FITC 5 μL Mouse 
IgG1 
Biolegend 
304005 
H130 
CD14 V450 5 μL Mouse 
IgG2b 
BD bioscience 
560349 
MΦP9 
CD16 V500 5 μL Mouse 
IgG1 
BD bioscience 
561394 
3G8 
CD11c PE-Cy7 5 μL Mouse 
IgG1 
Biolegend 
337215 
Bu15 
CD206 APC 5 μL Mouse 
IgG1 
Biolegend 
321109 
15-2 
 
Table 2.4: Anti-human antibodies used for flow cytometry  
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Antibody Fluorochrome Dilution 
used  
(for 
100,000 
cells) 
Isotype Catalogue 
number 
Clone 
CD45.2 FITC 1:200 Mouse  
IgG2a, κ 
BD 
Biosciences  
553772 
104 
CD45.2 eF450 1:200 Mouse  
IgG2a, κ 
eBioScience  
48-0454-82 
104 
CD11b PE 1:100 Rat  
IgG2b 
BD 
Biosciences  
557397 
M1/70 
CD11b Alexafluor 700 1:200 Mouse  
IgG2b, 
κ 
eBioScience  
56-0112-82 
M1/70 
CD11c APC 1:100 Ar Ham  
IgG 1 
λ2 
BD 
biosciences  
558079 
HL3 
CD11c PerCP-Cy5.5 1:100 Ar Ham  
IgG 
eBioscience  
45-0114-82 
N418 
Ly6C   PE-Cy7 1:100 Rat  
IgG2b, 
κ 
BD 
Biosciences  
552985 
RB68C5 
Ly6G FITC 1:100 Rat  
IgG2b, 
κ 
eBioScience  
11-5931-82 
RB6-
8C5 
CCR9 PE 1:200 Mouse  
IgG2a, 
eBioscience  
12-1991-82 
CW-1.2 
F4/80 BV 605 1:200 Rat  
IgG2a, κ 
Biolegend  
123137 
BM8 
 
Table 2.5: Anti-mouse antibodies used for flow cytometry  
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Apoptosis assay 
After isolation from liver, leukocytes were depleted of monocytes by plastic adherence to a 
T75 flask (BD falcon) for 1 hour. Non-adherent cells were washed and re-suspended in 
1%FCS in Roswell Park Memorial Institute media (RPMI) and varying concentrations of 
recombinant CXCL16 (Peprotech, New Jersey USA). Dead and apoptotic cells were 
identified using flow cytometry with 7AAD (Biolegend, California USA) and APC anti-
Annexin V (Biolegend) respectively.  
Proliferation assays 
Lymphocytes 
Immune cells were isolated as described above and monocytes depleted by plastic adhesion. 
Lymphocytes were washed and stained with 10μM CFSE Celltrace (Life Technologies, 
California, USA) at 37oC for 30 minutes. Five volumes of ice-cold media was added to 
quench staining and cells were incubated on ice for 5 minutes. Cells were then re-suspended 
at 2x106/ml in RPMI/10%FCS with varying concentrations of CXCL16. After 48 hours cells 
were washed again and stained for CD3, CD56 and 7AAD and analysed by flow cytometry 
as described above.  
Hepatoma Cell Lines 
Proliferation of hepatoma cells (HuH7 and HepG2) was assessed using Hoescht staining of 
DNA, and by FACS analysis using Celltrace (Life Technologies), as described above.  
 
To assess proliferation with Hoescht dye, 100,000 hepatoma cells were added into each well 
of 24 well plate and left for to adhere 24 hours. Varying concentrations of CXCL16 were 
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then added to the remaining wells and measurements taken every 24 hours. For 
measurement of proliferation, cells were fixed with ethanol for 5 minutes and then 
incubated with Hoescht dye at a concentration of 2.5ug/ml for 5 minutes. After being 
washed three times with PBS, emission at 460nm with excitation at 560nm was measured 
using a Biotek plate reader. A baseline reading was taken by fixing adherent cells in 4 wells 
after 24 hours adherence step. Results were normalized to baseline assays. 
 
Proliferation was assessed using Celltrace by incubating hepatoma cells with 10uM CFSE 
Celltrace at 37oC for 30 minutes. Five volumes of ice-cold media was added to quench 
staining and cells were incubated on ice for 5 minutes. After washing, cells were seeded into 
12 well plates with varying concentrations of recombinant CXCL16 (Peprotech, New Jersey 
USA). After 5 days cells were trypsinised and washed before re-suspension in MACS buffer 
and analysis by flow cytometry.  
 
Flow Based Adhesion Assay 
Slides with six microchannels (Ibidi, Germany) were coated with rat-tail collagen (RTC) 
diluted at 1:100 in sterile water, by adding RTC to each channel for thirty minutes and then 
removing the remainder.  HSEC isolated from explanted livers with a variety of liver diseases 
and cultured up to 3 passages, were suspended at 1x 106ml,  and cultured in the channels at 
37oC/5% CO2 until confluent, then stimulated with TNFα and IFNγ (Peprotech, New Jersey, 
USA, both10ng/mL) for 24 hours.  
 
Isolated mononuclear cells were incubated in a T25 flask for at least an hour to deplete 
monocytes. Prior to initiating the flow assay lymphocytes were pretreated with either 10uM 
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CXCR6 inhibitor, 10μM DMSO or 40ng/mL sCXCL16 for 20 minutes. For CXCR6 blocking 
experiments, lymphocytes were incubated with a small molecule inhibitor of CXCR6 
(C0335224-4B, ) dissolved in Dimethyl sulfoxide 
(DMSO) or DMSO alone, at 10uM for 20 minutes.  Lymphocytes were then washed, re-
suspended to 0.5x106 cells/mL in lymphocyte media and flowed over confluent HSEC at a 
rate of 0.28ml/minute to mimic shear stress of the hepatic sinusoid. Images were recorded 
for two minutes whilst lymphocytes were flowing over HSEC. After 4 minutes, media 
without lymphocytes was flowed at the same rate, and then further images recorded for 2 
minutes. Images were analysed with regard to numbers of cells which were rolling, static, 
shape changing or transmigrated. Numbers of cells counted were normalised to number of 
cells/mm2/cells infused using the formula (number cells / (flow * bolus * area)) * (1 / # 
million cells). 
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Figure 2.1: flow assay system 
Isolated hepatic endothelial cells are grown to confluence in a monolayer in a microslide. 
Lymphocytes suspended at a known concentration are flowed at physiological shear rate across this 
endothelial monolayer by a syringe and syringe driver. The interaction of lymphocytes and 
endothelium is visualised in real time and recorded to DVD for analysis (Lalor et al., 1997).  
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Animal experiments 
Mouse experiments were performed or at  
. In both locations animals were housed according to local and national 
standards. In the UK and in the US, animal facilities were maintained at 23°c with twelve 
hour light/dark cycles. Male mice were used for all experiments, and were housed in the 
research locations for at least three days after delivery before investigations were started.  
 
Animal work in the UK was performed under the auspices of a personal home office licence 
and under project licences held by senior investigators  
 
 
Unless otherwise stated, mouse experiments used male C57/Black 6 (C57/Bl6) mice bred in 
controlled clean conditions, aged 6-8 week at the start of experiments. C57/Bl6 mice were 
obtained from .  
 
C57/Bl6 mice in which the Cxcr6 gene was replaced with a gene expressing green fluorescent 
protein (GFP) were used in mouse experiments that analysed the role of CXCR6 in liver 
injury, were purchased from . Animals were genotyped before 
experiments using end-point PCR. 
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Animal models of NAFLD 
MCD diet 
Feeding mice a diet deficient in methionine and choline (methionine-choline deficient diet, 
MCD diet) produces steatosis through increased hepatic uptake of fatty acids and decreased 
lipid secretion (Rinella et al., 2008). Methionine and choline are important precursors of 
phosphatidylcholine, the principal phospholipid comprising the outer coat of VLDL particles 
(3). When these nutrients are in short supply, VLDL production is impaired and triglycerides 
accumulate in hepatocytes (2, 4).  Inflammation develops through oxidative stress(Anstee 
and Goldin, 2006) leading to steatohepatitis. Weight loss is a major feature of this diet, in 
contrast to human NAFLD Mice were fed MCD diet for a period of 5-6 weeks and
when 30% of body weight was lost. A control group of littermates were fed a control diet 
(sufficient in methionine and choline) for the duration of the experiment, without 
intervention. MCD and control diet were obtained from    
High fat diet 
A high fat diet (HFD) in which 60% of calories are obtained from fat was used to produce a 
model of steatohepatitis akin to human disease. Male mice were given HFD for 16 weeks. A 
control group of littermates were fed control diet (10% of calories from fat) for the duration 
of the experiment, without intervention. HFD and control diet were obtained from
 
 
Animal models of acute liver injury 
Acute liver injury was modelled in mice by using Carbon tetrachloride (CCl4) or 
paracetamol. 
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Acute carbon tetrachloride liver injury 
CCl4 was diluted 1:4 in corn oil (Sigma-Aldrich, Missouri USA) and a single dose of 1 ml/kg 
was administered to mice by intra-peritoneal (IP) injection. CCl4 was handled and stored in a 
fume hood, and animal injections also performed in a fume hood. Corn oil without CCl4 was 
used as control. 
 
Paracetamol-induced liver injury 
Paracetamol (Sigma-Aldrich, Missouri USA) was dissolved in sterile PBS at 10mg/mL by 
warming to 30°C with sonication. After initial experiments with non-fasted mice gave wildly 
divergent results, mice were fasted overnight before paracetamol administration to deplete 
hepatic glutathione and exaggerate liver injury. Paracetamol was administered by IP injection. 
Sterile PBS alone was used for sham injection. A maximum volume of 1mL was required.  
 
Chemokine receptor antagonism 
Small molecule inhibitors of chemokine receptors were manufactured by  
. Small molecule inhibitors of CCR2 (CCX872) or CCR9 (CCX507) 
were dissolved in 1% hydroxypropyl methylcellulose (HPMC) and administered to mice by 
subcutaneous injection. CCX872 was given at a dose of 30mg/kg daily. CCX507 was used at 
a dose of 30mg/kg as a single injection.  An equivalent volume of 1% HPMC was used in 
control mice. A maximum volume of 350uL was used. 
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Analysis of animal experiments 
 
 
 Blood 
sampling and perfusion of organs with PBS were carried out through cardiac puncture. Blood 
was placed into tubes containing citrate or EDTA for isolation of serum or plasma 
respectively. After centrifuging in the tubes at 2000rpm/870g for ten minutes, serum or 
plasma were frozen at -20°c for later analysis. 
 
Laparotomy was performed and liver, subcutaneous fat, and omental fat removed. Liver 
tissue was divided into individual lobes. Some were placed in cold RPMI for subsequent 
isolation of immune cells, some snap frozen with liquid nitrogen and a lobe placed in formalin 
for subsequent embedding in paraffin. Omental fat samples were placed into ice cold RPMI 
for isolation of immune cells or snap frozen. Subcutaneous fat samples were snap frozen.  
 
Triglyceride content of liver tissue 
Triglyceride content of murine liver tissue was assessed using a commercially available 
colorimetric assay kit (Cayman Chemical Company, Ann Arbor MI USA) according to the 
manufacturer’s instructions. In short, 400mg of liver tissue was suspended in 2ml of assay 
diluent and homogenised. 10ul of homogenate was added to wells of a 96 well plate, each 
sample was assayed in triplicate. Triglycerides were enzymatically hydrolysed to free fatty 
acids and glycerol using the supplied enzyme mixture. After 15 minutes incubation colour 
change was measured with a plate reader (Synergy HT, BioTek, Vermont, USA) measuring 
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absorbance at 540nm. A standard curve was generated by assaying known concentrations of 
triglyceride on the same plate as the samples, and the triglyceride concentration of samples 
interpolated from this curve. Triglyceride content of liver tissue was expressed as milligram 
per gram of liver tissue.  
 
Glycaemic control 
Glucose metabolism in mice was assessed with insulin and glucose challenge experiments. 
Insulin challenge was performed by administering 0.75U/kg of insulin to non-fasted mice via 
intra-peritoneal injection. Plasma glucose was measured with an AccuCheck glucometer 
(Roche, Basel, Switzerland) using a drop of blood from a tail vein. Plasma glucose was 
measured at baseline and 15, 30, 60, 90 and 120 minutes after insulin.  
 
Mice were fasted overnight before glucose tolerance tests. Glucose was administered at 
2g/kg of glucose (as 45% glucose solution), given by gastric lavage. Plasma glucose was 
measured baseline and 15, 30, 60, 90 and 120 minutes after administration of glucose using 
an AccuCheck glucometer and drops of blood from tail vein. 
 
Statistical Analysis 
Averages are expressed as mean and standard error of mean (SEM) for normally expressed 
data, and median and interquartile range (IQR) for skewed data. Normality was assessed 
with the Kolmogorov-Smirnov test. Normally distributed data were compared between 
groups with student’s t-test, and the Mann-Whitney test used for skewed data. Variance 
across multiple groups, for example over a range of concentrations was analysed with one-
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way analysis of variance (ANOVA). Variance between multiple groups across more than one 
variable, for example lymphocyte subsets was analysed with two-way ANOVA. Survival 
analysis was analysed by Kaplan-Meier curves with p values assessed with log-rank test. 
Median time to death in animals that died was also calculated.  
 
Data were analysed using Prism version 5 (Graphpad Inc., California, USA). 
CHAPTER 3: The role of CCR2 in Human Non-Alcoholic 
Fatty Liver Disease 
 
Non-alcoholic fatty liver disease (NAFLD) is common: hepatic steatosis is present in up to 
one-third of individuals (Browning et al., 2004) whilst the more severe non-alcoholic 
steatohepatitis (NASH) is seen in approximately 10% (Williams et al., 2011).  
 
Obesity-associated macrophage infiltration of adipose and hepatic tissue is mediated by 
CCR2 (Kanda et al., 2006, Weisberg et al., 2006, Lumeng et al., 2007, Obstfeld et al., 2010). 
Experiments in mice confirm that obesity up regulates CCL2 (Kirovski et al., 2011). Absent 
or reduced CCL2 activity reduces hepatic steatosis (Kanda et al., 2006) (Weisberg et al., 
2006, Nio et al., 2012) and inflammation of liver tissue (Obstfeld et al., 2010, Miura et al., 
2012). A central role for the CCR2/CCL2 axis has been suggested in human NAFLD 
(Haukeland et al., 2006, Kirovski et al., 2011).  
 
The CCR2/CCL2 axis has been targeted with a variety of pharmaceutical agents in animal 
models of fatty liver disease. These studies have demonstrated reduced disease activity when 
either CCR2 or CCL2 are targeted (Tamura et al., 2008, Yang et al., 2009, Miura et al., 2012) 
(Tamura et al., 2010)(Baeck et al., 2012) (Cynis et al., 2013)  
 
Despite a large amount of data describing a role for CCR2 and CCL2 in development of 
obesity and insulin resistance, this axis has not been investigated in depth in human NAFLD. I 
used ex vivo human samples to examine expression of CCL2 in human NAFLD and 
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correlated this with the expression of CCR2 on liver-infiltrating monocytes in healthy and 
diseased liver tissue.  
 
Expression of CCL2 in NAFLD 
Hepatic CCL2 gene expression is higher in liver tissue from patients with NASH  
To determine whether gene expression of CCL2 was altered in liver tissue of patients with 
NASH, RNA was isolated from normal liver (from hepatic resections of malignant lesions - 
uninvolved tissue distal to the tumour was used), or explanted liver with NASH cirrhosis, 
and subsequently transcribed to cDNA. CCL2 gene expression was analysed by quantitative 
real-time PCR (qRT-PCR) using 18S as a housekeeping gene. 18S has been shown to have 
lowest level of variability across stages of alcoholic liver disease (ALD) suggesting it is 
reliable as a housekeeping gene in steatohepatitis (Boujedidi et al., 2012). CCL2 gene 
expression was significantly up regulated in NASH cirrhosis (Mann Whitney test p=0.009) 
(figure 3.1). 
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Figure 3.1: CCL2 mRNA expression is elevated in patients with NASH  
RNA was isolated from normal liver (n=6) and NASH cirrhosis liver tissue (n=6). CCL2 gene 
expression was analysed by qRT-PCR, 18S was used as a housekeeping gene. CCL2 expression was 
normalised to overall median expression of CCL2 in normal liver. Line at median, boxes represent 
IQR and whiskers represent interquartile range. 
  
 52 
Serum concentration of CCL2 is increased in fatty liver disease  
After examining gene expression of CCL2, I measured CCL2 protein in serum by ELISA in 
individuals with biopsy-proven NAFLD (n=20), PBC (n=5) or healthy volunteers (n=10). 
Serum CCL2 concentration was significantly higher in patients with NAFLD compared to 
healthy controls (median 305.1pg/ml (IQR 211.8 – 385.7) vs. 224.7 (105.2 – 255.4), Mann-
Whitney test p=0.021), and individuals with PBC (median 88.67 pg/ml, (IQR 35.9 – 168.5, 
Mann-Whitney test p=0.002) (figure 3.2).  This is consistent with previous reports in 
NAFLD (Haukeland et al., 2006, Kirovski et al., 2011). 
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Figure 3.2: Increased serum CCL2 in NAFLD 
Serum CCL2 concentration in healthy volunteers (n=10) and patients with PBC (5) or NAFLD 
(n=20) was measured by ELISA. *p<0.05, **p<0.01 by Mann Whitney test. Each point represents 
a single patient sample, data are shown with a line at the median and whiskers represent IQR. 
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Serum CCL2 in patients with NAFLD  
 To investigate association between serum CCL2 concentration and disease, the NOBLES 
study was used to provide a larger dataset of biopsy-proven NAFLD. The NOBLES study 
was set up by my colleague Dr Chris Corbett to collect serum from patients with a variety 
of liver diseases who were undergoing liver biopsy, in order to assess serum markers of liver 
fibrosis and inflammation. All patients undergoing routine liver biopsy at University Hospitals 
Birmingham were invited to take part in the NOBLES study. Blood samples were taken two-
three hours prior to liver biopsy and serum was frozen at -80°C until analysis. Several 
putative markers of fibrosis were measured and compared to histologically confirmed 
fibrosis. Dr Chris Corbett collected serum samples and performed the ELISA experiments 
on these samples. I collected data regarding biopsy characteristics of the group of patients 
with NAFLD and analysed the association with serum CCL2 concentration. Characteristics 
of this group are shown in table 3.1. 
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Variable   
Age (years, median) 57 Range 20 - 67  
Gender (% female) 60  
BMI (kg/m2, median) 33.1 Range 24.5 - 49 
Platelets (x109/L, median) 200 93 – 367 
Aspartate aminotransferase 
(AST) (U/mL, median) 
36 15 -149 
Alanine transferase (ALT) 
(U/mL, median) 
51 14 - 172 
 
Table 3.1: characteristics of patients with NAFLD included in NOBLES study cohort 
(n=39) 
 
Fibrosis Inflammation 
Score Interpretation Criteria Score Interpretation 
0 No fibrosis Steatosis 
0 <5% 
1 5-33% 
2 >33% - 66% 
3 >66% 
1 
Perisinusoidal or periportal 
fibrosis 
Lobular 
inflammation 
0 
No foci of 
inflammation 
1 
< 2 foci per 
200x field 
2 2-4 foci 
3 >4 foci 
2 
Perisinusoidal and portal or 
periportal 
Ballooning 
0 
No ballooned 
hepatocytes 
1 
Few ballooned 
hepatocytes 
2 
Many 
ballooned 
hepatocytes 
3 Bridging fibrosis 
 
4 Cirrhosis 
 
Table 3.2 Histological grading of NAFLD (Kleiner et al., 2005) 
 
Liver biopsy samples are assessed using the Kleiner-Brunt system which gives a measure of the 
degree of fibrosis and inflammation.  
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NAFLD was assessed histologically using the NAFLD activity score (NAS) proposed by 
Kleiner and Brunt in 2005 (Kleiner et al., 2005), which grades inflammation from 0-8 
depending on assessment of steatosis, ballooning degeneration of hepatocytes and lobular 
inflammation. Under this classification fibrosis is staged from 0 (no fibrosis) to 4 (cirrhosis) 
(table 3.2).  Histological scoring was done by Professor Stefan Hubscher, Department of 
Pathology at University Hospitals Birmingham NHS Foundation Trust. 
 
Serum CCL2 concentration is not associated with body mass index but does correlate with 
insulin resistance 
Serum CCL2 concentration was not correlated with BMI (r2 0.063, p=0.122), whereas a 
positive correlation was seen between serum CCL2 and insulin resistance, measured by 
HbA1c (figure 3.3). This is reflects a difference between simple fat mass (i.e. body mass) 
and inflammation of fat causing insulin resistance and is consistent with CCL2 as a pro-
inflammatory chemokine in the metabolic syndrome. 
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Figure 3.3 Serum CCL2 concentration correlates with insulin resistance but not BMI in 
patients with NAFLD 
Serum concentration of CCL2 from patients with NAFLD in the NOBLES study was compared with 
A body mass index (n=39) and B insulin resistance, measured by HbA1c (n=32). No correlation 
was observed between CCL2 concentration and BMI, whereas a significant correlation was seen 
between CCL2 concentration and HbA1c.  
 
 
Figure 3.4 Serum CCL2 concentration correlates with inflammation but not fibrosis in 
NAFLD 
Serum CCL2 concentration from patients with NAFLD in the NOBLES study was compared with 
histological assessment of disease.  
 
A: CCL2 concentration was higher in patients with worse inflammation grade *one-way ANOVA 
p<0.05. Overall n=39: NAS 0- n=2; NAS 2-3 n=10; NAS 4-5 n=19, NAS 6-8 n=8. B: No 
association was seen between serum CCL2 concentration and fibrosis stage. Overall n=9  8: F0 n=5; 
F1 n=9; F2 n=4; F3 n=16: F4 n=5 
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Serum CCL2 concentration is associated with hepatic inflammation but not fibrosis 
Serum CCL2 concentration was higher in individuals with worse histological inflammation 
grade (one way ANOVA p=0.025) but not with fibrosis stage (one way ANOVA p=0.347) 
(figure 3.4), consistent with a previous study demonstrating a correlation between CCL2 
and serum ALT (Kirovski et al., 2011). When individual components of the NAS were 
considered, serum CCL2 concentration was associated with higher lobular inflammation 
score (one-way ANOVA p=0.043) but not with steatosis or hepatocyte ballooning (figure 
3.5). This is consistent with the known role of CCL2 as a chemo-attractant, with higher 
CCL2 expression leading to greater cellular infiltration into injured liver.  
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Figure 3.5 Serum CCL2 correlates with lobular inflammation in patients with NAFLD.  
Serum concentration of CCL2 from patients with NAFLD in the NOBLES study was compared to 
with individual components of NAS. Serum CCL2 was associated with A overall NAS score and B 
lobular inflammation, but not C steatosis or D hepatocyte ballooning *one way ANOVA p<0.05. 
Overall n=39:  
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Expression of CCR2 on immune cells in NAFLD 
In view of data showing up regulation of CCL2 in NAFLD and its correlation with 
inflammation grade, I went on to investigate expression of CCR2 in liver disease with a focus 
on NAFLD.  
 
CCR2 is predominantly expressed by CD14+CD16- monocytes 
Monocytes in humans can be classified on the basis of CD14 and CD16 expression (figure 
3.6) into classical CD14++CD16- monocytes that predominate in blood; non-classical CD14-
CD16++ monocytes that are expanded under inflammatory conditions and an intermediate 
CD14++C16+ population of monocytes which also expand under inflammatory conditions. 
Previous reports from our laboratory have shown that diseased liver tissue in NASH and 
ALD is enriched for monocytes compared to normal tissue (Liaskou et al., 2013) due to 
increases in the non-classical CD14-CD16++ and intermediate CD14++CD16+ monocytes. 
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Figure 3.6: monocyte subsets identified by flow cytometry 
Monocytes were identified by forward and side scatter and then on the basis of CD14 and CD16 
expression. This identifies three subsets of monocytes: CD14++CD16- classical monocytes, 
CD14+CD16+ intermediate monocytes and CD14-CD16+ non-classical monocytes.
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Monocytes were extracted from liver by non-enzymatic digestion of tissue, avoiding the risk 
of stripping of CCR2 from cell membranes, and isolated over a gradient and compared by 
flow cytometry with blood monocytes for CCR2 expression. In both blood and liver, CCR2 
expression was predominantly on CD14+ monocytes, with a greater proportion of the 
classical CD14++CD16- subset showing CCR2+ expression compared with intermediate 
CD14+CD16+ cells or non-classical CD14-CD16+ population (figure 3.6). Mean 
fluorescence intensity (MFI) of CCR2 signal was also higher on CD14+CD16- monocytes but 
relatively preserved on CD14-CD16+ monocytes indicating fewer CD14-CD16+ cells 
expressing CCR2 but at a similar intensity to CD14+CD16+ monocytes. There was a trend 
for lower percentage CCR2 expression on liver-infiltrating monocytes but this was not 
significant (two-way ANOVA p=0.141), whereas MFI did differ between blood and liver 
(two-way ANOVA p=0.035).  
 
Monocyte percentage CCR2 expression was similar across all types of liver disease (two-
way ANOVA p=0.991), nor did CCR2 MFI differ between disease types (two-way ANOVA 
p=0.827) (figure 3.7). 
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Figure 3.7: CCR2 is predominantly expressed by CD14+CD16- monocytes 
Monocytes were isolated from blood or liver tissue and CCR2 expression analysed by flow cytometry. 
A Percentage expression of CCR2 on monocyte subsets in blood and liver. B CCR2 expression 
measured by mean fluorescent intensity on intrahepatic monocytes by disease. Data are shown as 
mean and SEM 
 
 
 
 
 
Figure 3.8: CCR2 expression on monocyte subsets across different types of liver 
disease 
Monocytes were isolated from liver tissue and CCR2 expression analysed by flow cytometry. No 
significant differences in monocyte CCR2 expression was observed between disease types, with 
regard to either A percentage expression or B MFI. Data are shown as mean and SEM 
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CD14+CD11c+CD206+ monocytes are enriched in liver tissue 
As CCR2 was widely expressed on monocytes in both blood and liver its use as a sole 
marker to describe a population of immune cells relevant to a particular disease is limited. 
Therefore a more focused investigation was undertaken to identify a subset that may be 
relevant to FLD. A recent paper described of a subset of CD14+ macrophages expressing   
CD11c and CD206 in human adipose tissue (Wentworth et al., 2010), which were 
associated with insulin resistance. As insulin resistance is a central feature of NAFLD, I 
examined this subset in further. Very few CD11c+CD206+ monocytes were observed in 
peripheral blood, whereas these cells were enriched in liver tissue (figure 3.9). 
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Figure 3.9: CD11c+CD206+ monocytes are enriched in liver tissue  
Monocytes were isolated from blood and liver and analysed by flow cytometry. A and B: gating 
strategy: A identification of CD14+CD16- cells, B CD45+CD14+ monocytes. Lower panels:  
CD11c+CD206+ monocytes in C blood and D liver from the same individual 
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Frequency of intrahepatic CD14+CD11c+CD206+ monocytes is associated with insulin 
resistance 
To begin to understand the function of CD11c+CD206+ monocytes, clinical parameters 
were examined. In keeping with previous descriptions of adipose infiltrating cells, a 
correlation between the number of intrahepatic CD14+CD11c+CD206+ monocytes and 
insulin resistance (measured with glycosylated haemoglobin (HbA1c)(Rohlfing et al., 2002) 
was observed (r2 0.562 p=0.0013)(figure 3.10). No significant correlation was observed 
with age, BMI or ALT (table 3.3). 
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Table 3.3: correlation of clinical markers with frequency of CD11c+CD206+ monocytes 
in liver tissue 
Monocytes were isolated from liver tissue (both NAFLD and non-NAFLD) and analysed by flow 
cytometry. Correlation of frequency of intrahepatic CD11c+CD206+ monocytes (as percentage of 
CD45+CD14+ cells) with clinical markers was investigated 
 
 
 
Figure 3.10: The frequency of intrahepatic CD14+CD11c+CD206+ monocytes is 
associated with insulin resistance 
Correlation of the frequency of intrahepatic CD14+CD11c+CD206+ monocytes (as percentage of 
CD14+cells) and insulin resistance (as assessed by HbA1c fraction) (r2=0.562, p=0.001). Each 
data point represents an isolate from an individual patient. 
 Correlation r2 p 
HbA1c 0.562 0.001 
Age 0.1434 0.148 
BMI 0.037 0.461 
ALT 0.158 0.128 
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CD14+CD11c+CD206+ monocytes are more frequent in NAFLD liver tissue than that from 
non-NAFLD-related chronic liver disease  
The frequency of CD11c+CD206+ monocytes, as a percentage of CD45+CD14+ cells, differed 
significantly between types of liver disease (one-way ANOVA p=0.034) with highest 
expression seen in NAFLD (table 3.4, figure 3.11). Interestingly a high frequency of these 
monocytes was also seen in alcoholic liver disease (ALD), which has many pathological 
processes in common with NAFLD. 
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Liver tissue CD11c+CD206+ 
(mean frequency of 
CD45+CD14+) 
SEM 
Normal 14.58 3.58 
ALD 5.51 5.58 
PSC/PBC 15.16 8.90 
NAFLD 39.25 10.20 
 
 
Table 3.4: Frequency of CD11c+CD206+ monocytes by disease 
 
Monocytes were isolated from liver tissue and analysed by flow cytometry. Greater frequency of 
CD11c+CD206+ monocytes was observed in NAFLD tissue 
 
 
 
 
Figure 3.11: frequency of CD11c+CD206+ monocytes in liver tissue differs between 
type of liver disease. 
Monocytes were isolated from liver tissue removed at resection or transplantation and analysed by 
flow cytometry. The frequency of CD11c+CD206+ monocytes differed significantly between types of 
liver disease and were more common in NAFLD tissue. Mean and SEM, *p<0.05 by one-way 
ANOVA. 
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CD14+CD11c+CD206+ monocytes express CCR2 in NAFLD 
Intrahepatic CD14+CD11c+CD206+ monocytes expressed higher levels of CCR2 in NAFLD 
compared to non-NAFLD liver tissue (median non-NAFLD expression 50.6% (IQR 33.8) vs 
76.8 (15.6) Mann-Whitney test p=0.008) (figure 3.12A, 3.13) although MFI was not 
significantly different (median MFI Non-NAFLD 201 (IQR 126) vs. 310 (153.9), Mann 
Whitney p=0.200)(figure 3.12B, figure 3.13). Interestingly high CCR2 expression on this 
population was also observed in ALD, although fewer CD11c+CD206+ monocytes were seen 
overall (figure 3.11). 
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Figure 3.12: CD14+CD11c+CD206+ monocytes express CCR2 more frequently in 
NAFLD but total CCR2 expression is not significantly different 
Monocytes were isolated from liver tissue removed at resection or transplantation and analysed by 
flow cytometry. A CD11c+CD206+ monocytes from patients with NAFLD express CCR2 more 
frequently than non-NAFLD patients B: mean fluorescence intensity of CCR2 was not significantly 
higher in NAFLD. ** student’s t-test p<0.01, ns student’s t-test test p>0.05 
 
Figure 3.13: CD14+CD11c+CD206+ monocytes express CCR2 more frequently in 
NAFLD but total CCR2 expression is not significantly different 
Example FACS plots gated on CD11c+ CD206+ cells from A NASH liver and B Non-NASH liver (in 
this case Primary Biliary Cirrhosis) to illustrate greater CCR2 expression in NASH liver tissue 
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Discussion 
My data show that the CCR2/CCL2 axis is activated in human NAFLD. Greater gene 
expression of CCL2 was seen in liver tissue from patients with NAFLD, as well as increased 
serum concentrations of CCL2, which correlated with disease activity on liver biopsy and 
lobular inflammation in particular. CCR2 expression is common on CD14+CD16- monocytes 
in both blood and liver, and no significant differences were found between liver diseases of 
varying aetiologies. This was also true of CD14+CD16+ and CD14-CD16+ monocyte 
populations. 
 
A subset of CD14+ monocytes that express CD11c and CD206 have been associated with 
insulin resistance in adipose tissue, where they secrete pro-inflammatory cytokines and T-
cell chemoattrants (Wentworth et al., 2010). I detected few of these cells in blood but found 
them to be markedly enriched in liver tissue, particularly in patients with NAFLD, and their 
frequency in liver tissue correlated with insulin resistance. Whilst my data do not provide 
information on the cells’ function they may also promote insulin resistance by secreting 
inflammatory cytokines as they were shown to in adipose tissue. The finding that few 
monocytes in blood express CD206 suggests that expression is induced after recruitment of 
monocytes into liver tissue, a process which may require a pro-inflammatory 
microenvironment as lower expression was seen in non-diseased liver tissue.  
 
CD11c+CD206+ monocytes express CCR2, with the highest levels and frequencies observed 
in NAFLD and ALD, a disease which shows the same histological appearances of 
steatohepatitis (Diehl et al., 1988). While modest alcohol intake is associated with improved 
insulin sensitivity (Hendriks, 2007), excessive alcohol intake is associated with insulin 
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resistance (Iturriaga et al., 1986) and its complications such as diabetes (Holbrook et al., 
1990) and cardiovascular disease (Hvidtfeldt et al., 2008). ALD is also associated with 
increased insulin resistance (Kruszynska et al., 1991). In addition, CCL2 is shown to mediate 
steatosis and inflammatory infiltration in animal models of ALD although this seemed 
independent of CCR2 (Mandrekar et al., 2011). There are therefore broad similarities 
between NAFLD and ALD that can explain the observation of CCR2 expression on 
CD11c+CD206+ monocytes, however many more CD11c+CD206+ cells were seen in NAFLD 
liver than ALD liver. 
 
These data support a role for CCR2-mediated infiltration of liver tissue by monocytes that 
contribute to disease in steatohepatitis. 
CHAPTER 4: CCR2 Antagonism in Animal Models of Non-
alcoholic Fatty Liver Disease  
 
In the previous chapter I described a role for CCR2 and CCL2 in human NAFLD. In view of 
these findings I investigated the effect of antagonism of CCR2 in two murine models of 
NAFLD, using a small molecule CCR2 antagonist (CCX872, 
). I examined the principle features of human NAFLD: steatosis, inflammation and 
fibrosis together with infiltration of myeloid cells into liver tissue in two animal models o 
methionine-choline deficient (MCD) diet and high fat diet (HFD). 
 
CCX872 is a small molecule inhibitor of mouse and human CCR2. It is an orally available 
compound that has been used safely in phase 1 studies where it was tolerated well without 
significant side effects (Bekker et al., 2013). It is a specific inhibitor of mouse and human 
CCR2 with a half-life of approximately 24 hours in serum.  
 
Methionine-Choline Deficient diet 
A methionine-choline deficient (MCD) diet causes steatohepatitis by inhibition of lipid 
export from hepatocytes (Anstee and Goldin, 2006) which progresses to fibrosis. Unlike 
human NAFLD, MCD diet does not cause obesity or insulin resistance and although animals 
develop fibrosis they do not develop cirrhosis. Thirty male C57/Bl6 mice aged 6 weeks were 
fed MCD diet for five weeks. Two weeks of diet without intervention was used to establish 
disease. After two weeks, mice were divided into two groups and given either 30mg/kg/day 
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of CCX872 or matched volume of vehicle (2% hydroxypropyl methylcellulose, HPMC), 
administered subcutaneously (figure 4.1). A group of five littermates were maintained on a 
normal diet for the duration of the experiment without intervention. 
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Figure 4.1: Experimental design of MCD experiment 
Twenty-five C57/Bl6 mice were fed MCD diet. After two weeks mice were divided into two groups 
and 30mg/kg of CCX872 or matched volume of vehicle was administered once daily by 
subcutaneous injection. A further 5 mice were given a control diet without any intervention. 
 
 
 
Figure 4.2: CCR2 antagonism does not alter MCD diet-induced weight loss 
C57/Bl6 mice were fed an MCD diet or control diet for 5 weeks. After two weeks mice on MCD diet 
were treated with either CCR2 antagonist CCX872 (n=10), or vehicle (n=10). A: Marked weight 
loss occurred in animals fed an MCD diet: vertical line indicates start of administration of CCX872 
or vehicle. Data are shown as median and interquartile range. B no difference in weight was 
observed between vehicle and control groups at the start (day 14) or end (day 35) of treatment. 
Data shown as mean and SEM, ns=non significant by students t-test 
30 C57/Bl6 mice 
25 MCD diet 2 
weeks 
5 for 
baseline 
measurements 
10 CCX872 
30mg/kg SC OD 
MCD diet 3 
weeks 
10 Vehicle 
SC OD 
MCD diet 3 
weeks 
5 C57/Bl6 mice 
control diet 5 
weeks 
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CCR2 antagonism does not alter weight loss on MCD diet 
The MCD diet induced marked weight loss, consistent with previous reports (Anstee and 
Goldin, 2006). No differences in weight loss were observed between mice treated with 
CCX872 or vehicle (figure 4.2). 
 
CCR2 antagonism does not alter hepatic steatosis caused by MCD diet 
Steatosis was assessed by measuring the triglyceride content of liver tissue with a 
commercially available colorimetric assay. Considering the experiment as a whole, there was 
a significant difference between the three groups (control diet, vehicle-treated and CCX872-
treated mice) (one-way ANOVA p=0.038) (figure 4.3). Considering comparisons between 
the groups of mice given MCD, there was no significant difference in the median liver 
triglyceride content of vehicle and CCX872 treated mice (70.1mg/g (IQR 80.9) vs. 57.9 
(61.5), Mann Whitney test p=0.190) (figure 4.3).  However, mice in the vehicle-treated 
group had significantly higher liver triglyceride content compared to mice on a control diet 
(70.1mg/g (IQR 80.9) vs. 36.1mg/g (80.9), Mann Whitney test p=0.003), whereas liver 
triglyceride content of mice treated with CCX872 did not differ significantly from control 
diet (Mann Whitney test p=0.371).  
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Figure 4.3: CCR2 antagonism does not alter hepatic steatosis caused by MCD diet.  
Triglyceride content of liver tissue was analysed using an enzyme-based colorimetric assay. Hepatic 
triglyceride content of mice given CCX872 or vehicle was comparable, but only vehicle treated mice 
differed significantly from control animals **p<0.01 by Mann Whitney test. (Each data point 
represents a single animal, lines at median, whiskers represent interquartile range). 
 
Figure 4.4: CCR2 antagonism does not reduce serum AST or ALT elevation by MCD 
diet 
C57/Bl6 mice were fed an MCD diet or control diet for 5 weeks. After two weeks mice on MCD diet 
were treated with a CCR2 antagonist, CCX872, or vehicle. A group of littermates were fed a control 
diet without intervention for 5 weeks. Liver injury was assessed by serum A AST and B ALT 
concentration. No differences were observed between CCX872 and vehicle-treated mice. Each point 
represents an individual mouse, data shown as mean and SEM, *p<0.05 **p<0.001 by student’s t-
test.  
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CCR2 antagonism does not reduce serum AST or ALT elevation by MCD diet 
Blood samples were taken by cardiac puncture at the time of . Serum was analysed 
for AST and ALT concentrations, as markers of hepatocyte injury and surrogate markers of 
inflammation. Mice that were fed MCD diet for five weeks had significantly higher serum 
AST and ALT concentrations than mice on a control diet (figure 4.4).  
 
Whilst overall differences between groups were seen by one-way ANOVA for both AST 
(p=0.003) and ALT (p=0.038), no differences in AST or ALT concentration were seen 
between vehicle and CCX872-treated mice (figure 4.4). No significant differences were 
seen between mice at baseline (at two weeks) and mice given MCD diet and CCX872 or 
vehicle for a further three weeks. 
 
CCR2 antagonism reduces infiltration of liver tissue by pro-inflammatory monocytes 
caused by MCD diet 
Inflammation was investigated by flow cytometry of liver tissue to identify sub-groups of 
infiltrating monocytes. No differences were seen in total infiltrating cells. Monocytes were 
classified as CD11b+F4/80lo and further subdivided by Ly6c expression. Fewer infiltrating 
Ly6chi monocytes were seen in mice given CCX872 compared to vehicle-treated mice 
(percentage of CD45+ cells, 5.52 (SEM 0.38) vs. 8.28 (1.17), student’s t-test p=0.038) (figure 
4.5A). No significant differences were seen in Ly6cdim monocytes (figure 4.5B). 
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Figure 4.5: CCR2 antagonism reduces infiltration of liver tissue by pro-inflammatory 
monocytes caused by MCD diet  
 
C57/Bl6 mice were fed an MCD diet or control diet for 5 weeks. After two weeks mice on MCD diet 
were treated with CCR2 antagonist CCX872, or matched volumes of vehicle. Fewer intrahepatic 
CD11b+Ly6chi monocytes were observed in mice treated with CCX872 compared to in mice given 
vehicle C No differences in CD11b+Ly6clo monocytes were observed. Each symbol represents one 
animal, lines represent mean and SEM, *p<0.05 by student’s t-test.  
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High Fat Diet 
Steatohepatitis can be induced in mice by feeding a high fat diet (HFD) (Anstee and Goldin, 
2006). This has greater relevance to human NAFLD as mice fed HFD exhibit obesity and 
insulin resistance which is not seen in the MCD diet model (Rinella and Green, 2004). Thirty 
male C57/Bl6 mice aged 6 weeks at the start of the experiment were given HFD for 16 
weeks. This diet delivered 60% of calories from fat. After eight weeks of HFD, four mice 
were to establish presence of liver injury. The remaining mice were divided into two 
groups: thirteen were treated with CCX872 (30mg/kg/day, administered by subcutaneous 
injection) and 13 received an equivalent volume of vehicle (1% HPMC). A further 8 
littermates were given control diet for the duration of the experiment (figure 4.6). 
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Figure 4.6: Experimental design of HFD experiment  
 
C57/Bl6 mice were fed a high fat diet for eight weeks. After eight weeks mice were divided into two 
groups and 30mg/kg of CCX872 or matched volume of vehicle was administered once daily by 
subcutaneous injection and diet continued for a further eight weeks. A further 8 mice were given a 
control diet, without any intervention for 16 weeks. 
38 C57/Bl6 mice 
30 mice HFD 8 weeks 
4 mice  to assess injury 
13 mice CCX872  30mg/kg  SC OD 
HFD 8 weeks 
13 mice vehicle  SC OD 
HFD 8 weeks 
8 mice control diet 16 weeks 
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CCR2 antagonism reduces weight gain caused by HFD 
Bodyweight of mice in vehicle and CCX872 treated groups did not differ at the start of 
treatment (8 weeks of diet). Over the course of treatment, both groups continued to gain 
weight but the CCX872 treated mice gained significantly less weight than those treated with 
vehicle (figure 4.7A, B). To investigate possible causes for this, food intake was assessed 
over the final two weeks of treatment by weighing the food given to mice when it was put 
into the cage, and then 24 hours later. This gave a crude indication of overall food intake for 
each cage. No differences were seen between vehicle and CCX872-treated mice (figure 
4.8A). Concern that reduced weight might be due to side effects of CCX872 prompted an 
ad hoc assessment of wellbeing of mice. Three observers examined each mouse individually 
without knowing which diet or treatment it was receiving. Mice were given a score for 
activity, appearance and wellbeing with a maximum score of ten. On this assessment mice in 
vehicle and CCX872-treated groups did not appear to differ (figure 4.8B). 
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Figure 4.7: CCR2 antagonism reduced weight gain caused by HFD 
C57/Bl6 mice were fed HFD (n=30) diet or control diet (n=8) for sixteen weeks. Mice on HFD were 
treated with a small molecule antagonist of CCR2, CCX872 (n=13), or vehicle (n=13) for the last 8 
weeks of diet. Weight was comparable between treatment groups at the start of treatment; both 
groups gained much more weight than mice fed a control diet. By the end of the experiment mice 
treated with CC872 had a lower average weight than mice treated with vehicle. Data shown as 
mean and SEM, vertical line indicates start of treatment with CCX872 or vehicle. ns=non-significant, 
*p<0.05 by student’s t-test 
 
 
 
Figure 4.8 No differences were observed in food intake or condition of mice 
A Dietary intake was assessed by weighing food over four 24 hour periods during the final two 
weeks of treatment. Each data point represents food intake for an individual cage for a single 24 
hour period. Food intake appeared comparable between mice treated with vehicle or CCX872. B 
The condition of animals during week 14 (after 6 weeks of treatment) was assessed by three people 
blinded to which diet or treatment mice were receiving. Mice were given a score between 1 and 10 
to indicate the wellbeing of individual animals. Mice treated with vehicle or CCX872 did not differ in 
appearance.  
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CCR2 antagonism reduces hepatic steatosis caused by HFD 
Steatosis was assessed by measuring triglyceride content of liver tissue with a commercially 
available colorimetric assay. After 16 weeks of HFD, there was marked steatosis in all mice 
on HFD. Mice treated with CCX872 had significantly less triglyceride accumulation in 
comparison with vehicle treated mice (169.6mg/g ±21.20 vs.  284.2 ±31.9, student’s t-test 
p=0.007) and was not significantly different from animals receiving control diet (figure 4.9). 
 
CCR2 antagonism lowers HFD-induced serum ALT concentration  
Blood samples were taken by cardiac puncture at the time of  Serum was analysed 
for AST and ALT concentrations, markers of hepatocyte necrosis. AST concentration was 
lower in CCX872 treated mice but this was not statistically significant (mean 357.8IU/ml 
±68.92 vs. 510.7 ±91.67, student’s t-test p=0.210). Serum ALT was lower in CCX872-
treated mice and this difference was statistically significant (mean ALT 252.5IU/ml ±56.02 vs. 
532.8 ±98.07, student’s t-test p=0.028). Serum AST concentration in mice fed a control diet 
was surprisingly high (figure 4.10). 
 
Whilst a similar pattern for AST and ALT was observed, This difference was only of 
statistical significance for ALT. ALT is a more liver-specific enzyme, whereas AST is also 
found for example in muscle. The more robust result for ALT may therefore reflect a liver-
specific improvement. Conversely an unanticipated effect on muscle function might explain 
these findings.  
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Figure 4.9: CCR2 antagonism reduces hepatic steatosis caused by HFD 
C57/Bl6 mice were given HFD diet or control diet for sixteen weeks. Mice on HFD were treated 
with a small molecule antagonist of CCR2, CCX872 or vehicle for the last 8 weeks of diet. Hepatic 
steatosis was assessed by measuring triglyceride content of liver tissue. Mice on a HFD treated with 
CCX872 showed significantly lower triglyceride content than mice given vehicle.  Each data point 
represents one animal, lines at mean and SEM **p<0.01 by student’s t-test.  
 
Figure 4.10: CCR2 antagonism lowers HFD-induced serum ALT concentration  
C57/Bl6 mice were given HFD diet or control diet for sixteen weeks. Mice on HFD were treated 
with a small molecule antagonist of CCR2, CCX872 or vehicle for the last 8 weeks of diet. Liver 
injury was assessed by measuring serum A AST and B ALT concentration.  No differences in AST 
concentration were seen between CCX872 and vehicle-treated mice, but ALT concentrations were 
lower in CCX872 treated mice. Each data point represents one animal, data shown as mean and 
SEM. **p<0.01 by student’s t-test 
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CCR2 antagonism does not reduce the proportion of monocytes in liver tissue in HFD 
Inflammation caused by HFD was investigated by flow cytometric analysis of isolated liver-
infiltrating immune cells. No overall differences were seen in overall cellular infiltrate. No 
differences were seen between groups of mice with regard to CD11b+F4/80hi monocytes or 
CD11b+F4/80lo Kupffer cells in liver tissue (figure 4.11).  
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Figure 4.11: CCR2 antagonism does not reduce frequency of intra-hepatic Kupffer 
cells or monocytes 
C57/Bl6 mice were fed HFD diet or control diet for sixteen weeks. Mice on HFD were treated with 
a small molecule antagonist of CCR2, CCX872 or vehicle for the last 8 weeks of diet. CCR2 
antagonism did not alter frequency of A CD11b+F4/80hi liver-resident Kupffer cells or B 
CD11b+F4/80dim liver-infiltrating monocytes. Each data point represents an individual animal, data 
shown as mean and SEM. ns: non-significant by student’s t-test 
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CCR2 antagonism reduces infiltration of adipose and liver tissue by monocytes associated 
with insulin-resistance 
HFD is a model of obesity and insulin resistance comparable to the human syndrome of 
NAFLD in contrast to the MCD model which is not associated with either obesity or IR.  
Given the findings that particular monocyte subsets are associated with human obesity 
(Wentworth et al., 2010) and my data in human fatty liver disease, I examined monocytes 
associated with insulin resistance in the HFD model. It is difficult to compare directly 
between subsets of monocytes in mice and humans based purely on expression of surface 
markers but previously published work indicated that a subset of CD11b+ macrophages that 
are CD11c+F4/80+ may be critical in the development of obesity mediated insulin resistance 
(Lumeng et al., 2007). I thus examined liver and adipose-infiltrating monocytes for the 
presence of this subset in mice given HFD.  
 
After 16 weeks of HFD, mice treated with CCX872 had fewer CD11b+CD11c+F4/80+ cells 
than mice treated with vehicle, in both visceral adipose tissue and liver tissue (figures 4.12).  
 
Adipose tissue was not examined in MCD diet as only HFD is characterised by weight gain 
and insulin resistance – a phenomenon resulting from adipose tissue inflammation. MCD diet 
causes weight loss. 
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Figure 4.12: CCR2 antagonism reduces infiltration of liver and adipose tissue by 
CD11c+F4/80+monocytes 
C57/Bl6 mice were given HFD diet or control diet for sixteen weeks. Mice on HFD were treated 
with a small molecule antagonist of CCR2, CCX872 or vehicle for the last 8 weeks of diet. Liver and 
adipose infiltrating monocytes were analysed by flow cytometry. A subset of CD11b+CD11c+F4/80+ 
cells were observed less frequently (as a percentage of CD11b)+ in both A liver and B adipose tissue 
of mice given CCX872 compared to vehicle treated mice and mice given a control diet. Data are 
shown as mean and SEM, *p<0.05 by student’s t-test 
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CCR2 antagonism does not affect hepatic fibrosis caused by sixteen weeks of HFD 
Paraffin-embedded liver sections were stained with Van Gieson’s stain to detect collagen. 
This was quantified by analysis with image-j software to calculate percentage collagen area. 
Modest increases in hepatic fibrosis were seen in HFD fed mice after 16 weeks of diet 
consistent with the modest fibrotic response reported by others in this model. No 
significant differences in fibrosis between mice given CCX872 or vehicle were observed 
(figure 4.13, figure 4.14A). To investigate whether there were measurable differences in 
pro-fibrotic gene transcripts RNA was isolated from liver tissue and the expression of 
Col1a1 and Acta2 were analysed by qRT-PCR. No significant expression was seen in any of 
the groups (figure 4.14B, C). 
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Figure 4.13: HFD caused minimal fibrosis with no significant differences between 
groups 
Van Gieson staining of paraffin-embedded liver sections from animals given A HFD and treatment 
with vehicle and B HFD and treatment with CCX872. Images taken at 10x magnification 
 
 
 
 
Figure 4.14: HFD causes little up-regulation of pro-fibrotic genes 
C57/Bl6 mice were given HFD diet or control diet for sixteen weeks. Mice on HFD were treated 
with a small molecule antagonist of CCR2, CCX872 or matched volumes of vehicle for the last 8 
weeks of diet. Fibrosis caused by HFD was assessed with histology and PCR of pro-fibrotic genes. No 
significant differences were observed in A percentage collagen area B Col1a gene expression or C 
Acta2 gene expression, between mice given CCR2 or vehicle. Data are shown as median and IQR 
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CCR2 antagonism improves glucose metabolism in mice given HFD 
HFD causes insulin resistance in mice in tandem with obesity. Glucose metabolism was 
assessed through glucose and insulin challenges. 
 
CCR2 antagonism improved response to glucose challenge 
Mice were fasted overnight before being given a challenge of 2g/kg glucose by gastric lavage. 
Plasma glucose concentration was measured from drops of tail vein blood with a glucometer 
at baseline and 15, 30, 60, 90 and 120 minutes after administration of glucose. 
 
Plasma glucose concentration over time was monitored for each mouse, and mean values for 
each group calculated. Groups were compared by area-under-the-curve values. At the start 
of treatment, response to glucose was similar between CCX872 and vehicle treated mice 
(figure 4.15A, C). However, after 8 weeks of treatment there was a significant 
improvement in response of CCX872 mice compared to vehicle treated mice (AUC 48545 
mg/dl/min vs. 31795 mg/dl/min, student’s t-test p<0.001)(figure 4.15B, C). 
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Figure 4.15: CCR2 antagonism improves glucose metabolism 
C57/Bl6 mice were fed HFD or control diet for sixteen weeks. Mice on HFD were given CCX872, a 
small molecule CCR2 antagonist, or matched volumes of vehicle for the last eight weeks of diet. 
Glucose metabolism was investigated with a glucose challenge A plasma glucose concentration in 
each group of mice before treatment, B after treatment with CCX872 or vehicle (n=13 each), or in 
mice receiving control diet (n=8) and C area under the curve analysis of plasma glucose 
concentration. Data re presented as mean and SEM,  ***p<0.001 by student’s t-test  
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CCR2 antagonism improved response to insulin challenge 
Insulin challenge was performed by administering a standard dose of 0.75units/g of insulin by 
intra-peritoneal injection to non-fasted mice. Plasma glucose concentration was measured 
from drops of tail vein blood with a glucometer at baseline and 15, 30, 60, 90 and 120 
minutes after administration of insulin. At the start of treatment, after eight weeks of HFD, 
changes in plasma glucose concentration were similar in both groups of mice given HFD 
(figure 4.16A, C). After a further 8 weeks of HFD and treatment with CCX872 or vehicle, 
there was a significant difference between groups (AUC 21719 mg/dl/min vs. 16553 
mg/dl/min, student’s t-test p<0.001)(figure 4.16 B,C). Mice given a control diet showed a 
similar response to mice on a HFD after insulin challenge.   
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Figure 4.16: CCR2 antagonism improves insulin sensitivity 
C57/Bl6 mice were given HFD diet or control diet for sixteen weeks. Mice on HFD were treated 
with a small molecule antagonist of CCR2, CCX872 or matched volumes of vehicle for the last 8 
weeks of diet. Glucose metabolism was investigated with an insulin challenge with a standardised 
amount of insulin. A mean and SEM plasma glucose concentration in each group of mice before 
treatment B after treatment with CCX872 or vehicle after and C area under the curve analysis of 
plasma glucose concentration before and after treatment. Data are shown as mean and SEM 
***p<0.001 by student’s t-test 
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Discussion 
The efficacy of CCR2 antagonism was investigated in two mouse models of NAFLD. CCR2 
antagonism limited hepatic accumulation of triglyceride and reduced infiltration of liver tissue 
by inflammatory Ly6chi monocytes in steatohepatitis induced by MCD diet. In HFD induced 
steatohepatitis, whilst serum markers of liver injury were reduced, no reduction in overall 
monocyte infiltration was seen. However a subset of monocytes that have been found to 
mediate insulin resistance were reduced in frequency in both adipose and liver tissue. 
Glucose metabolism was also improved, suggesting that CCR2 antagonism improves obesity-
mediated fatty liver disease through effects on both adipose and liver. The differences in the 
findings between the two models can be explained at least in part by the significant 
differences between the modes of injury. MCD diet causes retention of lipid in hepatocytes 
and significant weight loss, whereas HFD causes weight gain and insulin resistance. A HFD 
model is therefore closer to the human syndrome of obesity and NAFLD.  
 
It is interesting that whilst a clear reduction in liver-infiltrating monocytes was not observed 
between groups in the HFD model, a significant difference in a subset of 
CD11b+CD11c+F4/80+ cells was observed associated with improved steatosis, serum ALT 
and glycaemic control. This mirrors the findings in human liver disease of a subset of 
monocytes that were associated with NAFLD whilst overall monocyte infiltration did not 
differ between aetiologies of liver disease – discussed in the previous chapter. 
 
In obesity-induced steatohepatitis caused by HFD, less weight gain was seen in the CCX872 
treated animals. There are several explanations for this: CCX872 may reduce appetite by a 
direct effect or through reducing general well-being, or this is a consequence of a direct 
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effect on disease pathogenesis. When the difference in weight became apparent I measured 
food intake and assessed wellbeing, neither of which appeared to differ between groups. 
Thus it is likely that this is a direct consequence of CCR2 inhibition resulting in improved 
insulin resistance, and metabolic profile of these animals resulting in limited weight gain.  
 
The differences in weight between treatment groups raises the possibility that the beneficial 
effects of CCX872 may be due to the lower weight of this group. However, AST and ALT 
were lower in the CCX872 group than the vehicle treated group even for mice of the same 
weight, as were values for glucose and insulin challenges suggesting that an effect was seen 
beyond that of simple weight reduction. Less straight forward to answer is the question of 
whether reduction in hepatic inflammation is a direct effect of CCX872, or a consequence of 
improved adipose tissue inflammation. Reducing adipose tissue inflammation will improve 
insulin resistance and flux of free fatty acids, both of which will improve liver disease. From 
one perspective this may not matter or reduce the translational potential of these results, 
but from a scientific point of view this is an important question and should be addressed in 
on-going studies.  
 
Previous reports have shown that obesity in mice is associated with increased serum CCL2 
concentration and greater hepatic gene expression of CCL2 (Kirovski et al., 2011). In CCR2 
knockout-mice, less hepatic steatosis (Weisberg et al., 2006) and hepatic inflammation 
(Obstfeld et al., 2010, Miura et al., 2012) is seen in models of obesity-induced liver disease. 
Interestingly CCR2 knock-out mice are also protected against carbon tetrachloride-induced 
fibrosis (Miura et al., 2012), attributed to expression of CCR2 by hepatic stellate cells (Seki 
et al., 2009) although this could also be a monocyte/macrophage mediated effect. CCR2 has 
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been targeted with a variety of pharmaceutical agents in animal models of fatty liver disease. 
A CCR2 inhibitor (RS504393, Tocris Bioscience, 2mg/kg/day) administered via an 
implantable osmotic pump to AZIP transgenic mice (Yang et al., 2009) reduced liver weight, 
and macrophage accumulation. Miura et al used a CCR2 antagonist (RS102895, Sigma, 
10mg/kg/day) therapeutically (i.e. once disease was established) in a model of fatty liver 
induced by choline deficient diet (Miura et al., 2012). Again, macrophages were reduced in 
number in the livers of treated animals, assessed by immunohistochemistry. ALT and fibrosis 
were also reduced. Pharmaceutical inhibition of CCL2, rather than its receptor also has 
shown beneficial effects in MCD diet (Baeck et al., 2012). There is therefore a broad body of 
data suggesting that fatty liver disease is ameliorated through CCR2 or CCL2 antagonism.  
 
The data presented in this chapter differ from these previous reports in a number of ways. 
Both models used dietary manipulation to induce steatohepatitis rather than using genetically 
altered animals and I used therapeutic intervention to intervene after establishing disease 
rather than preventing disease from occurring. Whilst this approach may reduce the 
apparent efficacy of an intervention it is more relevant to clinical practice and translation.  
 
I used two types of diet-induced steatohepatitis in mice to model human NAFLD: 
methionine-choline deficient diet and high fat diet. The MCD model is widely used as a 
model of steatohepatitis, although it is far removed from the human condition of obesity and 
insulin resistance. The HFD model is superior in this respect, in that mice become obese and 
insulin resistant, however the lack of fibrosis in this model limited the similarity to human 
disease. Fructose consumption is a significant risk factor for development of NAFLD in 
humans (Ouyang et al., 2008, Abdelmalek et al., 2010). The addition of fructose to drinking 
 100 
water of mice may cause greater severity of steatohepatitis in mice with fibrosis (Tetri et al., 
2008). This would have provided a better model to test the effects of CCR2 antagonism and 
been more closely related to human disease. In addition, these findings are further limited by 
a lack of histological correlates of liver injury. Unfortunately this was not possible as tissue 
had deteriorated and was unsuitable for analysis. This is an important limitation as the gold 
standard for assessment of  human NAFLD is through histological analysis. 
 
CCR2 antagonism as a therapeutic tool in NAFLD is already being investigated in the 
CENTAUR trial.  This study is using Cenciviroc, a dual CCR2/CCR5 inhibitor that was 
initially developed for the treatment of HIV (NCT 02217475) (trials.gov, 2014). If CCR2 
really does control the inflammatory consequences of obesity, the use of CCR2 antagonists 
could be long-term treatment similar to current therapies for diabetes. The long-term 
consequences of CCR2 antagonism are unknown.  
CHAPTER 5: The Role of CCR9 in acute liver injury 
 
Acute liver failure (ALF) is a rare but devastating condition typified by hepatic 
encephalopathy and jaundice. It is often fatal. Chronic liver disease is typified by iterative 
episodes of inflammation and scarring over long periods of time that leads to cirrhosis, 
whereas in acute liver failure there is an overwhelming inflammatory process that leads to 
hepatic failure with no or minimal fibrosis (Antionades et al., 2008). In some cases ALF may 
be fulminant resulting in rapid destruction within hours or days of liver injury.  Here the 
dominant pathway of injury is direct toxicity to the liver from drugs or toxins whereas in 
other cases injury is driven by an uncontrolled immune response to an autoantigen or virus 
resulting in liver failure over days or weeks.   Recent work implicated CCR9 in a mouse 
model of acute liver injury (Nakamoto et al., 2012). The authors used concanavalin A (conA) 
to induce T-cell mediated hepatitis in mice. ConA treatment leads to a massive polyclonal 
activation of T cells resulting in immune mediated liver damage and hepatocyte apoptosis 
(Tiegs et al., 1992). Pro-inflammatory CCR9+ macrophages – defined as CD11b+CD11c- cells 
- were increased in number in injured liver tissue, and induced differentiation of naïve CD4+ 
T-cells towards a Th1 phenotype thereby implicating them in the local generation of immune 
activation and IFNγ secretion. On the basis of these studies I investigated the role of CCR9 
in human acute liver failure and the efficacy of inhibition of CCR9 in mouse models of acute 
liver failure.  
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Serum concentration of CCL25 is raised in acute liver failure 
CCR9 has a single ligand, CCL25. I measured CCL25 in serum from patients with ALF 
(n=39), acute-on-chronic liver failure (ACLF) (n=8) chronic liver disease (CLD) (n=8) and 
from healthy controls (n=19) by ELISA. ALF was defined as patients with acute jaundice and 
hepatic encephalopathy. ACLF refers to an acute deterioration of liver function in patients 
with cirrhosis, either secondary to superimposed liver injury or due to extra-hepatic 
precipitating factors such as infection culminating in the end-organ dysfunction (Jalan et al., 
2012). 
 
Serum from ALF contained significantly more CCL25 compared to serum from healthy 
controls (median 3.01ng/ml (IQR 1.3) vs. 0.62ng/ml (1.1), Mann-Whitney test p<0.001) 
(figure 5.1) and patients with chronic liver disease (median 1.17ng/ml (2.5), Mann-Whitney 
test p=0.006). There was no significant difference in serum CCL25 concentration between 
patients with ALF and ACLF (median 1.63ng/ml (2.57) Mann-Whitney p=0.178). 
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Figure 5.1: Serum concentration of CCL25 is raised in acute liver failure 
Serum samples from healthy controls (n=19) and patients with chronic liver disease (n=8), acute-on-
chronic liver failure (n=9) or acute liver failure (n=20) was analysed for CCL25 concentration by 
ELISA. **p<0.01 ***p<0.001 by Mann-Whitney test. Data shown as median and IQR. 
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Increased serum CCL25 concentration is an early event in human ALF  
In order to determine whether CCL25-CCR9 pathways are activated early in the 
development of ALF I worked with collaborators at Kings College London and Imperial 
College London (Dr L Possamai, Dr G Petts, Dr C Antoniades) to analyse CCL25 in serum 
samples taken from twenty-seven patients with ALF at varying time points after admission. 
This showed that CCL25 concentration was highest within 24 hours of admission to hospital 
and subsequently decreased (figure 5.2), suggesting an early role for CCR9/CCL25 in ALF. 
There were insufficient samples available to distinguish between differing aetiologies of ALF. 
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Figure 5.2 Increase in serum CCL25 concentration is an early event in human ALF  
 Serum from twenty-seven patients admitted to King’s College Hospital, London, with acute liver 
failure was analysed for CCL25 concentration by ELISA. Serum samples taken within 24 hours of 
admission had higher CCL25 concentration compared to later time points (One-way ANOVA 
p<0.001). Data shown as mean and SEM. n=27. 
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Serum CCL25 does not correlate with biochemical markers of liver injury or outcome 
In a small number of ALF patient samples (n=18) we were able to correlate serum 
concentration of CCL25 with markers of liver injury. No correlation was seen between 
CCL25 and serum amino transferase (AST), alanine transferase (ALT), bilirubin, creatinine or 
lactate concentration, or MELD score. MELD score is a composite score that is used to 
gauge severity of liver disease (table 5.1, figure 5.3). MELD is calculated by the following 
formula: [0.957xLn(creatinine) + 0.378xLn(bilirubin) + 1.120xLn(INR)] x 10. Similarly, no 
differences in serum CCL25 concentrations were observed when considering clinical 
outcomes (figure 5.4). All of these samples were collected on admission to hospital and 
represent a variety of sampling times.  
 
Variable r2 p 
Creatinine 0.04 0.385 
Bilirubin 0.13 0.140 
ALT 0.14 0.167 
AST 0.06 0.311 
Lactate <0.01 0.801 
MELD <0.01 0.685 
 
Table 5.1: correlation of serum CCL25 concentration with clinical parameters in 
patients with ALF  
(n=18) by linear regression. p value calculated by F test. 
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Figure 5.3: Serum CCL25 does not correlate with biochemical markers of liver injury  
Concentration of CCL25 in serum of patients with ALF (n=18) was analysed by ELISA, and 
correlated with selected clinical parameters: A creatinine B bilirubin C ALT D AST E pH F MELD 
score. No significant correlations were observed. p values were calculated by the F test. n=20 for 
each test.  
 108 
 
 
Figure 5.4: Serum CCL25 does not predict clinical outcomes 
Serum CCL25 concentration was measured in serum of patients with ALF. No differences in serum 
CCL25 concentration were seen between patients who survived (n=9), required liver transplantation 
(OLT, n=7) or patients who died (n=4) (one-way ANOVA p=ns). 
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CCR9 is expressed by intermediate CD14++CD16+ intrahepatic monocytes  
Monocytes were isolated from explanted liver tissue to examine CCR9 expression. These 
data were severely limited by the scarcity of liver tissue from patients with ALF. This flow 
cytometric analysis was performed with E. Triantyfillou. 
 
Analysis of liver-infiltrating monocyte subsets by flow cytometry (gated by FS/SS criteria and 
on CD45+ cells) showed that CCR9 was predominantly expressed by CD14++CD16+ 
monocytes, in keeping with previously published reports of CCR9 expression on blood 
monocytes (figure 5.5 and 5.6).  
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Figure 5.5: (previous page) CCR9 expression on liver infiltrating monocytes  
Monocytes were isolated from explanted liver tissue from patients undergoing liver transplantation 
for acute liver failure and chronic liver disease. In total 21 livers specimens were analysed: 3 normal 
liver (resection tissue), 7 autoimmune hepatitis, 6 alcoholic liver disease and 5 acute liver failure. 
Percentage CCR9 expression on monocytes was analysed by flow cytometry.  
A Identification of lymphoid, myeloid and granulocyte populations on the basis of forward and side 
scatter properties shows CCR9 expression predominantly in myeloid gate 
B CCR9 expression on monocyte subsets defined by CD14 and CD16 expression.  Data are shown 
as median and IQR. *p<0.05 ***p<0.001 by student’s t-test.  
 
 
 
 
 
 
Figure 5.6: CCR9 expression by monocyte subsets in different liver diseases 
Monocytes were isolated from explanted liver tissue from patients undergoing liver transplantation 
for acute liver failure and chronic liver disease and analysed by flow cytometry. Percentage CCR9 
expression on monocyte subsets did not significantly differ between aetiologies.  
 112 
Mouse models of acute liver injury 
 
. CCl4 was diluted 1:4 in corn oil (Sigma-Aldrich, Missouri USA) and 
administered to mice by intra-peritoneal (IP) at a dose of 1ml/kg. CCl4 induces a toxic acute 
liver failure by through generation of free radicals (Brattin et al., 1985) (Recknagel et al., 
1989) and mediated through macrophages and T-cells (Tiegs et al., 1992). Paracetamol at 
therapeutic doses is rapidly metabolised, predominantly through glucuronidation. A small 
amount of the highly toxic N-acetyl-p-benzoquinone imine (NAPQI) is generated through 
cytochrome P450 but is usually readily conjugated with glutathione to a nontoxic state. In 
overdose glucuronidation pathways are saturated and large amounts of NAPQI are 
generated. Glutathione stores are depleted at which point NAPQI accumulates and cause 
hepatic damage principally through oxidative stress (McGill et al., 2012). 
 
CCR9 is expressed on macrophages early in paracetamol-induced acute liver injury in mice 
Pilot experiments with paracetamol caused wide variation in the degree of liver injury as 
assessed by serum AST and ALT concentration (figure 5.7). Fasting animals overnight, to 
deplete hepatic glutathione stores, produced a more consistent pattern of injury and this 
approach was adopted for all subsequent experiments.  
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Figure 5.7: Large variations in liver injury caused by paracetamol in mice 
C57/Bl6 mice were given 400mg/kg of paracetamol by intra-peritoneal injections to establish the 
magnitude of liver injury caused be paracetamol. After 24 hours liver injury was assessed by 
measuring serum AST and ALT concentration. Large variations in serum AST and ALT were observed 
(n=40). Each dot represents a single animal. Aggregate data from three experiments shown. 
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Thirty C57/Bl6 male mice aged 6 weeks were administered  paracetamol at 
400mg/kg following an overnight fast, delivered by intra-peritoneal injection. Five mice were 
by CO2 inhalation at each of six time points: 0, 6, 12 24, 48 and 72 hours after 
administration of paracetamol. Serum was analysed for ALT concentration as a marker of 
hepatic injury, and liver-infiltrating cell subsets were analysed by flow cytometry.  
 
Mice lost weight, with maximum weight loss observed 24 hours after administration of 
paracetamol (figure 5.8A). Serum ALT showed considerable variation between animals, but 
was maximally elevated at 12 and 24 hours after paracetamol and quickly returned to normal 
(figure 5.8B). These results are consistent with previous reports (Nakamoto et al., 2012) 
and are comparable to the clinical syndrome of acute paracetamol poisoning. 
 
Analysis of infiltrating myeloid cells in liver tissue showed increases in CD11b+CD11c- 
macrophages and CD11b+F4/80dimLy6chi monocytes. CD11b+CD11c- macrophages peaked at 
12-24h post-paracetamol, and then fell but had not returned to baseline by 72 hours injury. 
Pro-inflammatory CD11b+F4/80dimLy6chi monocytes were elevated by 6 hours and numbers 
were maintained until 72 hours. This was paralleled by a decrease in CD11b+ F4/80dimLy6clo 
monocytes (figure 5.9A, B, C). The frequency of infiltrating CD11b+CD11c- macrophages 
correlated closely with serum markers of liver injury (figure 5.8B).  
 
CCR9 expression by CD11b+CD11c- monocytes peaks shortly after liver injury 
In addition the prevalence of CCR9 expressing CD11b+CD11c- macrophages correlated with 
clinical markers of injury, with an early peak around 6-24 hours after administration of 
paracetamol (figure 5.10). 
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Figure 5.8: Administration of 400mg/kg of paracetamol causes weight loss and liver 
injury  
Mice were at fixed time points after being given 400mg/kg of paracetamol A weight loss and 
B serum ALT concentration after paracetamol-induced liver injury. Data are shown as mean 
and SEM.  
Figure 5.9: Paracetamol causes influx of inflammatory macrophages and monocytes 
to liver tissue 
FACS analysis of liver-infiltrating monocyte subsets after paracetamol induced liver injury A 
CD11b+CD11c- macrophages B CD11b+Ly6chi monocytes C CD11b+Ly6clo monocytes. Gated on 
liver CD45+CD11b+ cells. Data shown as mean and SEM. 
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Figure 5.10: CCR9 expression by CD11b+CD11c- monocytes peaks shortly after 
paracetamol-induced liver injury 
CCR9 expression on CD11b+CD11c- macrophages after paracetamol induced liver injury. Gated on 
liver CD45+CD11b+ population.  Data shown as mean and SEM.  
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CCR9 is expressed on macrophages early in carbon tetrachloride induced acute liver injury 
Administration of CCl4 was also evaluated as a model of acute liver injury. Thirty male 
C57/Bl6 mice aged 6 weeks were given 1ml/kg of CCl4 by intra-peritoneal injection. Mice lost 
weight with maximum weight loss seen at 12 hours after CCl4 administration (figure 
5.11A). Peak ALT was seen at 24 hours after injury with rapid resolution to baseline levels 
at 72 hours (figure 5.11B). ALT took longer to peak than in paracetamol-induced liver 
injury (around 12 hours) but the average peak ALT concentration was much higher.  
 
Analysis of liver-infiltrating monocytes subsets showed early infiltration of CD11b+Ly6chi 
monocytes within 6 hours of CCl4 administration (figure 5.12B). CD11b+CD11c- 
macrophage infiltration of liver tissue paralleled serum ALT concentration with peak 
infiltrate seen at 24 hours after CCl4 administration (figure 5.11A).  
 
CCR9 expression on CD11b+CD11c- macrophages was seen to increase after CCl4 
administration with peak expression at 12 hours after injury which slowly returned to 
baseline by 72 hours post administration (figure 5.13).  
 
This pattern of infiltrating monocyte/macrophages was comparable to that seen in 
paracetamol-induced liver injury but with the interesting distinction that paracetamol 
induced a much more profound and persisting Ly6chi infiltrate and was associated with a 
much higher proportion of CCR9+ macrophages in the hepatic infiltrate.  
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Figure 5.11: Administration of 1mL/kg of CCl4 causes weight loss and liver injury 
C57/Bl6 mice were administered 1mg/kg of CCl4 and  at different time points following 
injury.  A weight loss and B serum ALT concentration were measured after CCl4. Data are shown as 
mean and SEM, n=30. 
 
 
 
  
Figure 5.12: CCl4 causes influx of inflammatory macrophages and monocytes to liver 
tissue  
FACS analysis of liver-infiltrating monocyte subsets after CCl4 mediated liver injury, gated on liver 
CD45+cells A CD11b+CD11c- macrophages B CD11b+Ly6chi monocytes C CD11b+Ly6clo 
monocytes. Data are shown as mean and SEM. 
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Figure 5.13: CCR9 expression by CD11b+CD11c- monocytes peaks shortly after CCl4-
induced liver injury  
C57/Bl6 mice were administered 1mg/ml of CCl4 and  at specified time point afterwards. 
CCR9 expression on liver-infiltrating CD11b+CD11c- macrophages after CCl4 induced liver injury. 
Data shown as mean and SEM, n=3-5 per time point as two mice died before the 72 hour time 
point. 
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Comparison of paracetamol and CCL4 induced liver failure models  
Paracetamol-induced liver injury induced a greater population of CCR9 expressing liver-
infiltrating macrophages when compared with CCl4 -induced injury (compare figures 5.10 
and 5.13). As paracetamol toxicity is the commonest cause of human acute liver failure this 
model has direct relevance to the human clinical syndrome. I therefore used paracetamol-
induced liver injury as a model to investigate the effect of CCR9 antagonism in acute liver 
injury. 
 
Inhibition of CCR9 in paracetamol-induced liver injury in mice 
Male C57/Bl6 mice aged 6 weeks and fasted overnight, were administered a small molecule 
inhibitor of CCR9 (30mg/kg of CCX507, ) by subcutaneous injection 1 
hour prior to administration of paracetamol. Previous pharmacokinetic experiments had 
shown that this dose of CCX507 caused over 90% of receptor coverage for over 24 hours 
(data not shown). A group of litter-mate control animals were given matched volumes of 
vehicle (1% hydroxypropyl methylcellulose, HPMC), without drug. Mice were 24, 
48, or 72 hours after administration of paracetamol, by CO2 inhalation. Blood samples were 
taken by cardiac puncture. A 24-hour initial time point was used despite peak liver injury 
being seen at 12 hours as a pragmatic measure - this allowed sufficient time for 
administration of inhibitor, paracetamol and analysis. 
 
CCR9 antagonism reduced serum AST and ALT concentration over the course of the 
experiment (figure 5.14): two-way ANOVA p=0.0034 and p=0.0079 respectively. 
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Figure 5.14: Inhibition of CCR9 in paracetamol-induced liver injury in mice 
C57/Bl6 mice were given a small molecule inhibitor of CCR9, or comparable volume of vehicle, prior 
to administration of 400mg/kg of paracetamol. Serum AST and ALT concentration was measured at 
various time points after administration of paracetamol. **Two-way ANOVA p<0.01. Data are 
shown as mean and SEM, 5 mice per time-point 
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CCR9 antagonism with CCX507 reduces tissue CD11b+CD11c- macrophages  
Monocyte infiltration of liver tissue was analysed by flow cytometry 24 hours after 
administration of paracetamol in ten mice – the peak of injury and inflammation (see figures 
10.8, 10.9 and 10.10). In view of previous reports implicating CCR9 expressing 
CD11b+CD11c- macrophages in the development of acute injury, the accumulation of these 
cells post-paracetamol administration was assessed by flow cytometry.  One mice died in the 
CCX507 group. Other mice treated with CCX507 had fewer liver-infiltrating 
CD11b+CD11c- macrophages as a proportion of CD45+CD11b+ cells when compared to 
vehicle treated controls (median 13.2% (IQR 10.25) vs. 19.3 (8.63), Mann-Whitney test 
p=0.0034)(figure 5.15). 
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Figure 5.15: CCR9 antagonism reduces infiltration of liver tissue by macrophages 
C57/Bl6 mice were given 400mg/kg of paracetamol and after 24 hours. Liver-infiltrating 
immune cells were analysed by flow cytometry, gated on CD45+ cells. CD11b+CD11c_ macrophages 
were reduced in mice given CCR9 antagonist CCX507 prior to paracetamol administration. *p<0.05 
by student’s t-test.  Data are shown as median and IQR, *p<0.05 by Mann-Whitney test. 
 124 
Prophylactic CCR9 antagonism does not improve survival after Paracetamol-induced liver 
injury 
Little mortality was seen when using 400mg/kg of paracetamol. A higher dose of paracetamol 
- 750mg/kg - was used to establish if inhibition of CCR9 could confer a survival benefit. 
Ninety C57/Bl6 mice aged 6 weeks were given 750mg/kg of paracetamol after an overnight 
fast, with CCX507 (30mg/kg) or matched volumes of vehicle given 1 hour before 
paracetamol. Over the course of three experiments, an overall trend towards greater 
survival was seen in the mice given CCX507, but this was not statistically significant (log-rank 
p=0.075) (figure 5.16). The median time to death in the two groups was significantly 
different (median time to death, 40 hours (IQR 32) vs. 46 (24),  Mann-Whitney test p=0.028) 
(figure 5.17).  
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Figure 5.16: Prophylactic CCR9 antagonism does not improve survival after 
Paracetamol-induced liver injury 
C57/Bl6 mice were given high dose paracetamol after administration of CCR9 antagonist CCX507 
or vehicle. n=45 in each group, p=ns by log-rank test.  
 
 
Figure 5.17: Prophylactic CCR9 antagonism improves median survival after 
Paracetamol-induced liver injury 
C57/Bl6 mice were given high dose paracetamol after administration of CCR9 antagonist CCX507 
or vehicle. Data are shown as median and IQR with whiskers showing minimum and maximum 
values. n=45 for each group, *p<0.05 by Mann-Whitney test. 
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Discussion  
The CCR9/CCL25 axis is up regulated in human acute liver failure, where increased serum 
levels of CCL25 were observed. Data from human and mouse studies show that an increase 
in levels of CCL25 in serum is an early feature of ALF. In patients admitted to hospital with 
ALF, levels of CCL25 were greater early after admission and declined subsequently. In mice 
there was a marked increase in CCR9+ macrophages within 12 hours of acute liver injury 
induced by either paracetamol or CCl4, which corresponded to peak levels of liver injury as 
assessed by serum ALT concentration. CCR9+ monocytes were observed in the explanted 
liver tissue of a patient undergoing liver transplantation for acute liver failure.  
 
To study the role of CCR9 in vivo I used murine models of liver failure induced by carbon 
tetrachloride or paracetamol. Paracetamol was used in experiment with a CCR9 antagonist 
as a model that most closely reflects human disease. Prophylactic antagonism of CCR9 in 
mice improved early liver injury as assessed by serum AST and ALT concentration and 
significantly reduced infiltration of liver tissue by CD11b+CD11c- macrophages.  In high dose 
paracetamol toxicity, CCR9 antagonism did not improve survival, although a trend towards 
improved mortality was seen. 
 
CCR9 was expressed on CD14++CD16+ monocytes in liver tissue from a patient with ALF. 
The CD14++CD16+ intermediate subset of monocytes is enriched in normal and diseased 
liver (Liaskou et al., 2013)and secretes pro-inflammatory and pro-fibrotic cytokines and 
chemokines. In the context of acute liver injury, CCR9-mediated recruitment of monocytes 
may contribute to early inflammatory changes in the liver. This is supported by the 
observation that serum CCL25 concentration is highest in the early phase of hospital 
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admissions, and mouse data showing early increase in circulating pro-inflammatory CCR9+ 
cells. This increase in serum CCL25 also suggests that monocytes are recruited from blood 
as CCR9+ cells rather than expressing CCR9 after transmigration into liver. Liver transplant 
is performed relatively late after the onset of liver injury, and thus findings in explanted liver 
tissue may not reflect an early, pro-inflammatory phenomenon. 
 
CCR9 is expressed on other cells other than monocytes/macrophages which are the focus 
of this chapter. As discussed in the introduction, CCR9 expression defines a population of 
gut-homing T lymphocytes (Svensson et al., 2002, Johansson-Lindbom et al., 2003) as well a 
T-lymphocytes observed in PSC (Eksteen et al., 2004). B-cell expression of CCR9 is also 
seen in the context of the gastro-intestinal tract (Mora et al., 2006). In terms of 
monocyte/macrophage CCR9 expression, pro-inflammatory myeloid cells expressing CCR9 
have been reported in inflammatory bowel disease (Linton et al., 2012) and rheumatoid 
arthritis (Schmutz et  al., 2010) in humans. Thus, the immunology of CCR9 antagonism has 
potentially more consequence than pure myeloid recruitment. However, in analysis of 
human liver specimens from patients with ALF, we saw the greatest CCR9 expression in 
cells of the myeloid gate (figure 5.6A) and confirmed that prophylactic CCR9 antagonism in 
mouse models of ALD reduced macrophage accumulation suggesting that this subset of 
leukocytes are mobilised at least in part by CCR9 in acute liver injury. In contrast 
plasmacytoid dendritic cells that were recruited via CCL25 were shown to be hepato-
protective (Reid D et al., 2013) in a sub-acute model of biliary injury. 
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In my data, an improvement in AST and ALT was observed at 24 hours after injury induced 
by paracetamol, as well as reduced accumulation of hepatic macrophages. That these changes 
occurred so early raises the possibility of other explanations other than immunological. 
Hepatocytes express some chemokine receptors with roles in regeneration – see chapter 7 
– but no evidence for hepatocyte expression of CCR9 has been found (Autschbach et al., 
2005). Inhibition of CCR9 signalling has been investigated in other models: in murine 
peritoneal sepsis models, CCR9 is found on macrophages where it appears to control 
recruitment of macrophages to the peritoneum of mice subjected to caecal ligation in to 
control systemic sepsis during early phases of peritoneal infection (Mizukami et al., 2012). 
Similar to my data, CCR9 knock-out mice were more vulnerable to microbial sepsis than 
wild-type black 6 mice and this was evident in terms of the clinical condition of mice as soon 
as 24 hours after the onset of caecal ligation. CCR9 antagonism may therefore have a very 
prompt effect on liver injury. 
 
Thus, CCL25/CCR9 appears to be activated in a variety of disease states and models where 
the function of immune cells that express CCR9 differs. The function of CCR9+ cells may 
depend n the environment in which they are found and could conceivably change within an 
individual over the course of a disease. Functional experiments may illuminate this further. 
CHAPTER 6: Role of CXCR6 in murine models of acute and 
chronic liver injury 
 
Work from our laboratory showed the CXCR6/CXCL16 receptor/ligand pairing playing a 
role in the recruitment of lymphocytes to biliary epithelium (Heydtmann et al., 2005). 
However contrasting results are evident in the published literature: Geissman et al. showed 
that CXCR6 knock out mice display reduced liver injury in a T-cell mediated model of acute 
liver damage induced by Concanavalin-A (Geissmann et al., 2005), an effect attributed to a 
reduction in liver-resident NKT cells. In contrast Wehr et al reported that CXCR6 appears 
harmful in liver injury (Wehr et al., 2013).   
 
This led me to investigate the role of CXCR6 in liver injury in vivo, using a strain of 
CXCR6GFP/GFP mice . These mice express green fluorescent protein 
instead of CXCR6 and are functional CXCR6 knockouts. The animals were backcrossed 
onto a C57/Black 6 (C57/Bl6) background, and C57/Bl6 mice were used as controls in all 
experiments.  
 
CXCR6GFP/GFP mice were indistinguishable from wild type mice before induction of liver 
injury in terms circulating liver enzymes (ALT) and liver histology. CXCR6GFP/GFP mice and 
control mice were subjected to an acute liver injury by administration of carbon 
tetrachloride (CCl4), or a chronic liver injury by administration of 5 weeks of hepatotoxic 
methionine-choline deficient (MCD) diet. The nature of injury differs between these two 
experiments: CCl4 causes an acute toxic injury to liver tissue mediated through oxidative 
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stress. MCD diet prevents the export of lipids from hepatocytes causing marked steatosis 
and liver injury over weeks. 
 
Knock out of CXCR6 in acute liver injury 
Six male mice (three wild type, three CXCR6GFP/GFP mice) aged 6 weeks were administered a 
single dose of 1mg/kg of CCl4 suspended in corn oil, or corn oil alone by intra-peritoneal 
injection. After 24 hours, mice were nd blood and liver samples were taken. 
 
CXCR6GFP/GFP mice and serum markers of liver injury 
Serum concentrations of AST and bilirubin were measured to assess liver injury. 
CXCR6GFP/GFP mice had lower levels of AST although this was not statistically significant 
(median concentration 101.0 IU/mL (IQR 142) vs. 250 IU/mL (379),  Mann-Whitney test 
p=0.200). Bilirubin concentration was the same between groups (median 4.0 μmol/L (IQR 
6.0) vs. 4.0 (1.00), student’s t-test p=0.427) (figure 6.1).  
  
 131 
 
Figure 6.1: Serum markers of liver injury after administration of carbon tetrachloride 
Acute liver injury was induced in C57/Bl6 mice and CXCR6GFP/GFP mice by administration of CCl4. 
When compared to WT C57Bl/6 animals CXCR6GFP/GFP mice had lower serum concentrations of A 
AST but B bilirubin did not differ, 24h post administration of CCl4 although these differences did not 
reach significance. Data are shown with a point representing each animal, with lines at median and 
IQR.  
 132 
Infiltration of liver tissue by leukocytes 
Sections of liver tissue were stained with haematoxylin and eosin, and imaged at 10x 
magnification with an Axioskop 40 microscope. Analysis of sections was performed by 
counting the number of infiltrating cells in ten 100μm2 areas over each section. In keeping 
with the data regarding liver injury, the CXCR6GFP/GFP tended to have fewer infiltrating cells in 
liver tissue but this was not statistically significant (median 7.1 cells per 100μm2 (IQR 2.5) vs. 
10.1 (IQR 4.4), Mann-Whitney test p=0.20) (figure 6.2)(figure 6.3). 
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Figure 6.2: Histological assessment of leukocyte infiltration after administration of 
carbon tetrachloride 
Acute liver injury was induced in C57/Bl6 mice and CXCR6GFP/GFP mice by administration of CCl4. 
When compared to WT C57Bl/6 animals CXCR6GFP/GFP mice had fewer infiltrating cells assessed by 
histology, although these differences did not reach significance. Data are shown with a point 
representing each animal, with lines at median and IQR.  
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Figure 6.3: histological appearance of liver injury after acute CCl4 injury 
Wild type and CXCR6GFP/GFP mice were given 1ml/kg of CCl4 and  24 hours later. 
Sections of tissue stained with haematoxylin and eosin from A wild type and B CXCR6GFP/GFP mice.   
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Knock-out of CXCR6 in chronic liver injury 
Response to MCD diet in the absence of CXCR6  
Five male CXCR6GFP/GFP and five male C57/Bl6 mice aged six weeks were administered a 
MCD diet for 6 weeks to induce a chronic model of hepatic injury.  Reduced lipid export 
from hepatocytes causes liver injury. Animals on an MCD diet typically develop 
steatohepatitis and a very mild fibrotic response over the course of the diet. At the end  
blood and liver samples were taken for analysis. 
 
MCD diet causes similar weight loss in CXCR6GFP/GFP and control mice  
It has been shown that the MCD diet induces significant weight loss (typically up to 40% 
over 5-6 weeks) and therefore the weight of each animal was monitored closely throughout 
the duration of the experiment. Control mice were heavier at baseline and throughout the 
experimental period, but proportional weight loss did not differ between groups  (figure 
6.4 A, B). 
 
MCD diet causes similar hepatic steatosis in CXCR6GFP/GFP and wild type mice 
MCD diet causes hepatic steatosis through inhibition of lipid export from hepatocytes. To 
assess steatosis, frozen sections of liver tissue were incubated with Oil-red-O which stains 
neutral triglycerides and lipids. Steatosis was quantified by proportion of the area of the 
section that stained positive for the dye as assessed by ImageJ analysis. No difference in 
steatosis was observed between CXCR6GFP/GFP mice and control mice (mean percentage area 
26.8% (SEM 0.45) vs. 26.8 (0.82), student’s t-test p=0.992) (figure 6.5, figure 6.6).  
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Figure 6.4: MCD diet causes similar weight loss in CXCR6GFP/GFP and control mice  
C57/Bl6 (n=5) and CXCR6GFP/GFP (n=5) male mice were given MCD diet for 5 weeks. A Absolute 
weight was higher in wild type mice, but B proportional weight loss did not differ between groups. 
Data shown as mean and SEM. 
 
 
  
 
Figure 6.5: MCD diet causes similar hepatic steatosis in CXCR6GFP/GFP and wild type 
mice 
C57/Bl6 (n=5) and CXCR6GFP/GFP (n=5) mice were given MCD diet for 5 weeks. Oil-red O staining of 
liver sections was performed, and hepatic steatosis quantified by measuring percentage area of 
staining over 5 fields at 10x magnification for each animal. Each data point represents one animal, 
lines represent mean and SEM, p=ns by student’s t-test. 
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Serum markers of liver injury are higher in CXCR6GFP/GFP mice on MCD diet 
Blood samples taken by cardiac puncture at the time of  were analysed for AST 
activity and bilirubin concentration. Serum AST concentration was significantly higher in 
CXCR6GFP/GFP mice than in wild type (mean 689 IU/ml (SEM 144) vs. 233 (45.5), students t-
test p=0.03) (figure 6.7). Bilirubin concentration also differed between groups but this was 
not statistically significant (mean 26 μmol/L (IQR 12.5) vs 9.3 (0.63), student’s t-test 0.229). 
 
Infiltration of NKT cells is reduced in CXCR6GFP/GFP mice 
Infiltrating lymphocytes were isolated from liver tissue and analysed by flow cytometry. No 
significant differences were observed between wild type mice and CXCR6GFP/GFP mice 
with regard to CD3+ T lymphocytes or CD3-Nk1.1+ NK cells as frequency of all lymphoid 
cells (table 6.1, figure 6.6 A, B). However the frequency of CD3+Nk1.1+ NKT cells as a 
proportion of all lymphoid cells was markedly reduced in CXCR6GFP/GFP mice (table 6.1, 
figure 6.8 C) as might be expected given the role of CXCR6 in the recruitment of this 
subset (see introduction). Distribution of leukocytes was similar in wild type and 
CXCR6GFP/GFP mice (figure 6.8). 
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Figure 6.6: histological appearance of liver injury after MCD diet 
Wild type and CXCR6GFP/GFP mice were given MCD diet for 5 weeks. Sections of liver tissue from 
A wild type mice and B CXCR6GFP/GFP mice were stained with haematoxylin and eosin. Images at 
10x magnification. Steatosis was similar between the two groups in terms of quantity and 
distribution.  
 
 
Figure 6.7: Serum markers of liver injury in CXCR6GFP/GFP mice on MCD diet 
C57/Bl6 and CXCR6GFP/GFP mice were given MCD diet for 5 weeks. A Serum AST concentration 
was higher in CXCR6GFP/GFP mice B no difference was seen in bilirubin concentration. * student’s t-
test p<0.05 
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 Control mice CXCR6GFP/GFP mice 
p 
 
Frequency of 
lymphoid gate 
(median) 
IQR 
Frequency of 
lymphoid gate 
(median) 
IQR 
CD3+  
T lymphocytes 17.9 6.82 12.36 15.34 0.421 
CD3+Nk1.1+ 
NKT cells 7.63 4.31 1.86 1.74 0.008 
CD3-Nk1.1+  
NK cells 15.5 4.80 23.2 21.1 0.151 
 
 
Table 6.1: C57/Bl6 (n=5) and CXCR6GFP/GFP (n=5) mice were given MCD diet for 5 
weeks.  
Infiltrating lymphocytes isolated from liver tissue were analysed by flow cytometry. Lymphocyte 
subsets were gated on CD45+cells and then categorised by CD3 and Nk1.1 expression as CD3 
lymphocytes, NKT cells or NK cells. Analysed with Mann-Whitney test. 
 
 
 
 
Figure 6.8: Infiltration of NKT cells is reduced in CXCR6GFP/GFP mice  
C57/Bl6 (n=5) and CXCR6GFP/GFP (n=5) mice were given MCD diet for 5 weeks. Infiltrating 
lymphocytes were isolated from liver tissue and analysed by flow cytometry. No differences were 
observed in frequency of infiltrating A T lymphocytes or B NK cells. C Fewer NKT cells were seen as 
proportion of all lymphoid cells. Each data point represents a single animal, lines at median and IQR 
**p<0.01, ns=p>0.05 by Mann Whitney test 
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Pro-fibrotic genes are up-regulated in CXCR6GFP/GFP mice following 5 weeks of MCD diet 
Fibrosis is a common feature of chronic liver injury. The MCD diet model of liver injury 
results in increased fibrogenesis although this is mild compared with human fatty liver 
disease.  
 
Frozen sections of liver tissue were processed with Van Gieson staining to detect total 
collagen. The extent of fibrosis was then quantified using Image-J software to measure the 
collagen proportionate area of the section that was stained. No significant differences in area 
of staining were observed  although there was a trend for more fibrosis in CXCR6GFP/GFP 
mice (mean percentage area 1.83% (SEM 0.05) vs. 1.99  (0.05), Mann-Whitney test p=0.151) 
(figure 6.7)(figure 6.10). 
 
Due to the mild nature of fibrosis routinely observed in the MCD diet model of liver injury 
early changes in fibrogenesis might be better reflected in gene expression of pro-fibrotic 
genes rather than by assessing mature matrix by van Gieson staining. To this end, the 
expression of Col1a1 (collagen 1a1) and Acta2 (α-smooth muscle actin) were analysed by 
qRT-PCR. Expression of both genes was significantly increased in the liver tissue taken from 
CXCR6GFP/GFP mice, suggesting that the absence of CXCR6 promotes fibrogenesis (figure 
6.11 A and B). 
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Figure 6.9: No differences in histological appearances of fibrosis between wildtype 
and CXCR6GFP/GFP mice after MCD diet 
C57/Bl6 and CXCR6GFP/GFP mice were fed an MCD diet for 5 weeks. Fibrosis induced by diet was 
assessed by Van Gieson staining of liver sections. Five mice in each group. Data are shown as 
median and IQR 
 
 
Figure 6.10 Pro-fibrotic genes are up-regulated in CXCR6GFP/GFP mice following 5 weeks 
of MCD diet 
C57/Bl6 and CXCR6GFP/GFP mice were fed an MCD diet for 5 weeks. Fibrosis induced by diet was 
assessed by Van Gieson staining of liver sections, A Col1a1 gene expression and D Acta2 gene 
expression Five mice in each group. Data are shown as mean and SEM. *p<0.05 by student’s t-test. 
 142 
Conclusion 
Acute and chronic models of liver injury in mice showed contrasting effects of CXCR6. In 
acute injury induced by CCl4, a pattern towards reduced injury in CXCR6
GFP/GFP mice was 
seen although numbers of mice was too small to allow for statistical significance. In contrast, 
in a chronic or sub-acute injury caused by MCD diet, mice without functional CXCR6 
demonstrated worse liver injury – higher serum AST concentration and more fibrosis - 
despite reduced infiltration of NKT cells.  
 
. Acute 
liver injury in this strain of mice has been reported by other investigators. In particular, 
Wehr et al. who administered a slightly lower dose of CCl4 than I did (0.6mL/kg compared 
to 1.0mL/kg) (Wehr et al., 2013). This group reported attenuated liver injury in 
CXCR6GFP/GFP mice, measured by ALT. Interestingly this difference was significant at 6 
and 72 hours after iniation of injury, but did not appear to be at 24 hours after injury, which 
was the time point that I used. This group were also able to analyse the infiltrate in CCl4 
injury where significantly fewer NKT cells and monocytes were seen. In a T-cell mediated 
hepatitis induced by injection of concanavalin-A, CXCR6GFP/GFP mice were protected with 
lower serum AST concentration and less pronounced necrotic changes on histology.  
 
Other models of acute liver injury have demonstrated the harmful role of CXCR6/CXCL16: 
Xu and colleagues gave primed mice with Bacille Calmette-Geurin (BCG) injection and then 
administered LPS to induce liver injury (Xu et al., 2005). Anti-CXCL16 antibodies reduced 
ALT concentration and protected against death. Sato et al. used a model of graft versus host 
disease (GvHD) with wild-type or CXCR6-/- lymphocytes,  where reduced CD8+ lymphocyte 
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recruitment was observed although direct measures of liver injury are not reported. My data 
regarding CCl4 are therefore consistent with other reports of the role of CXCR6 in acute 
liver injury. 
 
 
Liver injury induced by MCD diet is a much more chronic process than the injury caused by 
CCl4. I saw no effect on steatosis caused by MCD diet, which would be expected as this is 
mediated by dietary deficiency. However I saw a statistically significant increase in serum 
AST, despite a decrease in infiltrating NKT cells. The only other data reported on this type 
of injury in the context of CXCR6 knock out mice is from Wehr (Wehr et  al., 2013, Wehr 
et al., 2014). These investigators saw a similar decrease in infiltrating NKT cells, but reduced 
histological necrosis and fibrosis. Interestingly serum AST or ALT is not reported. The only 
differences between my experiment and this group seems to be the length of diet – I gave 
mice 5 weeks of MCD, whereas Wehr and colleagues report 4 and 8 week outcomes. It is 
hard to see how this might make a difference to the findings as similar results were seen at 
each time point.  
 
A possible explanation for this observation is that NKT cells, noted to be markedly reduced 
in CXCR6GFP/GFP mice by the Wehr group and myself, have been shown to be able to drive 
the migration and activate T regulatory (Treg) cells (Santodomingo-Garzon and Swain, 
2011). An absence of Treg activation by NKT cells could lead to the more severe liver injury 
that I observed. Unfortunately neither I nor the Wehr paper show data regarding Treg 
numbers of function.  An alternative explaination is suggested by the data previously 
discussed from Gao et al. (Gao et al., 2012) showing CXCR6 expression by hepatocytes. 
CXCR6 may play a protective role, where knock-out would be detrimental. 
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The divergent results between acute and sub-acute models of liver injury, and between my 
data and published work, and the important differences between the distribution of CXCR6 
on lymphoid cells between humans and mice lead to examination of CXCR6 in human liver 
disease, described in the next two chapters.   
 
 
CHAPTER 7: Expression and function of CXCR6 on 
hepatocytes 
 
 
Most of the focus on chemokine receptors as targets in liver disease has been on their 
expression and function of leukocytes and how this may regulate the balance between 
inflammatory and regulatory pathways in inflammatory diseases.  However chemokine 
receptors are also expressed on non haematopoetic cell types including stromal and 
epithelial cells and a full understanding of the effects of inhibiting chemokine signalling needs 
to take into account possible effects on these cell types.  
 
Hepatocytes express the chemokine receptors CXCR1 (Clarke et al., 2011) and CXCR2 
(Hogaboam et al., 1999, Bone-Larson et al., 2001, Kuboki et al., 2008). The expression of 
these receptors has been suggested to be protective against liver injury. Antagonism of 
CXCR1/2 exacerbated ischaemic/reperfusion injury while CXCR1-/- mice showed reduced 
hepatocyte proliferation (Clarke et al., 2011). Administration of recombinant CXCL10 (a 
CXCR2 ligand) protected mice against paracetamol-induced acute liver injury through 
induction of CXCR2 (Bone-Larson et  al., 2001) although these results are contradicted by a 
later study using ischaemia/reperfusion injury as a model of acute liver injury, where 
CXCR2-/- mice and CXCR2 antagonists were protective (Kuboki et al., 2008). The authors 
found evidence of opposing concentration-dependent effects of the CXCR2 ligand CXCL2:  
low concentrations were hepato-protective whereas higher concentrations were 
hepatotoxic.  
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CXCR6 is expressed by specific subsets of effector lymphocytes and is has been implicated 
in the development of inflammation and injury in several liver diseases making it a potential 
target for therapeutic intervention.  In addition, CXCR6 is expressed by hepatoma cell lines 
in vitro and has been described in vivo on tumour cell in tissue in HCC (Gao et al., 2012). In 
this report, CXCR6 expression in HCC specimens was associated with vascular invasion of 
tumours, and also HCC progression suggesting it plays a functional role. Outside of the liver, 
CXCR6 and its ligand CXCL16 are expressed in a variety of tumours where expression has 
been associated with a more aggressive phenotype (Porta, 2012). For example CXCR6 
expression has been shown in glial precursor cells in the central nervous system where it 
guides migration and invasion (Ludwig et al., 2005, Hattermann et al., 2008). Interestingly 
CXCR6 signalling has shown a protective function in the gut where it can facilitate epithelial 
restitution in gut tissue (Furuya et al., 2011). 
 
To further elucidate the role of this chemokine receptor:ligand pairing in the development of 
chronic liver disease I investigated the expression of CXCR6 on parenchymal liver cells, and 
used hepatoma cell lines in functional assays to explore the effects of CXCR6 signalling. 
 
CXCR6 expression on parenchymal liver cells 
CXCR6 is expressed by immune cells and hepatocytes in injured liver 
Immunohistochemistry was performed on formalin fixed paraffin-embedded liver sections to 
identify cells that expressed CXCR6. Initial experiments were unsuccessful with non-specific 
staining seen despite trying a variety of different antibody concentrations and protocols. 
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However, a low-temperature antigen-retrieval step proved to be successful and allowed us 
to study CXCR6 expression. CXCR6 was detected on infiltrating immune cells, as expected, 
but also on hepatocytes, particularly at the edge of regenerating nodules adjacent to fibrous 
septa (figure 7.1).  
 
To confirm these findings and better define cellular localisation, I used simultaneous staining 
of different cell lineages using antibodies conjugated to fluorochromes imaged by confocal 
microscopy. Hepatocytes were identified through staining sections with an antibody against 
CK18 and this confirmed CXCR6 expression on hepatocytes (figure 7.2). 
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Figure 7.1: CXCR6 is expressed by leukocytes and hepatocytes in injured liver 
Paraffin embedded sections of explanted liver tissue was stained for CXCR6. Sections are shown at 
40x magnification A CXCR6 was expressed on infiltrating immune cells (long arrows) and also on 
hepatocytes, particularly at the edge of regenerative nodules (short arrows). B staining with isotype 
matched antibody. 
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Figure 7.2: CXCR6 is expressed by hepatocytes 
Paraffin-embedded sections of liver tissue were stained with antibodies conjugated to fluorochromes 
and imaged with confocal microscopy at 63x magnification. In this image CK18 is shown in green, 
DAPI in blue and CXCR6 shown in red. CXCR6 is expressed by hepatocytes, marked by membrane 
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CK18 expression, and to a lesser extent by infiltrating immune cells in the fibrous septum. Image B 
shows staining with DAPI, CK18 and an isotype matched control antibody in place of CXCR6 
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CXCR6 gene expression in cirrhotic liver  
RNA was isolated from whole liver tissue from patients with cirrhosis removed at the time 
of transplantation, and non-involved liver tissue distal to resected liver tumours tissue from 
resections performed to remove malignancy, distal to the cancerous lesion) was used. 
CXCR6 gene expression was analysed by qRT-PCR relative to β-ACTIN as a control gene. 
Cirrhotic liver showed increased gene expression of CXCR6 compared to non-cirrhotic liver 
tissue (figure 7.3), although this was not statistically significant (median fold expression in 
cirrhotic tissue 2.09 (IQR 5.70) vs. 0.44 (1.22), Mann Whitney test p=0.095).  
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Figure 7.3 CXCR6 gene expression is not up-regulated in cirrhotic liver  
 RNA was isolated from cirrhotic (n=5) and non-cirrhotic (n=5) liver tissue. Gene expression of 
CXCR6 was analysed by qRT-PCR with reference to β-ACTIN as a housekeeping gene. Each data 
point represents a single isolate of liver tissue, normalized to average CXCR6 expression in normal 
liver tissue. Lines represent median and IQR. ns=p>0.05 by Mann Whitney test 
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Gene expression of CXCR6 is increased in hepatocellular carcinoma 
The finding of CXCR6 expression on hepatocytes was consistent with previous reports of 
CXCR6 expression in HCC (Gao et al., 2012). In view of this, CXCR6 gene expression in 
HCC was investigated.  
 
RNA was isolated from samples of tissue taken from both HCC and distal, non-cancerous 
tissue in the same liver. CXCR6 gene expression was analysed with qRT-PCR, using β-actin as 
a housekeeping gene and found to be significantly up regulated in HCC compared to distal 
tissue (mean fold expression in HCC 6.09 (SEM 8.56), paired t-test p=0.031)(figure 7.4). 
The increase in gene expression was not consistent in all samples. Expression appeared to 
segregate into at least two discrete populations and therefore the histological grade of 
tumour tissue was examined with regard to CXCR6 expression. There was a trend for the 
differentiation grade of the tumour to associate with CXCR6 expression although this was 
not significant (one-way ANOVA p=0.306)(figure 7.5A). However, when considering the 
background liver tissue, greater expression of CXCR6 was seen in tumours arising in 
cirrhotic liver tissue than those arising in non-cirrhotic tissue (mean fold CXCR6 gene 
expression from distal tissue 8.12 (SEM 3.12) in cirrhotic tissue vs. 0.916 (0.195) in non-
cirrhotic tissue, student’s t-test p=0.046) (figure 7.5B).  
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Figure 7.4: Gene expression of CXCR6 is increased in hepatocellular carcinoma 
 RNA was isolated from cancerous lesions or distal non-cancerous liver tissue and CXCR6 gene 
expression analysed by qRT-PCR. CXCR6 gene expression was higher in cancerous tissue. n=16, 
*p<0.05 by paired t-test. Each pair of data points represents tumour or distal tissue from one liver, 
where CXCR6 expression is normalized to expression in distal tissue. 
 
 
Figure 7.5: CXCR6 gene expression is associated with phenotype of background liver 
RNA was isolated from cancerous and distal non-cancerous liver tissue. Gene expression of CXCR6 
was analysed by qRT-PCR and changes in expression categorised by A grade of tumour 
differentiation categorised as well (n=2), well-moderate (n=5) or moderate (n=6) (one way ANOVA 
p=0.306) and B background liver disease categorised as non-cirrhotic (n=3) or cirrhotic (n=13) 
*p<0.05 by student’s t-test. 
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CXCR6 is expressed by HCC tumour tissue  
Paraffin-embedded paired sections of tumour tissue and non-involved liver tissue from 
patients with HCC were stained for CXCR6 expression. Immunohistochemistry showed 
diffuse staining for CXCR6 throughout liver parenchyma as described above, but particularly 
at the margins of regenerative nodules in liver resected for HCC (figure 7.6 and 7.7).  
 
In very few cases, it was possible to perform both qRT-PCR and immunohistochemistry. In 
these few samples, higher gene expression was associated with stronger staining. 
Comparison between gene expression data and immunohistochemistry was not possible in 
most cases due to limitations of tissue available – many samples were stored as frozen or in 
formalin, but not both. 
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Figure 7.6: CXCR6 is expressed by hepatocellular carcinoma 
Paraffin-embedded sections of tumour tissue and distal, non-involved liver form the same patient 
were stained for CXCR6. Images at 10x magnification are shown  
A margin of HCC showing strong CXCR6 expression in neighbouring regenerative nodule (red) B 
staining of same area with isotype matched control antibody C cartoon of image A to demonstrate 
relevant areas of image D staining of distal liver tissue from the same patient without evidence of 
CXCR6 expression 
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Figure 7.7: CXCR6 is expressed by hepatocellular carcinoma 
Paraffin-embedded sections of tumour tissue and distal, non-involved liver form the same patient 
were stained for CXCR6. Images at 40x magnification are shown  
A CXCR6 staining from margin of HCC showing strong CXCR6 expression in neighbouring 
regenerative nodule B CXCR6 staining of distal uninvolved liver from the same patient, without overt 
CXCR6 expression 
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Expression of CXCR6 in hepatoma cell lines 
Having confirmed increased gene and protein expression of CXCR6 in HCC, I investigated 
whether hepatocyte associated CXCR6 retained function. For these experiments, the 
hepatoma cell lines Huh-7 and HepG2 were used. The HuH-7 cell line was established from 
a well-differentiated hepatocellular carcinoma in a 57-year-old Japanese man in the early 
1980s (Nakabayashi et al., 1982). In contrast, the HepG2 cell line was established from 
biopsies of a hepatocellular blastoma in a fifteen-year-old Caucasian boy in the 1970s (Aden 
et al., 1979). These cell lines are useful surrogates for primary hepatocytes, or of cells from 
HCC for in vitro studies as they are amenable to culture. 
 
Expression of CXCR6 transcripts in hepatoma cell lines  
HepG2 and HuH-7 hepatoma cells were serum starved for 24 hours and then incubated 
with TNF-α and IFN-γ (both at 10ng/ml), or varying concentrations of the CXCR6 ligand 
CXCL16 for 24 hours. CXCR6 gene expression was then analysed by qRT-PCR. Both 
HepG2 and HuH-7 cells expressed CXCR6 (figure 7.8),  the levels of which were increased 
significantly upon the addition of 10ng/ml of CXCL16 for 24 hours (HuH cells, fold CXCR6 
gene expression 12.84 compared to no treatment, p<0.001 by student’s test, HepG2 cells, 
mean fold CXCR6 gene expression 7.06 compared to no treatment, p=0.015 by student’s t-
test) (figure 7.8). Conversely, the addition of a lower concentration of CXCL16 (2.5ng/ml) 
or a combination of the pro-inflammatory cytokines TNF-α and IFN-γ had no effect. 
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Figure 7.8: Hepatoma cell lines show CXCR6 gene expression 
Hepatoma cell lines were incubated in media treated with TNFa and IFNg or CXCL16. CXCR6 gene 
expression was analysed by qRT-PCR. n=5 for each replicate. Expression was measured relative to 
B-ACTIN, and normalized to the no treatment control. Data are shown as mean and SEM, 
ns:p<0.05, *p<0.05, ***p<0.001 by student’s t-test.  
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Function of CXCR6 on hepatoma cell lines 
Given the presence of CXCR6 in HCC, I studied the effect of CXCR6 on the proliferation 
of hepatoma cell lines as a measure of the functionality of CXCR6. The proliferation of 
hepatoma cells was analysed by analysis staining of DNA with Hoescht dye and by analysis of 
dividing cells with flow cytometry.  
 
CXCR6 increases proliferation of hepatoma cells 
Analysis of proliferation by DNA staining with Hoescht dye 
HuH-7 and HepG2 hepatoma cell lines were seeded into wells of a 24 well plate. Cells were 
serum starved for 24 hours and then incubated with varying concentrations of recombinant 
CXCL16 (rCXCL16) for 72 hours. At baseline and 24-hour intervals, cells were fixed and 
stained with Hoescht dye (reflecting DNA content), and the fluoresence of the dye was 
measured to determine the extent of cell proliferation. HuH-7 and HepG2 hepatoma cell 
lines demonstrated a dose-dependent increase in cellular proliferation when incubated with 
recombinant CXCL16 (one-way analysis of variance p=0.008 and p=0.024 respectively) 
(figure 7.9).  Proliferation was comparable between HepG2 and HuH-7 cells with greatest 
proliferation induced with 10ng/mL of rCXCL16, although data were more robust as 
evidence of proliferation in HuH-7 cells. One-way analysis of variance (ANOVA) tests were 
used to compare the effect of all concentrations of CXCL16 on proliferation. 
 
 
 161 
 
Figure 7.9: Incubation with CXCL16 increases proliferation of hepatoma cell lines 
Hepatoma cell lines were incubated with varying concentrations of CXCL16 and cellular proliferation 
was assessed by DNA staining with Hoescht dye, Results are presented as area-under-the-curve for 
fluorescence over time. CXCL16 increased proliferation of A HuH and B HepG2 cell lines * p<0.05 
**p<0.01 by one-way analysis of variance, n=5 for each concentration. 
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Analysis of proliferation by flow cytometry 
HuH-7 cells were stained with Celltrace-CFSE and incubated with standard media or varying 
concentrations of recombinant CXCL16. CFSE is taken up by cells and remains intra-cellular 
through mitosis. Cell division creates daughter cells with half the CFSE content of the parent 
cell. In this way generations of dividing cells are distinguishable by flow cytometry (FC). 
HuH-7 cells were used given the data described above showing slightly greater CXCR6 
expression and more robust proliferation in response to rCXCL16. The extent of cellular 
proliferation was assessed at 5 days (example plot shown in figure 7.10). Greater 
proliferation was seen with CXCL16 compared to standard media, with a dose-dependent 
response. Consistent with the Hoescht dye technique maximal proliferation was observed 
with 10ng/mL of rCXCL16.  
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Figure 7.10: Analysis of proliferation by flow cytometry 
HuH-7 cells were stained with CFSE dye. Cellular proliferation was assessed by flow cytometry to 
identify dividing cells, marked by a reduction in CFSE signal. Division of cells was quantified by noting 
reduction in CFSE signal by FACS.  
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Figure 7.11: CXCL16 increases proliferation of hepatoma cells, assessed by numbers of 
dividing cells by flow cytometry 
HuH-7 cells were stained with CFSE dye. Cells were then incubated with varying concentrations of 
CXLC16 for 5 days. Peak proliferation of HuH cells was observed following incubation with 10ng/ml 
recombinant CXCL16. Aggregate data from four experiments each run in triplicate. Data shown as 
mean and SEM, *p<0.05 by 1-way ANOVA 
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Function of CXCR6 in primary human hepatocytes 
CXCR6 signalling downregulates pro-apoptotic gene expression in hepatocytes 
To analyse how CXCL16/CXCR6 signalling might mediate its effects in hepatocytes, primary 
hepatocytes obtained from Bioreclaimation Inc. were incubated in the presence or absence 
of recombinant human CXCL16 (10ng/ml) for 24 hours. This dose was used based on 
results from experiments with hepatoma cells as described previously. The characteristics of 
hepatocyte donors are shown in table 7.1. A high-throughput PCR assay (SAbiosciences) 
allowed for simulataneous comparison of gene expression of multiple pathways between 
untreated and treated hepatocytes.  Data were analysed with online tools provided by 
Qiagen (http://www.qiagen.com/gb/).  
 
 Donor 1 Donor 2 
Age (years) 28 39 
Comorbidity Paraplegia Hypertension 
Cause of 
death 
Haemorrhagic stroke Anoxia secondary to 
cardiac arrest 
Weight (kg) 98.8 90.0 
Height (m) 1.78 1.60 
BMI (kg/m2) 31.2 35.2 
Table 7.1: characteristics of donors of primary hepatocytes used for PCR array 
 
Incubation of primary hepatocytes with rCXCL16 did not alter the gene expression of the 
majority of genes evaluated by the assay that were associated with a wide range of signalling 
pathways (figure 7.12A). Four genes (WNT3A, HEY1, HES5, HEYL) showed small increases 
in expression. Importantly, it should be noted that CXCR6  was not included in the panel of 
genes examined. The most striking feature was the down regulation of a genes, the majority 
of which  being regulators of apoptosis or the cell cycle (figure 7.12B, table 7.2). A full list 
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of differentially expressed genes upon addition of rCXCL16 is shown in appendix 1.  This is 
consistent with observations showing increased proliferation of hepatoma cell lines when 
incubated with rCXCL16. 
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Figure 7.12: CXCR6 signalling down regulates pro-apoptotic gene expression in 
hepatocytes 
Cell signalling pathways were analysed by qRT-PCR from pooled samples of primary human 
hepatocytes. Relative expression of genes between primary hepatocytes incubated with standard 
media (x-axis) or 10ng/ml of CXCL16 (y-axis). Data are shown as a cluster analysis showing up 
regulated genes in red and down regulated genes in green. The solid line represents no change 
between groups, dashed lines represent two-fold change in expression between groups. Red circles 
identify pro-apoptotic genes that are down regulated in primary hepatocytes after incubation with 
10ng/ml of recombinant CXCL16. 
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Up regulated Down regulated 
Gene 
symbol 
Protein Function Fold 
change 
Gene 
symbol 
Protein Function Fold 
change 
WNT3A 
wingless-type 
MMTV 
integration 
site family, 
member 3A 
These proteins have been 
implicated in oncogenesis and in 
several developmental processes 
5 CPT2 
carnitine 
palmitoyltransf
erase 2 
Nuclear protein which oxidizes 
long-chain fatty acids in the 
mitochondria 
-254 
HEY1 
hes-related 
family bHLH 
transcription 
factor with 
YRPW motif 1 
basic helix-loop-helix (bHLH)-
type transcriptional repressors. 5 BAX 
BCL2-
associated X 
protein 
forms a heterodimer with 
BCL2, and functions as an 
apoptotic activator 
-205 
HES5 
Hes family 
bHLH 
transcription 
factor 5 
Regulates cell differentiation 4 BCL2L1 BCL2-like 1 
regulates mitochondrial 
membrane channel opening 
thus controls production of 
inducers of apoptosis 
-167 
HEYL 
hes-related 
family bHLH 
transcription 
factor with 
YRPW motif-
like 
an effector of Notch signalling 
and a regulator of cell fate 
decisions. 
2.23 GCLC 
glutamate-
cysteine ligase, 
catalytic 
subunit 
Glutamate-cysteine ligase. First 
rate-limiting enzyme of 
glutathione synthesis. 
-89 
Table 7.2 Primary human hepatocytes were incubated in the absence or presence of 10ng/ml recombinant CXCL16. Gene 
expression covering to a range of signalling pathways were analysed by a qRT-PCR array.  
This table shows transcripts that exhibited the greatest regulation following incubation with CXC16 (treated vs. untreated). A complete list of 
differentially expressed genes upon the addition of recombinant CXCL16 is shown in appendix 1. 
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Discussion 
These data show that CXCR6 expression is not confined to immune cells, and is expressed 
by hepatocytes. Expression is increased in cirrhotic liver tissue compared to normal tissue. A 
subset of human hepatocellular carcinoma over express CXCR6, where expression is linked 
to particular biological phenotypes for example grade of differentiation. This finding is 
consistent with previous data published by Gao et al (Gao et al., 2012).  The data presented 
in this chapter suggest a role for CXCR6/CXCL16 signalling on proliferation of hepatocytes 
mediated via several pathways that regulate the balance between apoptosis and proliferation. 
A proliferative effect of this axis may be hepato-protective in liver injury – this is discussed 
again in the chapter dealing with mouse models of liver injury in CXCR6 knock out mice.   
 
Hepatoma immortalized cell lines were used for many of these experiments. Although these 
cell lines are very different from primary human hepatocytes they remain useful tools for 
research given the difficulty of isolation and culture of primary hepatocytes.  Hepatoma cell 
lines express CXCR6 and activation with CXCL16 increased proliferation. The same 
concentration of 10ng/mL of CXCL16 both increased proliferation and had a marked effect 
on expression of CXCR6 on hepatoma cells. This is consistent with an autocrine feedback 
loop in which CXCL16/CXCR6 signalling can amplify the CXCR6 response by increasing 
receptor expression. 
 
The PCR array data from primary hepatocytes supports the preceding data by 
demonstrating down-regulation of several pathways that govern cell function and pro-
apoptotic pathways. These data should be confirmed by further analysis with single-target 
PCR or western blotting.  
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CHAPTER 8: Expression and function of CXCR6 on 
Lymphocytes in Liver Disease 
 
The CXC chemokine receptor CXCR6 is expressed on multiple immune cells. CXCR6+ cells 
are enriched in diseased liver where CXCR6 is highly expressed on T cells, natural killer T 
(NKT) cells and natural killer (NK) cells (Boisvert et al., 2003). CXCR6 expression is 
associated with markers of an effector phenotype (Northfield et al., 2008, Billerbeck et al., 
2010). Importantly there are differences between humans and mice in the distribution of 
CXCR6 on intrahepatic lymphoid cells: in mice greatest expression of CXCR6 is seen on 
NKT (Campbell et al., 2001, Wehr et al., 2013) whereas in humans greatest expression is 
seen on NK cells (Boisvert et al., 2003, Heydtmann et al., 2005). Mouse data may therefore 
not accurately reflect the role of CXCR6 in the pathogenesis of human disease.  
 
Work with human tissue from our group has shown that CXCL16, the only identified ligand 
for CXCR6, is widely expressed in human liver, where adhesion of lymphocytes to biliary 
epithelial cells is mediated in part by CXCL16 (Heydtmann et al., 2005). This work 
concentrated on lymphocytes from hepatitis C infected liver tissue and despite showing 
greatest expression on CD56+ cells, did not differentiate between NKT and NK cells and 
used unfractionated leukocyte populations to investigate the role of CXCR6/CXCL16 in 
adhesion. I investigated CXCR6 expression by lymphoid cells in a range of human liver 
disease and focussed on the functional role of CXCR6 expression by NK cells.  
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Expression of CXCL16 in liver disease 
CXCL16 gene expression is increased in diseased liver 
CXCR6 has a single ligand, CXCL16. CXCL16 gene expression was analysed by qRT-PCR of 
total RNA isolated from whole liver tissue taken from a variety of chronic liver disease (15 
in total: NASH, n=8, ALD, n=3, PBC, n=3, PSC, n=1), acute liver disease (n=3) and normal 
liver tissue (n=3). β-ACTIN was used as a housekeeping gene. Gene expression of CXCL16 
was increased in both chronic and acute liver disease relative to that of normal liver (figure 
8.1A). The highest expression was observed in liver tissue from individuals with acute liver 
failure and in the context of chronic liver disease, liver tissue from PBC affected liver 
showed the highest expression (figure 8.1B).  
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Figure 8.1: CXCL16 gene expression is increased in diseased liver 
Total RNA was isolated from whole liver tissue and gene expression of CXCL16 measured by qRT-
PCR with β-ACTIN as a housekeeping gene. RNA as isolated from normal liver (n=3), acute live 
failure (n=3) and chronic liver disease: (15 in total: NASH, n=8, ALD, n=3, PBC, n=3, PSC, n=1)  A 
Gene expression of CXCL16 was increased in chronic and acute liver disease, B where highest 
expression was seen in liver tissue from PBC. Data were normalised to relative CXCL16 expression 
in normal liver tissue, and are shown as mean and SEM. 
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CXCL16 is expressed by endothelial cells, hepatocytes and biliary epithelial cells 
Hepatic endothelial cells (HSEC) and biliary epithelial cells (BEC) were isolated from 
explanted livers and cultured. The hepatoma cell line Huh7, originally isolated from an adult 
patient with HCC (Nakabayashi et al., 1982) was used to investigate hepatocyte function.  
 
Analysis of total RNA extracted from isolated cells or hepatoma cell lines showed CXCL16 
gene expression in all cell types, consistent with previous reports (Heydtmann et al., 
2005)(figure 8.2). Furthermore the addition of lipopolysaccharide (LPS, 10ng/ml), TNF-α 
alone (10ng/ml) or TNF-α and IFN-γ (10ng/ml) to media increased CXCL16 gene expression 
in all cell types at 24 hours, with the greatest response seen in BEC (figure 8.2).  Cells were 
serum starved prior to the addition of cytokines to media to ensure a pure effect of 
cytokine stimulation. 
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Figure 8.2: CXCL16 is expressed by endothelial cells, hepatocytes and biliary 
epithelial cells 
Isolated endothelial or epithelial cells and hepatoma cell line cells were cultured under a variety of 
conditions. Total RNA was isolated and gene expression of CXCL16 was measured by rt-PCR. 
CXCL16 was expressed by all cell types. The addition of LPS/inflammatory cytokines promoted gene 
expression, particularly in the case of BEC. Three isolates were used for each cytokine condition.  
Data are shown as mean and SEM. 
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CXCL16 is localized to biliary ductules in injured liver 
Given the increased expression of CXCL16 in PBC and its association with biliary epithelial 
cells I examined the expression of CXLC16 in liver by immunohistochemistry. This process 
was difficult to optimise with initial work using frozen sections showing non-specific staining 
despite careful titration of the antibody. Use of paraffin-embedded sections with multiple 
steps to block non-specific staining (sequential incubation steps with hydrogen peroxide, 
casein and horse serum) showed good results (detailed in chapter 2) and this technique was 
used to investigate CXCL16 expression in tissue.  
 
Immunohistochemistry showed that, consistent with the qRT-PCR data, CXCL16 was 
strongly expressed on biliary epithelium and also throughout the parenchyma of diseased 
liver tissue, with little or no expression in non-cirrhotic liver (figures 8.3 and 8.4). Some 
staining was seen on infiltrating immune cells within fibrous septa but this was weak 
compared to staining on liver tissue.  
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Figure 8.3 (previous page) CXCL16 is localized to biliary ductules in injured liver 
Paraffin-embedded sections of liver tissue were stained for CXCL16 or with an isotype matched 
control antibody. Photographs were taken at 20x magnification. The chromogen stains CXCL16 red-
brown against a blue background counter-stain. Corresonding ontrol sections, stained with a non-
specific isotype-matched antibody are shown in the left hand column. A, B normal liver, C, D 
alcoholic liver disease E, F primary biliary cirrhosis  
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Figure 8.4 (previous page) liver tissue stained for CXCL16 at 40x magnification.  
A Sections from PBC liver showing CXCL16 expressed on bile ductules (long arrows) and B matched 
area from section of same liver stained with isotype matched control antibody 
 
Serum CXCL16 concentration is increased in chronic liver disease but decreased in Primary 
Biliary Cirrhosis 
The concentration of soluble CXCL16 in serum samples from patients with chronic liver 
disease (CLD) (n=41: 9 NASH, 8 ALD, 3 HCV and 21 PBC) and healthy volunteers (n=10) 
was measured by ELISA. No statistically significant increase in circulating CXCL16 
concentration was observed between healthy volunteers and patients with CLD (mean 
CXCL16 concentration 2.78ng/ml (SEM 0.212) vs. 2.95 (0.289), student’s t-test 
p=0.756)(figure 8.5A).  
 
When PBC was considered separately to other causes of CLD, patients with PBC had 
significantly lower CXCL16 levels than healthy controls (2.07ng/ml (0.112), student’s t-test 
p<0.001)(figure 8.5B). 
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Figure 8.5: Serum CXCL16 concentration is increased in chronic liver disease but 
decreased in Primary Biliary Cirrhosis 
Serum samples from healthy controls (n=11), and patients with chronic liver disease (n=46) were 
analysed for CXCL16 concentration by ELISA. A There was no significant difference in the 
concentration of CXCL16 between healthy donors and patients with chronic liver disease. B The 
concentration of CXCL16 in PBC (n=21) was significantly lower than that of healthy controls and 
individuals with non-PBC related chronic liver disease (n=25). Data are shown as mean and SEM. 
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Expression of CXCR6 on lymphoid cells in liver disease 
CXCR6+ cells are present in diseased liver tissue 
Having demonstrated that the expression of CXCL16 was differentially expressed in chronic 
liver disease I then investigated the expression of its cognate receptor, CXCR6, on liver 
infiltrating lymphocyte populations. Immunohistochemistry for CXCR6 on paraffin 
embedded tissue sections identified CXCR6+ cells expressed by infiltrating immune cells 
around portal  tract in non-cirrhotic liver, and around fibrous septa and in the parenchyma in 
injured liver tissue (figure 8.6). 
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Figure 8.6: CXCR6+ cells are present in diseased liver tissue 
Paraffin embedded sections of tissue from explanted PBC liver stained for CXCR6. Images shown at 
40x magnification. A . Multiple cells expressing CXCR6 (in red) in inflammatory foci (long arrows) 
as well as hepatocyte expression (short arrows) B matched area from section from same liver 
stained with isotype matched control antibody  
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Flow cytometric analysis of CXCR6 on inflammatory cells 
To further characterise the nature of the intrahepatic CXCR6+ cell population lymphocytes 
were isolated from liver tissue and peripheral blood, and flow cytometry (FC) was used to 
characterise and identify CXCR6-expressing subpopulations.  
 
CXCR6 expression on lymphoid cells differs between blood and liver compartments  
Expression of CXCR6 on lymphocytes in liver and blood compartments was assessed by FC. 
Lymphocytes were identified by forward and side scatter characteristics, and doublets 
excluded by pulse width. CXCR6 expression was analysed on this whole population (figure 
8.7A, 8.7B). After gating on CXCR6+ cells, lymphocyte subpopulations were identified by 
CD3 and CD56 immunoreactivity to distinguish T cell, NKT cell and NK cell populations 
(figure 8.7C, 8.7D).  
 
In blood, the majority of CXCR6+ cells were CD3+CD56- T cells, whereas in liver most 
CXCR6+ cells were CD3–CD56+ NK cells (figures 8.8A, 8.8B). 
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Figure 8.7: Gating strategy to identify CXCR6+ lymphoid cells in liver tissue 
A gating on lymphocytes on the basis of forward and side scatter B CXCR6+ cells. T cells, NKT cells 
and NK cells were identified by CD3 and CD56 immunoreactivity. Representative plot from C 
peripheral blood and D liver-infiltrating lymphocytes.  
 
Figure 8.8: CXCR6 expression on lymphoid cells differs between blood and liver 
compartments  
Figures A and B show distribution of CXCR6+ expression in blood (n=11) and liver tissue (n=20) 
respectively, where each data point represents an isolate from single individual, lines at mean and 
SEM. 
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Natural Killer T cells show highest percentage expression of CXCR6  
In both blood and liver the percentage of cells expressing CXCR6 was highest on 
CD3+CD56+ NKT cells (figure 8.9A), although the surface expression of the receptor (as 
measured by median fluorescence intensity, MFI) was similar across all lymphocyte subsets 
(figure 8.9B) suggesting similar levels of expression on individual cells. Liver-infiltrating 
lymphocytes demonstrated markedly increased expression of CXCR6 compared to 
peripheral blood, both in terms of both percentage positive cells (Two-way ANOVA 
p<0.001) and MFI (Two-way ANOVA p<0.001). 
 
Expression of CXCR6 on T lymphocytes and NK cell subsets 
Analysis of T lymphocytes showed a greater expression of CXCR6 on CD8+ when 
compared to CD4+ T cells in both the blood and the liver (figure 8.10A). Within NK cells, 
CXCR6 expression was enriched in the CD56hi NK cell population in comparison to the 
CD56lo subset. This was particularly marked for intrahepatic NK cells (figure 8.10B).  
 
  
 187 
 
 
 
Figure 8.9: Expression of CXCR6 is higher on liver-infiltrating lymphocytes  
Lymphoid cells were isolated from blood (n=11) or liver (n=20). CXCR6 expression was analysed by 
FC. CXCR6 expression was higher on liver-infiltrating cells in terms of A percentage CXCR6 positivity 
and B MFI. Data are shown as mean and SEM, *** 2way ANOVA p<0.001.  
 
 
Figure 8.10: Lymphocytes were isolated from blood and liver and analysed by FC. T 
lymphocyte subsets were identified by labelling of CD4 and CD8.  
A CXCR6 expression was significantly higher on liver-infiltrating T lymphocytes, particularly in the 
CD8+ population. B CXCR6 expression (percentage) by NK cells was higher for all liver-infiltrating 
subsets and was particularly elevated on CD56hi cells. Each individual point represents a single 
isolation, lines at mean and SEM. *p<0.05, **p<0.01, ***p<0.001 by student’s t-test 
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CXCR6+ expression is increased on NK cells in injured liver 
Having established that CXCR6 expression was enriched on liver-infiltrating lymphoid cells 
and NK cells in particular, I investigated a possible association of CXCR6 expression with 
liver disease. Liver tissue slices were harvested from livers from individuals with chronic liver 
disease and from distal, uninvolved tissue from hepatic resections of malignant lesions. 
Lymphoid cells were subsequently isolated and analysed by FC, and CXCR6 expression was 
then compared between cells taken from normal and cirrhotic tissue.  
 
CXCR6 expression on lymphoid cells varied between normal and cirrhotic liver tissue 
(figure 8.11). Fewer T lymphocytes from cirrhotic patients expressed CXCR6 compared to 
cells isolated from normal liver (median percentage expression 36.4% (IQR 13.1) vs. 49.7% 
(13.7), Mann-Whitney test p=0.040); a similar pattern was observed for NKT cells (median 
53.1% (IQR 32.7) vs. 80.0% (14.0), Mann-Whitney test p=0.014). In contrast, NK cells 
tended to shower greater percentage CXCR6 expression in diseased liver although this was 
not statistically significant (55.4% (46.9) vs. 33.0 (26.5), Mann-Whitney p=0.211).  
 
NK CXCR6 expression is highest in Primary Biliary Cirrhosis 
As expression of CXCR6 decreased on other major lymphoid subsets but tended to 
increase on NK cells, I analysed differences in NK cell CXCR6 expression between differing 
aetiologies of liver disease. NK cell expression of CXCR6 was highest in PBC (one-way 
ANOVA p=0.035) but was not elevated in any other disease studied (figure 8.12). 
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Figure 8.11: CXCR6+ expression on liver lymphocytes in cirrhotic and normal liver  
Lymphocytes were isolated from liver and analysed by FC. CXCR6 expression on lymphocyte subsets 
in normal (n=4) and cirrhotic (n=16) liver. Data are shown as median and IQR. *p<0.05, ns: 
p>0.05 by Mann Whitney test 
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Figure 8.12: NK CXCR6 expression is highest in Primary Biliary Cirrhosis 
Lymphocytes were isolated from normal (n=4) and diseased liver n=16 (AIH, 2, PSC 2, 
steatohepatitis 5, PBC 4 and other causes 4 (2 polycystic, 1 acute liver failure, 1 chronic rejection)) 
and analysed by FC. Most frequent CXCR6 expression by NK cells was observed in PBC liver, which 
was the only category to differ significantly from normal liver tissue. Each data point represents a  
single sample, lines at median and IQR *p<0.05 by one-way ANOVA. 
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Immunophenotype of CXCR6+ Natural Killer cells 
CXCR6 expression on intra-hepatic NK cells is associated with markers of effector function 
To examine the phenotype and possible function of CXCR6+ NK cells, further FC analysis 
was performed on cells isolated from liver tissue. In addition to being associated with CD56hi 
expression (see above, figure 8.10), the expression of Nkp30 and CD16 were examined. 
CD16 expression is inverse to CD56 expression on NK cells (Vivier et al., 2008). The 
natural cytotoxicity receptors NKp30, NKp44, NKp46 induce strong NK cell activation 
when engaged by ligand (Biassoni et al., 2001).  
 
Expression of CXCR6 on NK cells was associated with NKp30, (figure 8.13B), and 
inversely associated with CD16 (figure 8.13C). These data indicate that CXCR6 expression 
on NK cells is associated with a tissue-infiltrating effector phenotype (Pende et al., 1999, Poli 
et al., 2009) 
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Figure 8.13: Lymphocytes were isolated from liver and analysed by FC.  
CXCR6 expression on NK cells correlated with A CD56hi B NKp30 expression and C low 
expression of CD16  
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In order to investigate the function of CXCR6+ NK cells, flow-assisted cell sorting (FACS) 
was used to isolate this population with a view to determine both the cytokine secretion 
profile of these cells and their ability to kill parenchymal and non-parenchymal liver cells. 
Initially PBMC isolated from peripheral blood that had been monocyte depleted by 
incubating in a plastic T75 flask for 1 hour, were stained for CD3, CD56 and CXCR6 and 
subsequently flow-sorted. The yield of CXCR6+ NK cells was very low, resulting in too few 
cells for analysis. To improve the yield and allow for useful number of cells to be collected, 
lymphocytes were isolated from liver, and following depletion of monocytes by plastic 
adherence, NK cells were isolated by bead isolation (Miltenyi, Germany) with about 90% 
purity. This enriched NK cell population was then sorted. However when isolating 
intrahepatic NK populations this technique involved a long delay between explant of the liver 
and eventual cell sorting. The cell yields were always low and of insufficient number and 
viability for functional studies.   
 
Function of CXCR6 on NK cells 
The role of CXCR6 in the recruitment of lymphoid cells to the liver was investigated using a 
dynamic flow assay. Whole lymphoid populations or purified NK cells were used. In some 
cases, bead isolation of CD3-CD56+ NK cells from peripheral blood was used as described 
above in order to investigate the function of CXCR6 on NK cells, (figure 8.12). NK cells 
isolated with this method were used for experiments to investigate the role of CXCR6 in 
the transendothelial migration of NK cells across hepatic endothelium. 
 
 194 
CXCR6 mediates recruitment of Natural Killer Cells across hepatic sinusoidal endothelium 
The flow assay system developed in the Adams group based on assays originally established 
by Nash and colleagues in Birmingham allows modelling of the conditions of the hepatic 
sinusoid to examine leukocyte trafficking under physiological levels of shear stress (Lalor et 
al., 1997). Primary human HSEC were cultured until confluent in chambers of a microslide. 
Once confluent HSEC were stimulated with TNFα and IFNγ (both 10ng/ml) for 24 hours. 
The HSEC were then washed with PBS and maintained in flow media (endothelial SFM 
containing 10% BSA). Lymphocytes were incubated in RPMI/10%BSA with a small molecule 
inhibitor of CXCR6 (C0335224, ) dissolved in DMSO to a 
final concentration of 10uM, or DMSO alone for twenty minutes. Cells were then washed 
and suspended in RPMI at a known density and flowed at physiological levels of shear stress 
across HSEC with direct visualization allowing for analysis of the adhesion cascade. From 
these data it is possible to evaluate the extent to which the inflammatory cells both adhere 
to and migrate across the hepatic endothelial cell monolayer. 
 
In preliminary experiments a mixed population of lymphocytes isolated from peripheral 
blood were studied. Antagonism of CXCR6 did not significantly reduce recruitment of 
lymphocytes across HSEC (two-way ANOVA p=0.992)(figure 8.14A). A similar effect was 
observed for liver-infiltrating lymphoid cells (two-way ANOVA p=0.859) (figure 8.14B). 
 
Given that earlier results demonstrated an increase in CXCR6 expression solely on NK cells 
in chronic liver disease, the effect of CXCR6 antagonism on recruitment of isolated NK cells 
was investigated. A marked reduction in transmigration was observed (Two-way ANOVA 
p=0.0073) (figure 8.15).  
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Figure 8.14: CXCR6 is not required for recruitment of leukocytes across hepatic 
sinusoidal endothelium 
Lymphocytes were isolated from blood or liver and incubated with a small molecule inhibitor of 
CXCR6 or DMSO before being flowed over confluent HSEC. No significant changes in leukocyte 
trafficking were observed following antagonism of CXCR6 with C0335224. Lymphocytes isolated 
from A peripheral blood or B liver tissue. ns: p>0.05 by two-way ANOVA. Data expressed as mean 
and SEM, three isolates of leukocytes examined for each condition. 
 
 
Figure 8.15: CXCR6 mediates recruitment of Natural Killer Cells across hepatic 
sinusoidal endothelium  
NK cells were isolated by negative selection from peripheral blood and incubated with a small 
molecule inhibitor of CXCR6 or DMSO.  Cells were flowed over confluent HSEC and the extent of 
leukocyte trafficking was assessed. A significant reduction in the transmigration NK cells was 
observed **p<0.01 by two-way ANOVA. Data expressed as mean and SEM, three isolates of 
leukocytes examined for each condition. 
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CXCR6 signalling does not affect NK cell survival  
In light of other experiments showing that CXCR6 can mediate proliferative signals in 
hepatocytes (see chapter 9), the function of CXCR6 in promoting survival of lymphoid cells 
was investigated.  
 
Liver-infiltrating lymphocytes were isolated and incubated in low-serum media for 24 hours 
to promote apoptosis and cell death. Recombinant CXCL16 was included in low-serum 
media at varying concentrations to evaluate the effect of CXCR6 signalling. Flow cytometry 
was used to identify lymphoid subsets and markers of apoptosis and cell death.  Cells were 
categorized as alive (7AAD negative, Annexin V negative), apoptotic (7AAD negative, 
Annexin V postive) or dead (7AAD positive) (figure 8.16). No significant effect of CXCL16 
on the proportion of surviving, apoptotic or dead cells was observed (One-way ANOVA 
>0.05 for all categories (figure 8.17).  
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Figure 8.16 Identification of dead and apoptotic cells by flow cytometry 
Flow cytometry was used to identify lymphoid subsets and markers of apoptosis and cell death.  
Cells were categorized as alive (7AAD negative, Annexin V negative), apoptotic (7AAD negative, 
Annexin V positive) or dead (7AAD positive).   
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Figure 8.17: CXCR6 signalling does not affect NK cell survival 
Lymphoid cells were isolated from liver tissue and incubated in low-serum media for 24 hours to 
induced apoptosis and cell death. Recombinant CXCL16 was added at varying doses to evaluate the 
effect of CXCR6 signalling on cell survival on NK cells. No effect was seen on A cell death B 
apoptosis or C cell survival. Three isolates tested in triplicate for each condition, data are presented 
as mean and SEM. 
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CXCR6 signalling does not affect NK cell proliferation 
To investigate the effect of CXCR6 signalling on NK cell proliferation, lymphoid cells were 
isolated from liver tissue and stained with Celltrace (a dye similar to CFSE). Cells were then 
incubated with varying concentrations of recombinant CXLC16 for 5 days. No effect of 
CXCL16 on cell proliferation was observed (one-way ANOVA p=0.990)(figure 8.18). 
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Figure 8.18: CXCR6 signalling does not affect NK cell proliferation 
Lymphoid cells were isolated from liver tissue and incubated with recombinant CXCL16 for 5 days. 
Proliferation was assessed by staining cells with CFSE to allow for identification of dividing cells. No 
effect of CXCL16 on proliferation of NK cells was observed. Three isolates prepared for each 
condition, data presented as mean and SEM  
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Conclusion 
The work presented in this chapter describes the hepatic expression of CXCL16 and 
distribution and function of CXCR6 on liver-infiltrating cells. In keeping with previous work 
from our laboratory and others, multiple cell types within the liver expressed CXCL16. 
However, biliary epithelium appeared to be the main source of CXCL16 as shown both by 
rt-PCR and immunohistochemistry. Interestingly, PCR of whole liver tissue showed greatest 
gene expression in PBC, a disease characterised by biliary inflammation although serum 
concentration of soluble CXCL16 was lowest in PBC. 
 
CXCR6 expression is predominantly a feature of CD8+ T lymphocytes in blood. In contrast 
to peripheral blood, NK cells are the major type of CXCR6+ cell in liver tissue where 
expression is associated with an effector phenotype. Moreover, CXCR6 expression by T 
lymphocytes and NKT cells was decreased in cirrhosis, whereas expression tended to 
increase on NK cells.  
 
The main role of chemokines and chemokine receptors is to regulate the trafficking and 
positioning of immune cells. Antagonism of CXCR6 significantly reduced the transendothelial 
migration of isolated NK cells, whereas no significant effect was seen in unselected 
lymphocyte populations. It should be borne in mind that I have not investigated the effect of 
the small molecule antagonist on endothelium; it is possible that there is an effect on HSEC 
that alters transmigration that may confound the results. Similarly a toxic effect on NK cells 
that reduces migration cannot be ruled out from these data although incubation with or 
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without the antagonist did not appear to reduce or increase apoptosis, necrosis or 
proliferation of NK cells.  
 
Within the limits of these caveats, this suggests that CXCR6 has a major role in the hepatic 
recruitment of NK cells whilst it may be dispensable for the recruitment of other cells types. 
No role was seen for CXCL16/CXCR6 interaction with regard to survival or proliferation 
of NK cells – in contrast to previously published mouse data showing decreased survival of 
NKT cells in CXCR6 deficient mice (Geissmann et al., 2005). These differences may be due 
to differences in murine and human immunology, and also the differing cell type that 
predominantly expresses CXCR6: NKT cells in mice and NK cells in humans. 
 
The data presented here supports a paradigm where recruitment of effector NK cells to 
injured liver and trafficking to inflamed bile ducts is mediated by CXCR6. Primary biliary 
cirrhosis is a disease typified by inflammation to small bile ductules. The CXCR6/CXCL16 
axis is particularly up regulated in this condition, which is characterised by higher frequencies 
of intrahepatic of CXCR6+ NK cells. This is in contrast to reports of CXCR6-mediated cell 
trafficking in mice where the major effect of CXCR6 signalling is described on NKT cells 
(Geissmann et al., 2005) (Wehr et al., 2013).  However, these findings are consistent with 
previous work with human tissue from our laboratory showing a role for CXCR6/CXCL16 
in trafficking of lymphocytes to inflamed biliary epithelium (Heydtmann et al., 2005). 
Targeting this axis may represent a new therapeutic angle in a PBC, which currently has few 
therapeutic options.  
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CHAPTER 9: General Discussion 
 
This thesis has focused on a range of chemokine receptors in diverse liver diseases. The 
principal framework is the study of leukocyte trafficking, a process in which chemokines and 
their receptors play a significant role. In addition, based on early findings with CXCR6, a 
non-canonical role of chemokine receptors in hepatocyte regeneration is also described. The 
common theme linking each of these lines of investigation is the identification of a 
chemokine receptor/ligand axis associated with a particular liver disease, or the use of 
murine models incorporating animals in which chemokine receptor expression has been 
modified genetically to determine the function of particular chemokines in liver disease.  
 
These data represent new insights into the pathogenesis of liver disease and offer potential 
new therapeutic angles in an area of medicine marked by a lack of effective treatments. 
 
The role of CCR2 in non-alcoholic fatty liver disease 
CC-chemokine receptor 2 (CCR2), first identified by Charo et al. in 1994 (Charo et al., 
1994) mediates the recruitment of monocytes into adipose tissue (Gerhardt et al., 2001) and 
is associated with adverse consequences of adipose tissue inflammation such as insulin 
resistance (Weisberg et al., 2006). Patients with NAFLD have higher serum concentrations 
of CCL2 than healthy, age and gender-matched controls (Haukeland et al., 2006) and levels 
of CCL2 are greater in advanced NASH and correlate with levels of ALT, a marker of liver 
injury (Kirovski et al., 2011). Although published human studies NAFLD are confined to 
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measurements of serum CCL2, experimental murine evidence from provides a rational for 
studying CCR2 in the pathogenesis of human NAFLD. 
 
In keeping with results from other investigators I found that serum concentrations of CCL2 
were significantly higher in patients with NAFLD, and correlated with histological 
inflammation, and lobular inflammation in particular. Gene expression of CCL2 was higher in 
liver from patients with all stages of NAFLD compared with normal liver tissue.  
 
In blood classical CD14++CD16- monocytes and to a lesser extent intermediate 
CD14++CD16+ monocytes express CCR2. I focused on a subset of CD14+ monocytes that 
express CD11c and the mannose receptor CD206 because they have recently been 
associated with insulin resistance in adipose tissue (Wentworth et al., 2010). These 
monocytes were present in liver tissue at a significantly higher frequency than in blood and 
their frequency as a percentage of CD14+ monocytes, correlated with insulin resistance. A 
proportion of the CD14+CD11c+CD206+ subset expressed CCR2 and levels were 
particularly high on monocytes isolated from liver tissue from patients with NAFLD.  
 
I detected very few dual positive CD11c+CD206+ monocytes in peripheral blood, a finding 
consistent with previous studies (Bourlier et al., 2008). This suggests that up regulation of 
CD206+ is triggered either during or after transmigration of monocytes across hepatic 
endothelium into the hepatic parenchyma. A decrease in CCR2 expression on liver-derived 
monocytes suggests that CCR2 drives recruitment of monocytes but is then down regulated, 
whilst CD11c and CD206 are expressed after recruitment into liver tissue, a phenomenon 
recently demonstrated in murine liver injury (Dal-Secco et al., 2015).  CD206 is a pattern 
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recognition receptor that mediates uptake and phagocytosis of a wide range of pathogens 
and also plays a role in antigen presentation (East and Isacke, 2002). Up-regulation of CD206 
by monocytes encountering an area of inflammation is therefore consistent with its known 
functional properties. This has been demonstrated in principle in vitro where treatment of 
human macrophages, with IL4 and TGF-β induces CD206 expression (Porcheray et al., 
2005).  
 
NAFLD is a common disease that may affect between one-third and one-quarter of the UK 
population. Although only around 10% of patients will develop progressive liver disease this 
still represents a large number of people. It is this group that require treatment to prevent 
development of significant hepatic fibrosis, or to reverse established fibrosis. Most trials to 
date have focused on drugs established in liver or diabetes management, e.g. pioglitazone or 
ursodeoxycholic acid, without compelling evidence of significant benefit (Musso et al., 2010). 
More recently, early phase trials of novel agents such as obeticholic acid have suggested 
benefit and will be investigated in phase III trials (Neuschwander-Tetri et al., 2015). 
Nevertheless these agents are still experimental and there is a need to identify and 
investigate novel therapeutic angles. There has been considerable interest in targeting CCR2 
in the treatment of complications of insulin resistance (Pirow, 2012) (Di Prospero et al., 
2014) but only one trial to date has been initiated to investigate CCR2 inhibition in NAFLD, 
this is a phase II trial using Cencriviroc, a dual CCR2/CCR5 inhibitor initially investigated in 
HIV (Klibanov et al., 2010) (02217475, 2014). 
 
These experimental data go beyond a simple model of circulating CCR2 monocytes being 
recruited to liver tissue during NAFLD pathogenesis, but describe a particular subtype of 
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monocytes that are active in the metabolic syndrome. Recruitment of this CD11c+CD206+ 
subset to liver tissue via CCR2 is associated with greater insulin resistance, a key element in 
the pathogenesis of NAFLD that prompts the development of NASH from simple steatosis. 
Animal models show the importance of CCR2 for recruitment of this subset where CCR2 
antagonism with a small molecule inhibitor reduced infiltration of an equivalent monocyte 
subset into both liver and adipose tissue with improvements in liver function and glycaemic 
control. 
 
The role of CCR9 in acute liver failure 
In humans CCR9 is expressed on T lymphocytes (Johansson-Lindbom et  al., 2003) and 
myeloid cells (Schmutz et al., 2010, Linton et al., 2012), and is expressed by a subset of liver-
infiltrating lymphocytes in in chronic liver injury most notably PSC (Eksteen et al., 2004) and 
on subsets of monocytes/macrophages (Linton et al., 2012) (Mizukami et al., 2012). In murine 
models of ALF CCL25 is up regulated early during injury and CCR9+ macrophages were 
shown to be critical for liver damage (Nakamoto et al., 2012).  
 
I investigated the CCL25/CCR9 axis in human acute liver failure and examined the efficacy of 
antagonism of CCR9 in mouse models of paracetamol-induced liver failure. Increased serum 
levels of CCL25 were seen early in human acute liver failure and CCR9+ intermediate 
CD14+CD16+ monocytes were detected in liver tissue in a patients undergoing liver 
transplantation for acute liver failure. In mice, increased CCR9+ myeloid cells were observed 
in the liver early after onset of toxic liver injury, a phenomenon that corresponded to peak 
serum ALT concentration. Prophylactic antagonism of CCR9 significantly reduced infiltration 
of liver tissue by CD11b+CD11c- macrophages, and improved liver injury as assessed by 
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serum AST and ALT concentration.  In high dose paracetamol toxicity, CCR9 antagonism 
caused a trend towards improved mortality although this was not significant.   
 
These data, particularly those described in the mouse models, are consistent with previous 
reports from Nakamoto et al who reported that CCR9+ macrophages infiltrate the liver 
early during concanavalin A induced liver injury and exacerbate liver damage. The same 
group examined blood from human subjects and found increased CCR9 expression on 
CD14+CD16+ monocytes compared to chronic liver injury or healthy controls. A role for 
CCR9/CCL25 has been described in the recruitment of T lymphocytes to liver tissue in 
primary sclerosing cholangitis (PSC) where CCL25 was increased, suggesting that CCL25 is 
implicated in some chronic as well as acute liver diseases. Whether CCL25 recruits different 
subsets of leukocytes in acute and chronic disease remains undetermined. 
 
The data from murine models and human data describes an early up regulation of CCL25 
leading to recruitment of CCR9+ cells into liver tissue. My data show that this is a transient 
phenomenon with CCL25 expression and the presence of CCR9+ cells falling away after the 
initial period of liver injury. This probably corresponds with a transition from pro-
inflammatory cellular infiltrate to an anti-inflammatory, pro-resolution infiltrate. 
CCL25/CCR9 are thus indicated as early drivers of inflammation and injury, in keeping with 
previous reports of mouse acute liver injury (Nakamoto et al., 2012). 
 
Whilst these data showing a role for CCR9/CCL25 in liver injury shed light on the 
pathogenesis of ALF, the need for prophylactic dosing to prevent injury in animal models 
limits their translational potential at present. Clearly in the context of drug-induced liver 
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injury, especially intentional paracetamol overdose, prophylactic treatment is not feasible 
although treatment early after poisoning might be Further investigations are required to 
evaluate the efficacy of therapeutic antagonism of CCR9. Many patients present several 
hours or even days after an overdose and inhibiting the very early stages of the disease 
process may therefore not be feasible. An alternative model of predictable acute liver injury 
is ischaemia-reperfusion injury during liver transplantation. Prophylactic intervention could 
be of benefit here but no data exist at present to suggest that CCR9/CCL25 might be of 
importance.   
 
The role of CXCR6 in PBC 
CXCR6, identified in 1997 (Deng et al., 1997, Liao et al., 1997, Loetscher et al., 1997) has 
only one ligand, CXCL16 (Matloubian et al., 2000). CXCL16 is widely expressed in liver by 
hepatic sinusoidal endothelium, hepatocytes and biliary epithelium (Heydtmann et al., 2005). 
Most reports on the role of CXCR6 in the liver have been based on murine experiments 
(Geissmann et al., 2005, Xu et al.,  2005). Recently in CCl4-induced liver injury CXCR6
-/- mice 
had lower serum ALT and demonstrated reduced fibrosis (Wehr et al., 2013). The fibrotic 
response was restored when CXCR6+ NKT cells were adoptively transferred to CXCR6-/- 
mice. However there are important differences between humans and mice in the distribution 
of CXCR6: in mice greater CXCR6 expression is seen on NKT cells (Campbell et al., 2001, 
Wehr et al., 2013) whereas in humans greatest expression is seen on NK cells (Kim et al., 
2001, Boisvert et al., 2003, Heydtmann et al., 2005). In addition, the relevance of CCl4 and 
MCD to human disease is debatable: CCl4 is an acute toxic injury uncommonly seen in 
humans, and MCD induces steatosis through inhibition of hepatocyte lipid transport and 
causes marked weight loss, in sharp contrast to common human liver disease. Mouse data 
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may therefore not accurately reflect the role of CXCR6 in the pathogenesis of human 
disease. Adhesion of human lymphocytes to biliary epithelial cells in vitro is a CXCL16-
dependent process (Heydtmann et al., 2005) and a greater frequency of CXCR6+ 
lymphocytes in liver tissue has been reported in liver disease, particularly hepatitis C 
infection (Kim et al., 2001, Heydtmann et al., 2005, Billerbeck et al., 2010). 
 
My data show that CXCR6 is enriched on all lymphoid subsets in the liver compared to 
peripheral blood, but expression is particularly marked on NK cells, where it is associated 
with markers of activation. Moreover, CXCR6 expression by T lymphocytes and NKT cells 
was significantly decreased in cirrhosis, whereas expression tended to increase on NK cells. 
 
CXCR6 expression by NK cells was particularly marked in PBC. In keeping with previous 
work from our laboratory and others, biliary epithelium was the dominant source of 
CXCL16. Interestingly, PCR of whole liver tissue showed greatest gene expression of 
CXCL16 in PBC (figure 12.2),  although the serum concentration of soluble CXCL16 was 
low in this disease (fig 12.5).  A lower peripheral concentration of CXCL16 may be a 
consequence of retention in liver tissue allowing for increased trafficking of CXCR6+ cells. 
CXCL16 is cleaved by the action of ADAM 10, a metalloproteinase (Le Gall et al., 2009) and 
it would be intriguing to assess the activity of this in the context of PBC.  
 
Antagonism of CXCR6 with a small molecule inhibitor significantly reduced the adhesion and 
transmigration of isolated NK cells across endothelial cells in vitro. This suggests that CXCR6 
has a role in the hepatic recruitment of NK cells but may be dispensable for the recruitment 
of other cells types (figures 12.14, 12.15). No role was seen for CXCL16/CXCR6 
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interaction with regard to survival or proliferation of NK cells in contrast to earlier mouse 
work showing reduced survival of NKT cells in CXCR6 knockout mice (Geissmann et al., 
2005).  
 
Taken together with previous work showing that adhesion to cholangiocytes is mediated by 
CXCL16 (Heydtmann et al., 2005), this supports a paradigm where CXCR6 directs NK cell 
recruitment to the liver and positioning around injured bile ducts, and suggests a pathogenic 
role of CXCR6+ NK cells in PBC.  
 
There are conflicting reports of the actions of NK cells in chronic liver injury: NK cells have 
been reported to show toxicity to biliary epithelium (Leon et al., 1997, Shimoda et al., 2011, 
Guo et al., 2012), where biliary epithelial cells isolated from PBC liver tissue are more 
susceptible to NK cell mediated cytotoxicity than those isolated from HBV, HCV or ALD 
liver (Shimoda et al., 2011). However NK cells may also have an anti-fibrotic action (Melhem 
et al., 2006, Radaeva et al., 2006, Abu-Tair et al., 2013). These apparently contrasting 
activities may be explained in part because reports of NK cell anti-fibrotic properties are 
shown in mice, whereas human data tends to show on NK cell cytotoxity. In addition, 
cytotoxic activity of intrahepatic NK cells in hepatitis C varies dependent on the severity of 
liver inflammation and fibrosis (Fugier et al., 2014). 
 
The role of hepatocyte CXCR6 in hepatocellular carcinoma 
Observations made early in my investigation of the role of CXCR6 on immune cells showed 
that hepatocytes expressed CXCR6. This is consistent with a previous paper reporting 
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CXCR6 expression in human HCC (Gao et  al., 2012). Hepatocytes have been shown to 
express other CXC chemokine receptors.  For example CXCR2 expression has been 
shown in mice (Hogaboam et al., 1999, Bone-Larson et al., 2001) and was reported to be a 
regenerative signal although a later manuscript described damaging effects of CXCR2 
signalling (Kuboki et al., 2008). There is also evidence that CXCR1 signalling facilitates 
regeneration of liver tissue after injury in mice (Clarke et al., 2011).  
 
I showed that in human liver tissue, hepatocytes express CXCR6 and in a subset of human 
HCC CXCR6 is overexpressed. CXCR6 expression in HCC was linked to particular 
biological phenotypes, for example grade of differentiation and the condition of background 
liver tissue. Further investigations in hepatoma cells and primary human hepatocytes showed 
that CXCR6 signalling can influence the proliferation of cells, through down-regulation of 
pro-apoptotic genes and other genes that regulate the cell cycle. Consistent with previous 
reports of CXC chemokine receptor expression in murine liver tissue, CXCR6 signalling 
may exert a protective role in liver injury, allowing regeneration of liver tissue but could 
become pathological if the regenerative process is unchecked.  
 
My experiments with acute and chronic models of liver injury in mice showed contrasting 
effects of CXCR6. Mice were protected against liver injury induced by CCl4 by knockout of 
CXCR6, whereas in a model of chronic liver injury, mice without functional CXCR6 
demonstrated worse liver injury despite reduced infiltration of NKT cells. These apparently 
contradictory findings correspond to investigations with human tissue that showed a role for 
CXCR6 in the recruitment of NK cells to liver tissue, but also a pro-proliferative effect of 
CXCR6 signalling on hepatocytes. My data therefore show CXCR6 as a ‘double-edged 
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sword’: contributing to liver injury through the recruitment of inflammatory cells, but also 
contributing to liver repair through hepatocyte proliferation. This latter process may 
become pathogenic if hepatocyte proliferation becomes uncontrolled leading to 
hepatocellular carcinoma.  
 
A recent paper from Wehr et al (Wehr et al., 2013) focussed on CXCR6 in liver injury and 
explored the underlying immunological mechanisms. The authors report data that in some 
parts complement my findings and in other contradict them. The found that acute liver injury 
caused by CCl4 was ameliorated in CXCR6 knock-out mice: serum ALT concentration 6 
hours after injury was significantly lower than in wild type mice, although differences did not 
appear significant at 12, 24 or 48 hours after injury. The inflammatory infiltrate in liver tissue 
was characterised by a lack of NKT cells (identified as CD4+NK1.1+ cells) and a rapid fall in 
monocyte-macrophages after 12 hours. The authors attributed the lower ALT to the 
reduction in macrophage-monocyte numbers although the two events were separated by 
over 24 hours. The authors went on to examine the role of CXCR6 in two models of 
chronic liver injury: chronic CCl4 injury and MCD diet. In both models less fibrosis was seen 
in CXCR6 knock out mice than in wild type controls, as well as fewer NKT cells. Adoptive 
transfer of wild type NKT cells into CXCR6 knock out mice restored the fibrotic response 
to 4 weeks of MCD diet.  
 
The findings of Wehr et al in acute liver injury - that knock-out of CXCR6 protected against 
liver damage - are consistent with my data in a similar injury model and suggest an acute, 
pro-inflammatory role for CXCR6 through recruitment of inflammatory cells. However in 
the MCD diet model of chronic liver injury the investigators reported reduced accumulation 
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of macrophages at eight weeks (but not four weeks) of diet and a reduction in fibrosis in 
CXCR6 knock out mice. In contrast, after 5 weeks of MCD diet I observed reduced 
expression of pro-fibrotic genes and greater liver injury, as assessed by serum AST in 
CXCR6 knock out mice. Wehr and colleagues did not report serum transaminase 
concentrations in the MCD diet model, and histology images were presented to 
demonstrate reduced periportal  infiltrates although this was not quantified or subjected to a 
statistical test. 
 
These contradictory findings in CXCR6 knock out mice given MCD may be due to a number 
of reasons. My data are based on 5 weeks of MCD diet, a limit imposed by Home Office 
regulations in view of the severe weight loss caused by MCD diet. Wehr et al subjected mice 
to 4 or 8 weeks of diet. However, differences between our results were evident at four 
weeks. Further, the MCD diet does not cause significant fibrosis, thus Wehr’s findings that 
hydroxyproline content of liver tissue at four and eight weeks was comparable to six weeks 
of CCl4 treatment is unusual. In addition, the authors stated categorically that CXCR6 was 
not expressed on hepatocytes, and ruled out a role for hepatocyte CXCR6 in explaining the 
differences seen between CXCR6 knockout and wild type mice. However, I detected 
CXCR6 on hepatocytes. It is possible that there are differences between murine and human 
hepatocyte expression of chemokine receptors – I have not demonstrated presence of 
CXCR6 in mouse liver. 
 
There are important differences in the distribution of CXCR6 on lymphoid cells between 
humans and mice. My data show that in humans intrahepatic CXCR6+ cells are 
predominantly NK cells, whereas in mice most intrahepatic CXCR6+ cells are CD4+ T 
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lymphocytes, with roughly equal number of NKT and NK cells (Wehr et al., 2013).  A 
greater percentage of NKT cells are CXCR6+ in both mice and human. These differences are 
important and limit the applicability of murine data to human disease, particularly as the 
effect of CXCR6 knock out is ascribed to differences in NKT biology (Wehr et al., 2013) 
through reduced direct cytotoxicity and also reduced recruitment of macrophages to liver. 
 
Conclusion 
Chemokines and their receptors play a critical role in the development of diverse liver 
diseases through their ability to recruit immune cells and possibly also to deliver signals to 
injured hepatocytes. My experiments with ex-vivo human tissue has shown the role of various 
chemokine/receptor pairings in liver disease, and pharmacological or genetic manipulation of 
the chemokine system has been able to ameliorate injury in animal models of liver disease. 
 
NAFLD is a common disease and although most individuals have relatively benign disease a 
substantial minority will not and treatment is required to prevent liver-related morbidity and 
mortality. My data show that targeting CCR2 in NAFLD is a rational target in NAFLD 
moreover the reagent I used to demonstrate efficacy in mice is a clinical grade inhibitor that 
has been shown to be safe in humans. The extra-hepatic effect of CCR2 inhibition in 
reducing adipose tissue inflammation and improved glycaemic control are another reason to 
consider this an attractive therapeutic angle in NAFLD where the risk of cardiovascular 
disease and diabetes is high (Adams et al., 2005a, Ekstedt et al., 2006, Ekstedt et al., 2014). 
 
The CCR9/CCL25 axis is up regulated in human and mouse acute liver failure die to 
paracetamol. Whilst fulminant liver failure is a devastating condition, it is thankfully rare. 
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Although the data presented here show evidence for this axis in human ALF, they do not 
show a benefit of CCR9 inhibition after administration of paracetamol and as such do not 
support consideration of this in clinical practice.  
 
Primary Biliary Cirrhosis is much less common than NAFLD but has few effective 
treatments. Inhibition of CXCR6 can reduce NK recruitment across hepatic endothelium in 
vitro and might be of benefit in PBC. The potential for translation is limited by the lack of an 
accurate mouse model of PBC. My finding that CXCR6 can contribute to hepatocyte 
replication raises the possibility that CXCR6 antagonism in a clinical setting may do more 
harm than good, if hepatocyte regeneration is compromised. However, this finding raises the 
possibility of intervention to control hepatocellular carcinoma through CXCR6 antagonism. 
 
In humans, exploration of drugs that target the chemokine system in liver disease remains a 
relatively new area of therapeutics but may have the potential to deliver new treatments. 
This is especially important in liver disease where few effective treatments are available.  
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Appendix 1 
Up regulated and down regulated genes in primary hepatocytes treated with CXCL16 
(information from entrez gene www.ncbu.nih.gov/gene) 
Gene symbol 
Relative 
regulation 
Protein Protein function 
CPT2 -254.1 carnitine palmitoyltransferase 2 
Nuclear protein which is 
transported to the mitochondrial 
inner membrane. Together with 
carnitine palmitoyltransferase I, the 
encoded protein oxidizes long-chain 
fatty acids in the mitochondria 
BAX -205.0 BCL2-associated X protein 
This protein forms a heterodimer 
with BCL2, and functions as an 
apoptotic activator 
BCL2L1 -166.5 BCL2-like 1 
regulate outer mitochondrial 
membrane channel (VDAC) opening 
and thus controls production of 
reactive oxygen species and release 
of cytochrome C by mitochondria, 
both of which are potent inducers 
of apoptosis 
GCLC -88.6 glutamate-cysteine ligase, catalytic subunit 
Glutamate-cysteine ligase. First rate-
limiting enzyme of glutathione 
synthesis. 
ACTB -50.5 actin, beta 
Actins are highly conserved proteins 
that are involved in cell motility, 
structure, and integrity. 
CEBPD -46.2 
CCAAT/enhancer binding protein (C/EBP), 
delta 
regulation of genes involved in 
immune and inflammatory 
responses, and may be involved in 
the regulation of genes associated 
with activation and/or differentiation 
of macrophages. 
BCL2A1 -42.5 BCL2-related protein A1 
reduces the release of pro-
apoptotic cytochrome c from 
mitochondria and block caspase 
activation 
ACSL3 -39.7 
acyl-CoA synthetase long-chain family 
member 3 
isozyme of the long-chain fatty-acid-
coenzyme 
ADM -37.5 adrenomedullin 
preprohormone which is cleaved to 
form two biologically active 
peptides, adrenomedullin and 
proadrenomedullin 
CDKN1B -31.5 cyclin-dependent kinase inhibitor 1B binds to and prevents the activation 
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of cyclin E-CDK2 or cyclin D-CDK4 
complexes, and thus controls the 
cell cycle progression at G1 
ATF4 -28.0 activating transcription factor 4 
transcription factor also isolated 
and characterized as the cAMP-
response element binding protein 2 
(CREB-2). belongs to a family of 
transcription factors involved in 
protein-protein interactions 
CDKN1A -27.5 cyclin-dependent kinase inhibitor 1A 
potent cyclin-dependent kinase 
inhibitor which binds to and inhibits 
activity of cyclin-CDK2 or -CDK4 
complexes, thus functions as a 
regulator of cell cycle progression 
at G1. 
EMP1 -18.4 epithelial membrane protein 1  
CCL5 -18.2 chemokine (C-C motif) ligand 5 
a chemoattractant for blood 
monocytes, memory T helper cells 
and eosinophils. 
BBC3 -18.1 BCL2 binding component 3 
member of the BH3-only pro-
apoptotic subclass. The protein 
induces mitochondrial outer 
membrane permeabilization and 
apoptosis 
ACSL5 -14.8 
acyl-CoA synthetase long-chain family 
member 5 
isozyme of the long-chain fatty-acid-
coenzyme A ligase family 
B2M -13.9 beta-2-microglobulin 
serum protein found in association 
with the major histocompatibility 
complex (MHC) class I heavy chain 
on the surface of nearly all 
nucleated cells 
GADD45B -12.7 
growth arrest and DNA-damage-inducible, 
beta 
proteins binding and activating 
MTK1/MEKK4 kinase, an upstream 
activator of both p38 and JNK 
MAPKs. The function of these genes 
or their protein products is involved 
in the regulation of growth and 
apoptosis.. 
ARNT -11.8 
aryl hydrocarbon receptor nuclear 
translocator 
binds to ligand-bound aryl 
hydrocarbon receptor and aids in 
the movement of this complex to 
the nucleus 
ACSL4 -9.9 
acyl-CoA synthetase long-chain family 
member 4 
isozyme of the long-chain fatty-acid-
coenzyme A ligase family 
CCND2 -8.5 cyclin D2 
This cyclin forms a complex with 
CDK4 or CDK6 and functions as a 
regulatory subunit of the complex, 
activity is required for cell cycle 
G1/S transition 
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GADD45A -7.9 
growth arrest and DNA-damage-inducible, 
alpha 
The protein encoded by this gene 
responds to environmental stresses 
by mediating activation of the 
p38/JNK pathway via MTK1/MEKK4 
kinase. 
BMP4 -6.8 bone morphogenetic protein 4 
member of the bone morphogenetic 
protein family which is part of the 
transforming growth factor-beta 
superfamily. 
BTG2 -5.9 BTG family, member 2 
member of the BTG/Tob family. 
This family has structurally related 
proteins that appear to have 
antiproliferative properties. This 
encoded protein is involved in the 
regulation of the G1/S transition of 
the cell cycle. 
BIRC3 -5.7 aculoviral IAP repeat containing 3 
inhibits apoptosis by binding to 
tumor necrosis factor receptor-
associated factors 
GSR -5.3 Glutathione reductase 
central enzyme of cellular 
antioxidant defense: reduces 
oxidized glutathione disulfide 
(GSSG) to the sulfhydryl form GSH, 
an important cellular antioxidant 
WISP1 -5.3 
WNT1 inducible signaling pathway protein 
1 
binds to decorin and biglycan, two 
members of a family of small 
leucine-rich proteoglycans present 
in the extracellular matrix of 
connective tissue, and possibly 
prevents the inhibitory activity of 
decorin and biglycan in tumor cell 
proliferation 
WNT5A -5.1 
wingless-type MMTV integration site family, 
member 5A 
member of the WNT family that 
signals through both the canonical 
and non-canonical WNT pathways. 
This protein plays an essential role 
in regulating developmental 
pathways during embryogenesis. 
RPLP0 -5.1 ribosomal protein, large, P0 
ribosomal protein that is a 
component of the 60S subunit. 
BMP2 -4.4 bone morphogenetic protein 2 
acts as a disulfide-linked homodimer 
and induces bone and cartilage 
formation 
FTH1 -4.4 ferritin, heavy polypeptide 1 
heavy subunit of ferritin, the major 
intracellular iron storage protein in 
prokaryotes and eukaryotes. It is 
composed of 24 subunits of the 
heavy and light ferritin chains. 
CCND1 -3.6 cyclin D1 This cyclin forms a complex with 
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and functions as a regulatory 
subunit of CDK4 or CDK6, whose 
activity is required for cell cycle 
G1/S transition. 
STAT1 -3.1 
signal transducer and activator of 
transcription 1 
Transcription factors: mediates the 
expression of a variety of genes, 
which is thought to be important 
for cell viability in response to 
different cell stimuli and pathogens 
FOSL1 -3.0 FOS-like antigen 1 
implicated as regulators of cell 
proliferation, differentiation, and 
transformation. 
SQSTM1 -3.0 sequestosome 1 
binds ubiquitin and regulates 
activation of the nuclear factor 
kappa-B (NF-kB) signaling pathway 
BCL2 -2.8 B-cell CLL/lymphoma 2 
an integral outer mitochondrial 
membrane protein that blocks the 
apoptotic death of some cells 
CA9 -2.6 carbonic anhydrase IX 
transmembrane protein, one of only 
two tumor-associated carbonic 
anhydrase isoenzymes known. It 
may be involved in cell proliferation 
and transformation. 
EPO -2.2 erythropoietin 
regulates red cell production by 
promoting erythroid differentiation 
and initiating hemoglobin synthesis. 
This protein also antiapoptotic 
functions in several tissue types 
TNF -2.1 tumor necrosis factor 
proinflammatory cytokine that 
belongs to the tumor necrosis 
factor (TNF) superfamily. 
HPRT1 -2.0 Hypoxanthine phosphoribosyltransferase 
Generation of purine nucleotides 
through purine salvage pathway 
MMP7 1.9731 Matrix metalloproteinase 7 Degrades various proteins 
HEYL 2.1295 
hes-related family bHLH transcription 
factor with YRPW motif-like 
It is thought to be an effector of 
Notch signaling and a regulator of 
cell fate decisions. 
HES5 2.2353 HES5 
Hes family bHLH transcription 
factor 5 
HEY1 2.3141 
hes-related family bHLH transcription 
factor with YRPW motif 1 
basic helix-loop-helix (bHLH)-type 
transcriptional repressors. 
WNT3A 3.5813 
wingless-type MMTV integration site family, 
member 3A 
These proteins have been 
implicated in oncogenesis and in 
several developmental processes 
Fold-Change (2^(- Delta Delta Ct)) is the normalized gene expression (2^(- Delta Ct)) in the 
Test Sample divided the normalized gene expression (2^(- Delta Ct)) in the Control Sample. 
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